

Clinical outcomes of antimicrobial resistance in cancer patients: A systematic review of multivariable models

Anders Skyrud Danielsen^{1,2}, Léa Franconeri^{3,4}, Samantha Page³, Anders Eivind Myhre⁵, Ragnhild Agathe Tornes⁶, Oliver Kacelnik³, Jørgen Vildershøj Bjørnholt^{1,2}

¹Department of Microbiology, Oslo University Hospital

²Institute of Clinical Medicine, Faculty of Medicine, University of Oslo

³Department of Infection Control and Preparedness, Norwegian Institute of Public Health

⁴ECDC Fellowship Programme, Field Epidemiology path (EPIET), European Centre for Disease Prevention and Control, (ECDC), Stockholm, Sweden

⁵Department of Haematology, Oslo University Hospital

⁶The Library for the Healthcare Administration, Norwegian Institute of Public Health

Corresponding author: Anders Skyrud Danielsen, andersskyrud.danielsen@fhi.no

Keywords: antimicrobial resistance, infection, mortality, risk factors, cancer, malignancy, systematic review

Abstract

Background

Infections are major causes of disease in cancer patients and pose a major obstacle to the success of cancer care. The global rise of antimicrobial resistance threatens to make these obstacles even greater and hinder continuing progress in cancer care. To prevent and handle such infections, better multivariable models building on current knowledge are needed. This internally funded systematic review (PROSPERO registration: CRD42021282769) aimed to review multivariable models of resistant infections/colonisations and corresponding mortality, what risk factors have been investigated, and with what methodological approaches.

Methods

We employed two broad searches of antimicrobial resistance in cancer patients, using terms associated with antimicrobial resistance, in MEDLINE and Embase through Ovid, in addition to Cinahl through EBSCOhost and Web of Science Core Collection. Primary, observational studies in English from January 2015 to November 2021 on human cancer patients that explicitly modelled infection/colonisation or mortality associated with antimicrobial resistance in a multivariable model were included. We extracted data on the study populations and their malignancies, risk factors, microbial aetiology, and methods for variable selection, and assessed the risk of bias using the NHLBI Study Quality Assessment Tools.

Results

Two searches yielded a total of 27151 unique records, of which 144 studies were included after screening and reading. Of the outcomes studied, mortality was the most common (68/144, 47%). Forty-five per cent (65/144) of the studies focused on haemato-oncological patients, and 27% (39/144) studied several bacteria or fungi. Studies included a median of 200 patients and 46 events. One-hundred-and-three (72%) studies used a p-value-based variable selection. Studies included a median of seven variables in the final (and largest) model, which yielded a median of 7 events per variable. An in-depth example of vancomycin-resistant enterococci was reported.

Conclusions

We found the current research on this topic to be heterogeneous, in both the methodological and epidemiological approaches. Methodological choices resulting in very diverse models made it difficult or even impossible to draw statistical inferences and summarise what risk factors were of clinical relevance. The development and adherence to more standardised protocols that build on existing literature are urgent.

Background

Cancer patients have a higher risk and worse outcomes of infectious disease complications, compared with healthy people [1]. Autopsy studies have indicated that infections may play a role in more than half of all cancer patient fatalities [1]. A recent study has also shown that cancer patients have a higher risk of contracting infections with antimicrobial-resistant organisms [2]. Importantly, infections often necessitate caregivers to postpone or withhold adequate cancer treatment, which may impair cancer outcomes. In recent years, there have been major changes in disease-causing microbial ecology, particularly in hospitals [3]. Bacteria and fungi are becoming increasingly resistant to antimicrobial drugs, and in Europe alone it is estimated that more than 33,000 people die each year from resistant microbes [4,5]. Not only are microbes acquiring antimicrobial resistance, but the microbial spectrum is changing, with an increasing proportion of species with a propensity for intrinsic resistance [6]. Infections in cancer patients are increasingly often caused by resistant organisms, which threaten recent years' advances in the treatment of cancer [7]. In other words, there is a pressing need to understand the changing epidemiology of bacterial and fungal infections among cancer patients, but also to design better preventive measures.

To adapt to this new reality, it is essential to understand the mechanisms by which infections occur and cause disease. The research that leads to the discovery and description of these mechanisms, as well as testing them in preliminary models, has been called 'prognostic factor research' by the PROGRESS Group [8]. Prognostic factor research forms the basis for more advanced risk stratification tools and scoring systems clinicians may use to guide anti-infective therapy. Such risk stratification tools or scoring systems are usually based on clinical prediction models, which are typically regression models where individual-level clinical data are used to predict a clinical outcome of interest [9,10]. Some examples widely used in the management of infectious complications in cancer patients are the Multinational Association for Supportive Care in Cancer (MASCC) risk indices for febrile neutropenic patients or the Pitt bacteraemia score. These risk indices were developed in relatively small patient cohorts in the early 1990s [11,12].

Because of the changing epidemiology, there is a need to update the multivariable regression models that estimate and predict the risks associated with antimicrobial resistance in cancer care, like the additional risk of death attributable to resistance. In this work, it is important to build on already existing multivariable models and use factors that previously have been shown to be associated with the outcomes of interest. It is thus necessary to map the existing literature on such multivariable models to facilitate the use of current knowledge in future research. In this systematic review, we aimed to review multivariable models of resistant infections/colonisations and corresponding mortality in cancer patients, what risk factors have been included, and with what methodological approaches.

Methods

Protocol registration and reporting standards

To review what risk factors for resistant infections and/or carriage/colonisation (hereafter “infections/colonisations”) and corresponding mortality in cancer patients have been investigated, we conducted a systematic review employing a broad and extensive search for literature published from 1st of January 2015 to 19th of November 2021. It was not possible to separate studies on infection and colonisation, so these outcomes were combined. Although first coined in 1961, the term ‘risk factor’ remains an elusive term as it is used to describe any covariate associated with an outcome [13,14]. We will here use the term ‘risk factor’ colloquially as a common designation for both causal risk factors and predictive risk markers, as this terminology is often used in the primary studies included [15]. This systematic review was registered at PROSPERO (ID: CRD42021282769) [16] and follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline (checklist can be found in Supplementary Material 7) [17].

Search strategy

Our search strategy was implemented in three steps. First, we performed preliminary searches in PubMed to identify some main keywords to be included and to get an overview of the size of the literature. We then performed a first search and, after screening and sorting the results of the search, we manually reviewed the records and references to discover keywords that were not covered by our initial search. We then performed a second search designed to expand the first search findings.

The first search was conducted by a research librarian from 22nd to 24th June, 2021. It consisted of terms covering all cancers and terms covering antibiotic resistance and infections. A spectrum of synonyms with appropriate truncations and proximity operators was used for searching title, abstract, and author keywords. In addition, controlled subject headings were searched when available. The search strategy was tailored to each database’s search interface. The search was run in the OVID MEDLINE and OVID Embase, in addition to EBSCO Cinahl and Web of Science Core Collection (Science Citation Index Expanded, Social Sciences Citation Index, Arts & Humanities Citation Index and Emerging Sources Citation Index - searched simultaneously). The strategies were limited to Danish, English, Norwegian, Spanish, and Swedish. They also included a time limit for publications

from the 1st of January 2015 onwards. A total of 25 881 records were retrieved. After removing duplicate records in EndNote, 14 153 references were identified.

The second search expanded on this by including specific antibiotics, resistance mechanisms, and bacteria and fungi often associated with either acquired resistance or high levels of intrinsic resistance. The terms covering antibiotics were variations of piperacillin/tazobactam, meticillin/methicillin, cephalosporin, carbapenem, aminoglycoside, gentamicin, amikacin, fluoroquinolone, linezolid, vancomycin, echinocandin, azole, colistin. The terms covering mechanisms of resistance or microbial properties associated with resistance were beta-lactamase/ β -lactamase, extended-spectrum beta-lactamase/ β -lactamase/betalactamase, carbapenemase, biofilm-producing, non-fermenting. The terms covering bacteria and fungi were *Pseudomonas aeruginosa*, *Acinetobacter spp.*, *Acinetobacter baumannii*, *Stenotrophomonas maltophilia*, *Clostridium/Clostridioides difficile*, *Enterococcus faecium*, *Enterococcus faecalis*, coagulase-negative staphylococci, *Candida non-albicans*, *Candida auris*, *Aspergillus fumigatus*. Those were selected from a wide range of terms during a multidisciplinary meeting which led to a consensus. This search was run on 19th of November 2021 in the same databases (except for Cinahl) and with the same limitations as the June version.

Search strategies can be found in Supplementary Materials 1 and 2.

Study selection

The titles of all records were first screened by AD and LF to exclude any records that were not about antimicrobial resistance and cancer using the Rayyan tool [18]. We then screened all abstracts of the records where the subject was antimicrobial resistance and cancer to sort these into different study designs. The remaining original records with an observational study design were then read in full text by both AD and LF to see if they matched the eligibility criteria (Table 1). If there was uncertainty about the inclusion of a record, both authors discussed it until reaching a decision.

Table 1. Eligibility criteria.

| Inclusion criteria | Exclusion criteria |
|--|--|
| <ul style="list-style-type: none"> • Primary study with original data • Observational study design (prospective/retrospective cohort study, case-control study, cross-sectional study) • The study population consists only of cancer patients, haematological or otherwise, of any age, sex, or ethnicity, and in any institution in any country. • The study includes a multivariable model. • A resistant bacterial or resistant fungal infection is either a risk factor or an outcome • The outcome is either infection (or colonisation) or death • Published after 1st of January 2015. • Published in English. • Studies in humans. | <ul style="list-style-type: none"> • Any other publication type than a primary observational study. • Cancer is a covariate or comparator, not everyone in the study population has cancer. • Resistance to antimicrobial drugs is not included in the model (neither as a risk factor nor as an outcome). • The outcome is not infection or mortality, e.g. distribution of bacteria or bacterial strains. • Studies where the causal assumption is reversed, so that infection causes cancer (e.g. increased risk of gastric cancer after <i>Helicobacter pylori</i> infection) |

Data extraction and statistical analysis

Data extraction

The risk of bias in all included studies was assessed by AD and LF separately in a blinded process using the National Institutes of Health study quality assessment tools [19], and an arbitration meeting was held where OK/JB acted as an arbiter to come to a consensus about the final risk of bias assessment. The guidance for the use of these tools was followed, but the tool was modified to include an item with a question of whether the outcome was well defined in case-control studies.

Data extraction was then performed by AD and LF. We extracted the year of publication, the title of the study, the authors, the number of patients, the country of the study setting, the study aim statement, the patient population statement, the risk factors included in the final model, the microbial aetiology, whether the studies employed a screening for statistical significance, and the events per variable in the final model. This was included together with the risk of bias assessment and a short commentary in three different tables of all included studies, one for studies with an infection/colonisation outcome, one for studies with a mortality outcome and one for studies with both outcomes. These three tables may be found in the Supplementary Material S3, S4, and S5. The studies were checked against pre-specified criteria for a potential meta-analysis, being that models would have the same aetiology, outcome, and risk factors. These criteria were not met for any aetiology. To provide a genuine example of the heterogeneity of the models, population, variables and outcomes investigated, a qualitative in-depth example of the investigation of risk factors was reported. We chose researches that included vancomycin-resistant enterococci (VRE), as they represented a typical cross-section of the studies selected. Furthermore, VRE is a typical hospital-associated microbe that may readily be prevented.

Statistical analysis

A table describing the outcomes and extracted data on the country, microbial aetiology, patients, events, events per variable, variables screened, variables in the final model, and p-value-based variable selection were created. The table summarised the findings by presenting frequencies with percentages for categorical variables and medians with interquartile ranges for continuous variables. To summarise what risk factors have been investigated, we grouped the microbial aetiology into five large groups (*Clostridioides difficile*, fungi, Gram-negative bacteria, Gram-positive bacteria, and several bacteria/fungi) and categorised the risk factors. We then created a table of how many times the different types of risk factors had been included in the final multivariable model in the included studies for each of the large microbial aetiology groups. A full list of the risk factors and their respective categories can be found in the appendix. Analyses were performed in R using RStudio version 4.1.1 [20], and the scripts used to produce the results can be found on [GitHub](#) [21].

Results

Study selection

After excluding 47048 duplicates, the two searches yielded a total of 27151 unique records from a total of three major databases - Ovid MEDLINE, Ovid Embase, and Web of Science -

in addition to the Cinahl database (EBSCO) (Figure 1). Title screening for relevance to both antimicrobial resistance and cancer excluded 25341 records, whereas most excluded records were only about cancer, e.g. basic research on the drug resistance of the cancer disease. Abstract screening for a non-observational study design excluded a further 845 records, where 103 had a review design, 50 had an interventional design, 454 were case reports, and 238 were miscellaneous, mostly commentary articles and conference abstracts. Finally, after full-text screening; 821 records were excluded, of which 165 included other diagnoses than cancer (including healthy individuals), 197 did not include an infection/colonisation or mortality outcome (often microbial distribution or endpoints like the length of stay), 130 did not explicitly include antimicrobial resistance in the model, 311 did not include a multivariable model, 16 were not in English, and we failed to gain access to two leaving 144 studies included.




Figure 1: PRISMA flowchart of the study selection [17].

Study characteristics

Of the 144 studies, 55/144 (38%) had an infection/colonisation outcome, 66/144 (46%) had a mortality outcome, and 23/144 (16%) had both outcomes, all of which are listed in detail and cited in tables with all extracted data, including the investigated risk factors, in Supplementary Material S3, S4, and S5, respectively. In total, there were 23/144 (16%) studies of patients with solid cancers [22–44], 65/144 (45%) studies of patients with haematological cancers [45–109], and 56/144 (39%) studies with patients of both or unspecified cancer types [110–165]. Most studies selected (39/144, 27%) reported and modelled several bacteria and/or fungi that were tested for resistance towards several antimicrobials [22–37,45–57,110–119]. Eight of 144 (6%) reporting and modelling several microorganisms focused only on Gram-negative bacteria [58–62,120–122] and 1/144 (1%) focused only on fungi [63]. Twelve of 144 (8%) studies studied the family *Enterobacteriales* (especially *Escherichia coli* and *Klebsiella pneumoniae* combined), either ESBL- or carbapenemase-producing [38,64–68,123–128]. The most commonly studied single organism was *Clostridioides difficile* with 27/144 (19%) studies [39–41,69–81,129–139]. Also studied were three non-fermenters with 5/144 (3%) studies about *Acinetobacter baumannii* [82,140–143], 4/144 (3%) studies about *Pseudomonas aeruginosa* [83,84,144,145], and 5/144 (3%) studies about *Stenotrophomonas maltophilia* [85–88,146], often specified as either multidrug- or extensively drug-resistant. We also found several studies focusing on four well-known healthcare-associated bacteria, with 11/144 (8%) focusing on VRE [89–98,147,148], 7/144 (5%) focusing on carbapenemase-producing *K. pneumoniae* (KPC) [99–102,149–151], 2/144 (1%) focusing on methicillin-resistant *Staphylococcus aureus* (MRSA) [42,152], and 6/144 (4%) focusing on extended-spectrum beta-lactamase-producing *Escherichia coli* (ESBL-E) [103,104,153–156]. We also found that fungi typically resistant to antifungals were studied, 3/144 (2%) studies about *Aspergillus* spp. [43,105,106] and 9/144 (6%) studies about *Candida non-albicans* [44,107,157–163], respectively. Finally, there was one of 144 (1%) studies for each of the microbes *Staphylococcus epidermidis* (with linezolid-resistance) [108], *Bacillus* spp. [164], *Streptococcus pneumoniae* (several resistance mechanisms) [165], and *Aeromonas sobria* [109].

Summary of findings

The most common microbial aetiologies were several bacteria/fungi (39, 25%), followed by *C. difficile* (27, 19%) and Enterobacteriaceae (12, 8%) (Table 2). The most common country for the study setting was the United States of America (USA) (40, 28%), followed by China (15, 10%), and Italy (11, 8%). The selected studies included a median of 200 patients (IQR 102-338) and 46 events (IQR 25-83.5). 103 (72%) studies used a p-value-based variable selection, either bivariable screening or stepwise regression. These studies screened a median of 16 variables (IQR 9-27) and included a median of 7 variables in the final (and largest) model. The median events per variable were close to 7.

Table 2. Summary of findings.

| Characteristics | Frequencies |
|------------------------|--------------|
| Outcome | % (n) |
| Infection/colonisation | 38 (55) |

| | |
|--|-------------------|
| Death | 46 (66) |
| Both | 16 (23) |
| Country/setting | % (n) |
| USA | 28 (40) |
| China | 10 (15) |
| Italy | 8 (11) |
| Spain | 7 (10) |
| Germany | 6 (9) |
| South Korea | 6 (9) |
| Microbial aetiology | % (n) |
| Several bacteria and / or fungi | 27 (39) |
| <i>C. difficile</i> | 19 (27) |
| Enterobacteriaceae | 8 (12) |
| Vancomycin-resistant enterococci | 8 (11) |
| Carbapenemase-producing <i>K. pneumoniae</i> | 5 (7) |
| Patients (median) | 200 (IQR 102-338) |
| Events (median) | 46 (IQR 25-84) |
| Events per variable (median) | 7 (IQR 4-13) |
| Variables screened (median) | 16 (IQR 9-27) |
| Variables in the final model (median) | 7 (IQR 4-10) |
| Stepwise regression | % (n) |
| | 72 (103) |
| Total | 144 |

The most commonly investigated risk factors in models of resistant infection and/or colonisation in cancer patients were antibiotic use, with a total of 118 occurrences in the included studies (Table 3). In the models of mortality, however, the most commonly investigated risk factors were related to infection with a total of 208 occurrences. A full list of the risk factors and their respective categories may be found in Supplementary material S6.

Table 3. Categories of risk factors investigated in the final, multivariable model in the included studies, by large groups of microbial aetiology.

| Infection/colonisation | | Mortality | |
|--|--------------|--|--------------|
| Risk factors by microbial aetiology | Count | Risk factors by microbial aetiology | Count |
| <i>Clostridioides difficile</i> | | <i>Clostridioides difficile</i> | |
| Basic characteristics | 29 | Basic characteristics | 10 |
| Antibiotic use | 28 | Comorbidities/clinical condition | 8 |

| | | | |
|---|----|--------------------------------------|----|
| Cancer-related | 18 | Hospital-related | 6 |
| Comorbidities/clinical condition | 14 | Infection-related | 6 |
| Hospital-related | 14 | Other | 3 |
| Fungi | | Fungi | |
| Antifungal use | 7 | Infection-related | 21 |
| Basic characteristics | 7 | Hospital-related | 9 |
| Other | 6 | Basic characteristics | 7 |
| Infection-related | 6 | Comorbidities/clinical condition | 7 |
| Cancer-related | 4 | Antibiotic use | 6 |
| Gram-negative bacteria | | Gram-negative bacteria | |
| Antibiotic use | 65 | Infection-related | 71 |
| Infection-related | 35 | Comorbidities/clinical condition | 40 |
| Hospital-related | 23 | Cancer-related | 31 |
| Basic characteristics | 21 | Antibiotic use | 27 |
| Cancer-related | 15 | Basic characteristics | 24 |
| Gram-positive bacteria | | Gram-positive bacteria | |
| Antibiotic use | 14 | Infection-related | 14 |
| Infection-related | 11 | Cancer-related | 11 |
| Cancer-related | 7 | Basic characteristics | 8 |
| Basic characteristics | 5 | Neutropenia | 6 |
| Chemotherapy/immunosuppressants | 5 | Antibiotic use | 5 |
| Several bacteria and/or fungi | | Several bacteria and/or fungi | |
| Transplantation-related | 5 | Infection-related | 96 |
| Antibiotic use | 4 | Comorbidities/clinical condition | 39 |
| Laboratory findings (non-microbiological) | 4 | Cancer-related | 31 |
| Surgery-related | 4 | Basic characteristics | 31 |
| Comorbidities/clinical condition | 2 | Antibiotic use | 27 |

In-depth example of VRE

As a model organism, we explored how risk factors for and of VRE in cancer patients were described and modelled in the selected studies. Of our selection, 46/144 (32%) of the studies mention either *Enterococcus* spp., *E. faecium*, or *E. faecalis*, which is either described as vancomycin-resistant or “multidrug-resistant” (sometimes not further specified), or where the resistance mechanism is not described at all. Most of the studies (30/46, 65%) that mention the organism include it in a larger group, like Gram-positive bacteria or multidrug-resistant organisms, which hampers any specific focus on VRE [22–34,45–53,110–117].

Eight studies model the risk of being either colonised or infected with VRE. The number of patients included ranged from 72 to 342, and the variables screened ranged from 6 to 46. One study focused on patients undergoing liver transplantation for hilar cholangiocarcinoma, and seven focused on haematological cancer patients. Although a plethora of risk factors was investigated, five of the studies selected variables based on their corresponding p-values in bivariable analyses, and as such dropped several variables from the analysis due to their failure to achieve the p-value criterion. The authors did not necessarily conclude that all risk factors investigated in the multivariable model were of importance. The risk of bias was rated low for three, medium for five, while none had a “fatal flaw”. However, five of eight studies had less than ten events per variable in the final model, which may lead to a lack of statistical power. Among the common conclusions from the studies of VRE infection or colonisation, four concluded that antibiotic exposure was a risk factor for VRE infection or colonisation, and two highlighted neutropenia. None of the antibiotic exposure risk factors

was the same (one was vancomycin, one was carbapenem, one was general antibiotic exposure and one was daptomycin). When looking at the findings in detail, Aktürk et al. found that severe neutropenia and previous bacteraemia with another pathogen may increase the risk of progressing from VRE colonisation to VRE infection in paediatric haematological cancer patients [147]. In 2015, Ford et al. found that severe neutropenia and the number of stools per day were associated with VRE bloodstream infections in leukaemia patients, and in 2019 some of the same authors concluded that VRE colonisation rates fell when the hospital started using less carbapenem [89,90]. Herc et al reported that only previous daptomycin exposure was associated with daptomycin-resistant VRE infections in patients with haematological malignancies [91]. Hefazi et al found that VRE colonisation is associated with VRE infection in stem cell transplantation patients and Ramanan et al found that VRE colonisation pre-transplantation was associated with any infection post-transplantation [35,92]. Heisel et al found that cephalosporin use and intravenous vancomycin were associated with VRE infections in patients with acute myeloid leukaemia or myelodysplastic syndrome undergoing intensive induction therapy, and finally, Klein et al found that in multiple myeloma patients, granulocyte-colony stimulating factor was associated with fewer VRE cases than antibiotic prophylaxis [93,94].

Another eight studies analyse the deaths associated with VRE in cancer patients. The number of patients included ranged from 95 to 1424, and the variables screened ranged from 11 to 56, although the exact number was indeterminable for one of the studies. Six studies selected variables based on a specified p-value threshold, but for one study the method for variable selection could not be determined. We assessed the risk of bias among these studies and found four studies at low risk and four studies at a medium risk of bias. Of the eight studies, six had less than 10 events per variable in the final model. The studies had few conclusions about risk factors for mortality among cancer patients associated with VRE in common. However, three studies found that VRE bacteremia was a risk factor for death and two studies found no risk factors after running their model. When looking at the findings in detail, Akhtar et al. found that only shock (not further specified) was associated with the difference in mortality between VRE and VSE bacteraemia in cancer patients [148]. Kamboj et al did not find any factors that were associated with higher mortality in stem cell transplantation patients with VRE bacteraemia [95]. Kern et al modelled the mortality associated with enterococcal bacteraemia in haematological cancer patients but did not specify vancomycin resistance [54]. Kirkizlar et al found that in leukaemia patients colonised with VRE, a low neutrophil count and coinfection were associated with increased mortality [96]. Mendes et al included VRE in a bivariable screening but discarded the factor as it did not meet the criterion of $p < 0.1$ [55]. Ornstein et al found that leukaemia patients with a VRE bacteraemia at the induction of chemotherapy had poorer survival than patients with other bloodstream infections [97]. Papanicolaou et al found that VRE bacteraemia increased the mortality in patients receiving their first stem cell transplantation, but did not disclose how variables were selected for the multivariable model [98]. Finally, Pugliese et al modelled the risk of mortality associated with several bacteria in leukaemia inpatients, among them *Enterococcus* spp. (no vancomycin resistance mentioned), but did not find an association [56].

Discussion

In our systematic review of studies with multivariable models with risk factors for infection/colonisation and mortality associated with antimicrobial resistance in cancer patients, we selected 144 studies that were eligible for inclusion. Most studies focused on haematological cancer patients and explored a host of different microbes. Studies on infection/colonisation with resistant microbes as outcomes most often investigated risk factors relating to antibiotic use, while studies with mortality as an outcome often included risk factors relating to the infection itself. Studies often had small sample sizes, screened a large number of variables, and used p-value-based methods for variable selection like bivariable screening or stepwise regression. In general, the models were highly heterogeneous, with nuances in the study populations and microbial aetiologies, and major differences in which risk factors were modelled, as we have exemplified through the research on VRE in cancer patients.

The issues with heterogeneity when performing a systematic review of basic prognostic factor research have been described before [166]. Although it is not possible to infer which factors are of importance, we find that known general risk factors for infections like immunosuppression and specific risk factors for resistant infections like previous antibiotic use are recurring, as other non-systematic reviews do [1,2,6,7]. A comprehensive list of these factors can be found in the supplementary material. To the best of our knowledge, no previous systematic review has investigated the risk factors for all resistant infections in cancer patients. However, three systematic reviews have looked at risk factors for methicillin-resistant *S. aureus*, extended-spectrum β -lactamase-producing *Enterobacteriaceae*, and vancomycin-resistant enterococci, specifically [167–169]. These studies were able to pool the prevalence of such infections and identify some risk factors of importance, providing a good basis for future research. Some systematic reviews also investigate the changing epidemiology of antimicrobial-resistant infections in cancer patients without a particular focus on risk factors [6,170].

Some conservative choices were made in the selection process which may have reduced the final number of studies included. Some studies were excluded because study participants had other diagnoses than cancer, e.g. recipients of hematopoietic stem cell transplantation due to non-malignant haematological disorders [171,172]. Several of these studies did not describe the full diagnostic panorama, although comprehensive patient characteristics remain an important backbone in epidemiological research. Other studies did not explicitly model resistant microbes by including resistance as a variable or an outcome [173,174]. Given the rapid increase in antimicrobial resistance, current research in the epidemiology of infectious diseases in healthcare settings should include detailed data on antimicrobial resistance. The most common reason for excluding observational studies during full-text reading was the lack of a multivariable model [175,176]. These studies seemed to have a low number of patients, and a multivariable model may have been avoided due to low statistical power. As discussed by the PROGRESS Research Group in their recommendations for prognostic factor research, the discovery and investigation into new prognostic factors should rely on multivariable modelling to discern these from factors already known to be of importance, and to provide a basic adjustment of confounders [8]. Studies simply testing whether factors differ between groups often rely heavily on null-hypothesis statistical significance testing and are subject to the multiple comparison problem

[177]. Although exploratory studies are important, such studies sometimes either test risk factors that are already known to be associated with the outcome, test factors in too small samples, or test too many factors at once. This may lead to wrong inferences due to known issues such as sparse data bias or winner's curse inflating effect sizes [178,179]. An alternative can be to establish larger research collaborations that can pool data into larger cohorts as we found several examples of [63,144]. Worth noting, we found two clinical prediction models. In one of them, the IRONIC group developed a scoring system for the risk of multidrug resistance in bloodstream infections by *P. aeruginosa*, and in another, Colombian researchers developed a scoring system for the risk of ESBL-producing *Enterobacteriaceae* [128,144].

Studies were assessed for their risk of bias using the NIH Quality Assessment tool, in which we found several recurring issues. Most studies did not include a sample size calculation or described the blinding of exposure assessors. Differences in the risk of bias assessments were often determined by allowing continuous variables to be treated continuously or by the correct definition of the exposure. We also found that several studies lacked a reliable definition of the outcome, in particular the definition of mortality. As discussed by the NIH Quality Assessment reviewers, even though death as an outcome seems to be objective by nature (i.e. researchers rely on "face validity"), even this outcome should be defined. Such a definition should include information on particulars like from which register or medical record information about the death was collected if the patient perished within or outside of the institution, and if the latter was the case, who reported the death. Most studies did have a sufficient follow-up time to capture infectious disease outcomes (in particular mortality), but these follow-up times varied greatly for all studies. However, the NIH Quality Assessment tool included items that were not relevant to all studies (e.g. "the adjustment of confounders" in a prediction context) and the issue with finding good quality assessment tools for prognostic factor research has been described earlier [180]. Systematic reviews of clinical prediction models should use other more specialised tools like PROBAST [181].

We chose to summarise the research by describing an in-depth example of studies on VRE, which provided us with a representative cross-section in terms of the patient population, sample size, methodological approaches, and the number of variables. This example showed how heterogeneity in how the subject is studied may hamper our ability to build on this basic research, either through the development of more comprehensive predictive models or through pooling or meta-analysis. Most studies studying resistant enterococci group the bacteria together with other bacteria and/or fungi. Furthermore, authors often study the bacteria in a highly selected patient population, in which it is difficult to infer how baseline characteristics pertain to the risk factors studied, either from a table of characteristics or the model. However, the major source of heterogeneity that reduces our ability to build on the research is the arbitrary way in which variables are selected.

We find that throughout the entire material, there was widespread use of either stepwise regression or a bivariable screening of variables as a method for variable selection in regression models, where variables that achieve some pre-specified p-value threshold are included in the final model. This method is, however, not recommended for either estimating the effect of an exposure or predicting an outcome [10,182–184]. In short, the reason is its reliance on p-values as a criterion for variable selection, although the p-value is not an indicator of a causal relationship or predictive power. A factor confounding a causal effect

may not be statistically significant, and there may be situations in which a variable that is not statistically significant in a bivariable analysis may increase the predictive power of a multivariable model. Consequently, including all candidate factors in a multivariable model and testing them through statistical significance may not be a valid method of discovering new prognostic factors. Unfortunately, there is no alternative to these methods based on statistical significance that is as simple and practical, or as automated and data-driven. The basis for all modelling is a theoretical understanding of covariates, outcomes and the relationship between them. All in all, it is difficult and maybe even impossible to summarise what risk factors are shown to be of relevance in this literature. Simply counting how many times a certain risk factor is found to be statistically significant tells us little of its relative importance.

The strengths of our study are the large scope of our searches, which has resulted in a comprehensive overview of the current state of this research topic. However, there are several limitations to our study. First, we only searched for studies where any type of antimicrobial resistance was mentioned in the title, abstract, controlled vocabulary, or keywords, which may have excluded some studies that only mention infections in broader terms, but still model the risk of contracting resistant infections or any potential outcomes of such infections. Furthermore, we narrowed our inclusion criteria to studies that model either infection/colonisation or mortality as an outcome, but this does not fully cover how resistant microbes may increase the disease burden among cancer patients, like repeated hospitalisations, increased costs and/or increased length of stays. Several of the studies that were excluded mainly had patients with a haematological malignancy, but also some patients with aplastic anaemia or other haematological disorders. Other studies did not explicitly include (acquired or intrinsic) resistance in the models, although they may have included resistance in other implicit ways, like the failure of an empiric carbapenem cure. Patients with other haematological disorders or other infectious etiologies may have similar risk profiles, and their exclusion may have unreasonably narrowed the scope of the review. We also searched for records in Swedish, Danish and Spanish, but records in these languages were not included to ensure this systematic review would be available and reproducible for all readers. As many of the studies we included were from countries where English is not the native language, the exclusion of other languages may represent a limitation of our review.

Conclusions

In this systematic review, we found a great level of heterogeneity in the approach to studying risk factors for resistant infections/colonisations and mortality due to resistant infections among cancer patients. We argue that it's difficult or even impossible to use these models to infer which risk factors are of particular importance. This is due to differences in the patient populations selected, and the different ways of grouping microbes. Furthermore, studies on this subject often have a small sample size and use p-value-based variable selection methods, which lead to very diverse models. The consequence of this heterogeneity is not only that the literature is unprepared for either a meta-analysis or a pooled analysis. It also means that it is difficult to use this research to understand the mechanisms by which resistant microbes cause disease in cancer patients, and thus that it is difficult for clinicians to use the research to guide their prevention of such conditions. This represents a serious shortcoming of this body of literature. There is a need to develop and adhere to more

standardised protocols when investigating new risk factors. Such protocols should include a clear aim of what risk factors are to be explored and build on existing literature, e.g. by selecting similar patient populations and being careful to include factors previously shown to be of importance regardless of their p-value in a bivariable screening.

Declarations

Acknowledgements

We would like to thank bachelor's student Sofie Almark Jeppesen for assistance in the screening process. We would also like to thank the authors who shared their research with us to which we did not otherwise have access. Thanks also to the South-Eastern Norway Regional Health Authority for funding.

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Availability of data and materials

All data extracted or generated and then analysed are included in the article or the supplementary material.

Competing interests

The authors declare that they have no competing interests.

Funding

The study was internally funded. AD is funded by a grant from the South-Eastern Norway Regional Health Authority.

Authors' contributions

AD conceived the idea, drafted the manuscript, screened the search, extracted and organised the data, and performed the risk of bias assessment. LF revised the manuscript, screened the search, extracted and organised the data, analysed the data, and performed the risk of bias assessment. SP revised the manuscript. AM revised the manuscript. RT revised the manuscript and performed the search. OK revised the manuscript, and performed the risk of bias assessment. JB conceived the idea and revised the manuscript.

References

- [1] Zembower TR. Epidemiology of Infections in Cancer Patients. In: Stosor V, Zembower TR, editors. *Infect. Complicat. Cancer Patients*, Cham: Springer International Publishing; 2014, p. 43–89. https://doi.org/10.1007/978-3-319-04220-6_2.
- [2] Nanayakkara AK, Boucher HW, Fowler Jr VG, Jezek A, Outtersson K, Greenberg DE. Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward. *CA Cancer J Clin* 2021;71:488–504. <https://doi.org/10.3322/caac.21697>.
- [3] Jarlier V, Högberg LD, Heuer OE, Campos J, Eckmanns T, Giske CG, et al. Strong correlation between the rates of intrinsically antibiotic-resistant species and the rates

- of acquired resistance in Gram-negative species causing bacteraemia, EU/EEA, 2016. *Eurosurveillance* 2019;24:1800538. <https://doi.org/10.2807/1560-7917.ES.2019.24.33.1800538>.
- [4] World Health Organization. Antimicrobial resistance: global report on surveillance. World Health Organization; 2014.
- [5] Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. *Lancet Infect Dis* 2019;19:56–66. [https://doi.org/10.1016/S1473-3099\(18\)30605-4](https://doi.org/10.1016/S1473-3099(18)30605-4).
- [6] Treçarichi EM, Tumbarello M. Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact. *Curr Opin Infect Dis* 2014;27:200–10. <https://doi.org/10.1097/QCO.0000000000000038>.
- [7] Rolston KVI. Infections in Cancer Patients with Solid Tumors: A Review. *Infect Dis Ther* 2017;6:69–83. <https://doi.org/10.1007/s40121-017-0146-1>.
- [8] Riley RD, Hayden JA, Steyerberg EW, Moons KGM, Abrams K, Kyzas PA, et al. Prognosis Research Strategy (PROGRESS) 2: Prognostic Factor Research. *PLOS Med* 2013;10:e1001380. <https://doi.org/10.1371/journal.pmed.1001380>.
- [9] Steyerberg EW, Moons KGM, Windt DA van der, Hayden JA, Perel P, Schroter S, et al. Prognosis Research Strategy (PROGRESS) 3: Prognostic Model Research. *PLOS Med* 2013;10:e1001381. <https://doi.org/10.1371/journal.pmed.1001381>.
- [10] Steyerberg EW. *Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating*. 2nd ed. 2019. Cham: Springer International Publishing; Imprint: Springer; 2019.
- [11] Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. *J Clin Oncol Off J Am Soc Clin Oncol* 2000;18:3038–51. <https://doi.org/10.1200/JCO.2000.18.16.3038>.
- [12] Korvick JA, Bryan CS, Farber B, Beam TR, Schenfeld L, Muder RR, et al. Prospective observational study of Klebsiella bacteremia in 230 patients: outcome for antibiotic combinations versus monotherapy. *Antimicrob Agents Chemother* 1992;36:2639–44. <https://doi.org/10.1128/AAC.36.12.2639>.
- [13] Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J. Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study. *Ann Intern Med* 1961;55:33–50. <https://doi.org/10.7326/0003-4819-55-1-33>.
- [14] Huitfeldt A. Is caviar a risk factor for being a millionaire? *BMJ* 2016;355:i6536. <https://doi.org/10.1136/bmj.i6536>.
- [15] Porta M, editor. *A dictionary of epidemiology*. 6th ed. Oxford, England: Oxford University Press; 2014.
- [16] Danielsen AS, Franconeri L, Kacelnik O, Tornes RA, Bjørnholt JV. Antimicrobial resistance and cancer patients: A systematic review of risk factor modelling. PROSPERO 2021. https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=282769 (accessed April 11, 2022).
- [17] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. <https://doi.org/10.1136/bmj.n71>.
- [18] Rayyan – Intelligent Systematic Review n.d. <https://www.rayyan.ai/> (accessed April 11, 2022).
- [19] National Heart, Lung and Blood Institute. *Study Quality Assessment Tools* n.d. <https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools> (accessed April 11, 2022).

- [20] RStudio Team. RStudio: Integrated Development Environment for R. Boston, MA: RStudio, PBC.; 2020.
- [21] GitHub. AMRreview 2023.
- [22] Bednarsch J, Czigany Z, Heij LR, Luedde T, van Dam R, Lang SA, et al. Bacterial bile duct colonization in perihilar cholangiocarcinoma and its clinical significance. *Sci Rep* 2021;11:2926. <https://doi.org/10.1038/s41598-021-82378-y>.
- [23] Gianotti L, Tamini N, Gavazzi F, Mariani A, Sandini M, Ferla F, et al. Consequences of Increases in Antibiotic Resistance Pattern on Outcome of Pancreatic Resection for Cancer. *J Gastrointest Surg Off J Soc Surg Aliment Tract* 2017;21:1650–7. <https://doi.org/10.1007/s11605-017-3483-1>.
- [24] Lee D-S, Ryu J-A, Chung CR, Yang J, Jeon K, Suh GY, et al. Risk factors for acquisition of multidrug-resistant bacteria in patients with anastomotic leakage after colorectal cancer surgery. *Int J Colorectal Dis* 2015;30:497–504. <https://doi.org/10.1007/s00384-015-2161-6>.
- [25] Szvalb AD, El Haddad H, Rolston KV, Sabir SH, Jiang Y, Raad II, et al. Risk factors for recurrent percutaneous nephrostomy catheter-related infections. *Infection* 2019;47:239–45. <https://doi.org/10.1007/s15010-018-1245-y>.
- [26] Zhou T, Yang W, Yang Q, Xuan B, Zhang L, Li X, et al. Distribution, diagnosis, and analysis of related risk factors of multidrug-resistant organism in patients with malignant neoplasms. *Int J Clin Exp Pathol* 2020;13:2648–55.
- [27] Antonio M, Gudiol C, Royo-Cebrecos C, Grillo S, Ardanuy C, Carratalà J. Current etiology, clinical features and outcomes of bacteremia in older patients with solid tumors. *J Geriatr Oncol* 2019;10:246–51. <https://doi.org/10.1016/j.jgo.2018.06.011>.
- [28] Himmelsbach V, Knabe M, Ferstl PG, Peiffer K-H, Stratmann JA, Wichelhaus TA, et al. Colonization with multidrug-resistant organisms impairs survival in patients with hepatocellular carcinoma. *J Cancer Res Clin Oncol* 2022;148:1465–72. <https://doi.org/10.1007/s00432-021-03741-0>.
- [29] Jiang A-M, Liu N, Ali Said R, Ren M-D, Gao H, Zheng X-Q, et al. Nosocomial Infections in Gastrointestinal Cancer Patients: Bacterial Profile, Antibiotic Resistance Pattern, and Prognostic Factors. *Cancer Manag Res* 2020;12:4969–79. <https://doi.org/10.2147/CMAR.S258774>.
- [30] Marín M, Gudiol C, Castet F, Oliva M, Peiró I, Royo-Cebrecos C, et al. Bloodstream infection in patients with head and neck cancer: a major challenge in the cetuximab era. *Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex* 2019;21:187–96. <https://doi.org/10.1007/s12094-018-1905-5>.
- [31] Matsutani N, Yoshiya K, Chida M, Sakaguchi H, Kikkawa T, Fukuda H, et al. Postoperative empyema following lung cancer surgery. *Oncotarget* 2018;9:29810–9. <https://doi.org/10.18632/oncotarget.25629>.
- [32] Mei T, Yang X, Yu Y, Tian X, Deng Q, Xu Y, et al. Secondary Infections After Diagnosis of Severe Radiation Pneumonitis (SRP) Among Patients With Non-Small Cell Lung Cancer: Pathogen Distributions, Choice of Empirical Antibiotics, and the Value of Empirical Antifungal Treatment. *Int J Radiat Oncol Biol Phys* 2022;112:179–87. <https://doi.org/10.1016/j.ijrobp.2021.08.022>.
- [33] Royo-Cebrecos C, Gudiol C, García J, Tubau F, Laporte J, Ardanuy C, et al. Characteristics, aetiology, antimicrobial resistance and outcomes of bacteraemic cholangitis in patients with solid tumours: A prospective cohort study. *J Infect* 2017;74:172–8. <https://doi.org/10.1016/j.jinf.2016.10.008>.
- [34] Stratmann JA, Lacko R, Ballo O, Shaid S, Gleiber W, Vehreschild MJGT, et al. Colonization with multi-drug-resistant organisms negatively impacts survival in patients with non-small cell lung cancer. *PloS One* 2020;15:e0242544. <https://doi.org/10.1371/journal.pone.0242544>.
- [35] Ramanan P, Cummins NW, Wilhelm MP, Heimbach JK, Dierkhising R, Kremers WK, et al. Epidemiology, risk factors, and outcomes of infections in patients undergoing liver transplantation for hilar cholangiocarcinoma. *Clin Transplant* 2017;31. <https://doi.org/10.1111/ctr.13023>.

- [36] Sugimachi K, Iguchi T, Mano Y, Morita M, Mori M, Toh Y. Significance of bile culture surveillance for postoperative management of pancreatoduodenectomy. *World J Surg Oncol* 2019;17:232. <https://doi.org/10.1186/s12957-019-1773-7>.
- [37] Perdikouri EIA, Arvaniti K, Lathyris D, Apostolidou Kiouti F, Siskou E, Haidich AB, et al. Infections Due to Multidrug-Resistant Bacteria in Oncological Patients: Insights from a Five-Year Epidemiological and Clinical Analysis. *Microorganisms* 2019;7:E277. <https://doi.org/10.3390/microorganisms7090277>.
- [38] Golzarri MF, Silva-Sánchez J, Cornejo-Juárez P, Barrios-Camacho H, Chora-Hernández LD, Velázquez-Acosta C, et al. Colonization by fecal extended-spectrum β -lactamase-producing Enterobacteriaceae and surgical site infections in patients with cancer undergoing gastrointestinal and gynecologic surgery. *Am J Infect Control* 2019;47:916–21. <https://doi.org/10.1016/j.ajic.2019.01.020>.
- [39] Liu NW, Shatagopam K, Monn MF, Kaimakliotis HZ, Cary C, Boris RS, et al. Risk for *Clostridium difficile* infection after radical cystectomy for bladder cancer: Analysis of a contemporary series. *Urol Oncol* 2015;33:503.e17-22. <https://doi.org/10.1016/j.urolonc.2015.07.007>.
- [40] Rodríguez Garzotto A, Mérida García A, Muñoz Unceta N, Galera Lopez MM, Orellana-Miguel MÁ, Díaz-García CV, et al. Risk factors associated with *Clostridium difficile* infection in adult oncology patients. *Support Care Cancer Off J Multinatl Assoc Support Care Cancer* 2015;23:1569–77. <https://doi.org/10.1007/s00520-014-2506-7>.
- [41] Zheng Y, Luo Y, Lv Y, Huang C, Sheng Q, Zhao P, et al. *Clostridium difficile* colonization in preoperative colorectal cancer patients. *Oncotarget* 2017;8:11877–86. <https://doi.org/10.18632/oncotarget.14424>.
- [42] Lin S, Melki S, Lisgaris MV, Ahadzadeh EN, Zender CA. Post-operative MRSA infections in head and neck surgery. *Am J Otolaryngol* 2017;38:417–21. <https://doi.org/10.1016/j.amjoto.2017.03.013>.
- [43] Avcı N, Hartavi M, Kaçan T, Bayındır M, Avcı M, Özakin C, et al. Retrospective analysis of the microbiological spectrum of pneumonia in Turkish patients with lung cancer. *Contemp Oncol Poznan Pol* 2016;20:63–6. <https://doi.org/10.5114/wo.2016.58502>.
- [44] Tarapan S, Matangkasombut O, Trachootham D, Sattabanasuk V, Talungchit S, Paemuang W, et al. Oral *Candida* colonization in xerostomic postradiotherapy head and neck cancer patients. *Oral Dis* 2019;25:1798–808. <https://doi.org/10.1111/odi.13151>.
- [45] Ballo O, Tarazzit I, Stratmann J, Reinheimer C, Hogardt M, Wichelhaus TA, et al. Colonization with multidrug resistant organisms determines the clinical course of patients with acute myeloid leukemia undergoing intensive induction chemotherapy. *PLoS One* 2019;14:e0210991. <https://doi.org/10.1371/journal.pone.0210991>.
- [46] Cattaneo C, Zappasodi P, Mancini V, Annaloro C, Pavesi F, Skert C, et al. Emerging resistant bacteria strains in bloodstream infections of acute leukaemia patients: results of a prospective study by the Rete Ematologica Lombarda (Rel). *Ann Hematol* 2016;95:1955–63. <https://doi.org/10.1007/s00277-016-2815-7>.
- [47] Chen S, Lin K, Li Q, Luo X, Xiao M, Chen M, et al. A practical update on the epidemiology and risk factors for the emergence and mortality of bloodstream infections from real-world data of 3014 hematological malignancy patients receiving chemotherapy. *J Cancer* 2021;12:5494–505. <https://doi.org/10.7150/jca.50802>.
- [48] Di Domenico EG, Marchesi F, Cavallo I, Toma L, Sivori F, Papa E, et al. The Impact of Bacterial Biofilms on End-Organ Disease and Mortality in Patients with Hematologic Malignancies Developing a Bloodstream Infection. *Microbiol Spectr* 2021;9:e0055021. <https://doi.org/10.1128/Spectrum.00550-21>.
- [49] Facchin G, Candoni A, Lazzarotto D, Zannier ME, Peghin M, Sozio E, et al. Clinical characteristics and outcome of 125 polymicrobial bloodstream infections in hematological patients: an 11-year epidemiologic survey. *Support Care Cancer Off J Multinatl Assoc Support Care Cancer* 2022;30:2359–66. <https://doi.org/10.1007/s00520-021-06640-9>.

- [50] Garcia-Vidal C, Cardozo-Espinola C, Puerta-Alcalde P, Marco F, Tellez A, Agüero D, et al. Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance. *PLoS One* 2018;13:e0199531. <https://doi.org/10.1371/journal.pone.0199531>.
- [51] Scheich S, Reinheimer C, Brandt C, Wichelhaus TA, Hogardt M, Kempf VAJ, et al. Clinical Impact of Colonization with Multidrug-Resistant Organisms on Outcome after Autologous Stem Cell Transplantation: A Retrospective Single-Center Study. *Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant* 2017;23:1455–62. <https://doi.org/10.1016/j.bbmt.2017.05.016>.
- [52] Seong GM, Lee Y, Hong S-B, Lim C-M, Koh Y, Huh JW. Prognosis of Acute Respiratory Distress Syndrome in Patients With Hematological Malignancies. *J Intensive Care Med* 2020;35:364–70. <https://doi.org/10.1177/0885066617753566>.
- [53] Waszczuk-Gajda A, Drozd-Sokołowska J, Basak GW, Piekarska A, Mensah-Glanowska P, Sadowska-Klasa A, et al. Infectious Complications in Patients With Multiple Myeloma After High-Dose Chemotherapy Followed by Autologous Stem Cell Transplant: Nationwide Study of the Infectious Complications Study Group of the Polish Adult Leukemia Group. *Transplant Proc* 2020;52:2178–85. <https://doi.org/10.1016/j.transproceed.2020.02.068>.
- [54] Kern WV, Roth JA, Bertz H, Götting T, Dettenkofer M, Widmer AF, et al. Contribution of specific pathogens to bloodstream infection mortality in neutropenic patients with hematologic malignancies: Results from a multicentric surveillance cohort study. *Transpl Infect Dis Off J Transplant Soc* 2019;21:e13186. <https://doi.org/10.1111/tid.13186>.
- [55] Mendes FR, da Silva WF, da Costa Bandeira de Melo R, Silveira DRA, Velloso EDRP, Rocha V, et al. Predictive factors associated with induction-related death in acute myeloid leukemia in a resource-constrained setting. *Ann Hematol* 2022;101:147–54. <https://doi.org/10.1007/s00277-021-04687-6>.
- [56] Pugliese N, Salvatore P, Iula DV, Catania MR, Chiurazzi F, Della Pepa R, et al. Ultrasonography-driven combination antibiotic therapy with tigecycline significantly increases survival among patients with neutropenic enterocolitis following cytarabine-containing chemotherapy for the remission induction of acute myeloid leukemia. *Cancer Med* 2017;6:1500–11. <https://doi.org/10.1002/cam4.1063>.
- [57] Calik S, Ari A, Bilgir O, Cetintepe T, Yis R, Sonmez U, et al. The relationship between mortality and microbiological parameters in febrile neutropenic patients with hematological malignancies. *Saudi Med J* 2018;39:878–85. <https://doi.org/10.15537/smj.2018.9.22824>.
- [58] Andria N, Henig O, Kotler O, Domchenko A, Oren I, Zuckerman T, et al. Mortality burden related to infection with carbapenem-resistant Gram-negative bacteria among haematological cancer patients: a retrospective cohort study. *J Antimicrob Chemother* 2015;70:3146–53. <https://doi.org/10.1093/jac/dkv218>.
- [59] Tang Y, Wu X, Cheng Q, Li X. Inappropriate initial antimicrobial therapy for hematological malignancies patients with Gram-negative bloodstream infections. *Infection* 2020;48:109–16. <https://doi.org/10.1007/s15010-019-01370-x>.
- [60] Tang Y, Xu C, Xiao H, Wang L, Cheng Q, Li X. Gram-Negative Bacteria Bloodstream Infections in Patients with Hematological Malignancies - The Impact of Pathogen Type and Patterns of Antibiotic Resistance: A Retrospective Cohort Study. *Infect Drug Resist* 2021;14:3115–24. <https://doi.org/10.2147/IDR.S322812>.
- [61] Shin DH, Shin D-Y, Kang CK, Park S, Park J, Jun KI, et al. Risk factors for and clinical outcomes of carbapenem non-susceptible gram negative bacilli bacteremia in patients with acute myelogenous leukemia. *BMC Infect Dis* 2020;20:404. <https://doi.org/10.1186/s12879-020-05131-2>.
- [62] Scheich S, Weber S, Reinheimer C, Wichelhaus TA, Hogardt M, Kempf VAJ, et al. Bloodstream infections with gram-negative organisms and the impact of multidrug resistance in patients with hematological malignancies. *Ann Hematol* 2018;97:2225–34. <https://doi.org/10.1007/s00277-018-3423-5>.

- [63] Criscuolo M, Marchesi F, Candoni A, Cattaneo C, Nosari A, Veggia B, et al. Fungaemia in haematological malignancies: SEIFEM-2015 survey. *Eur J Clin Invest* 2019;49:e13083. <https://doi.org/10.1111/eci.13083>.
- [64] Satlin MJ, Cohen N, Ma KC, Gedrimaite Z, Soave R, Askin G, et al. Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies. *J Infect* 2016;73:336–45. <https://doi.org/10.1016/j.jinf.2016.07.002>.
- [65] Woerther P-L, Micol J-B, Angebault C, Pasquier F, Pilorge S, Bourhis J-H, et al. Monitoring antibiotic-resistant enterobacteria faecal levels is helpful in predicting antibiotic susceptibility of bacteraemia isolates in patients with haematological malignancies. *J Med Microbiol* 2015;64:676–81. <https://doi.org/10.1099/jmm.0.000078>.
- [66] Liang T, Xu C, Cheng Q, Tang Y, Zeng H, Li X. Epidemiology, Risk Factors, and Clinical Outcomes of Bloodstream Infection due to Extended-Spectrum Beta-Lactamase-Producing *Escherichia coli* and *Klebsiella pneumoniae* in Hematologic Malignancy: A Retrospective Study from Central South China. *Microb Drug Resist* 2021;27:800–8. <https://doi.org/10.1089/mdr.2020.0033>.
- [67] Alrstom A, Alsuliman T, Daher N, Abouharb R. The Impact of Modifying Empirical Antibiotic Therapy Based on Intestinal Colonization Status on Clinical Outcomes of Febrile Neutropenic Patients. *Infect Chemother* 2021;53:63–74. <https://doi.org/10.3947/ic.2020.0111>.
- [68] Jaiswal SR, Gupta S, Kumar RS, Sherawat A, Rajoreya A, Dash SK, et al. Gut Colonization with Carbapenem-resistant Enterobacteriaceae Adversely Impacts the Outcome in Patients with Hematological Malignancies: Results of A Prospective Surveillance Study. *Mediterr J Hematol Infect Dis* 2018;10:e2018025. <https://doi.org/10.4084/MJHID.2018.025>.
- [69] Alonso CD, Braun DA, Patel I, Akbari M, Oh DJ, Jun T, et al. A multicenter, retrospective, case-cohort study of the epidemiology and risk factors for *Clostridium difficile* infection among cord blood transplant recipients. *Transpl Infect Dis Off J Transplant Soc* 2017;19. <https://doi.org/10.1111/tid.12728>.
- [70] Ballo O, Kreisel E-M, Eladly F, Brunnberg U, Stratmann J, Hunyady P, et al. Use of carbapenems and glycopeptides increases risk for *Clostridioides difficile* infections in acute myeloid leukemia patients undergoing intensive induction chemotherapy. *Ann Hematol* 2020;99:2547–53. <https://doi.org/10.1007/s00277-020-04274-1>.
- [71] Ford CD, Lopansri BK, Webb BJ, Coombs J, Gouw L, Asch J, et al. *Clostridioides difficile* colonization and infection in patients with newly diagnosed acute leukemia: Incidence, risk factors, and patient outcomes. *Am J Infect Control* 2019;47:394–9. <https://doi.org/10.1016/j.ajic.2018.09.027>.
- [72] Lavallée C, Labbé A-C, Talbot J-D, Alonso CD, Marr KA, Cohen S, et al. Risk factors for the development of *Clostridium difficile* infection in adult allogeneic hematopoietic stem cell transplant recipients: A single-center study in Québec, Canada. *Transpl Infect Dis Off J Transplant Soc* 2017;19. <https://doi.org/10.1111/tid.12648>.
- [73] Morrisette T, Van Matre AG, Miller MA, Mueller SW, Bajrovic V, Abidi MZ, et al. Oral Vancomycin Prophylaxis as Secondary Prevention Against *Clostridioides difficile* Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population. *Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant* 2019;25:2091–7. <https://doi.org/10.1016/j.bbmt.2019.06.021>.
- [74] Petteys MM, Kachur E, Pillinger KE, He J, Copelan EA, Shahid Z. Antimicrobial de-escalation in adult hematopoietic cell transplantation recipients with febrile neutropenia of unknown origin. *J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract* 2020;26:632–40. <https://doi.org/10.1177/1078155219865303>.
- [75] Przybylski DJ, Reeves DJ. Moxifloxacin versus levofloxacin or ciprofloxacin prophylaxis in acute myeloid leukemia patients receiving chemotherapy. *Support Care Cancer Off J Multinatl Assoc Support Care Cancer* 2017;25:3715–21. <https://doi.org/10.1007/s00520-017-3797-2>.

- [76] Ran-Castillo D, Oluwole A, Abuaisha M, Banks Paulino AR, Alkhatatneh A, Jang J, et al. Risk, Outcomes, and Trends of Clostridium Difficile Infection in Multiple Myeloma Patients from a Nationwide Analysis. *Cureus* 2019;11:e4391. <https://doi.org/10.7759/cureus.4391>.
- [77] Scappaticci GB, Perissinotti AJ, Nagel JL, Bixby DL, Marini BL. Risk factors and impact of Clostridium difficile recurrence on haematology patients. *J Antimicrob Chemother* 2017;72:1488–95. <https://doi.org/10.1093/jac/dkx005>.
- [78] Amberge S, Kramer M, Schröttner P, Heidrich K, Schmelz R, Middeke JM, et al. Clostridium Difficile infections in patients with AML or MDS undergoing allogeneic hematopoietic stem cell transplantation identify high risk for adverse outcome. *Bone Marrow Transplant* 2020;55:367–75. <https://doi.org/10.1038/s41409-019-0678-y>.
- [79] Bhandari S, Pandey RK, Dahal S, Shahreyar M, Dhakal B, Jha P, et al. Risk, Outcomes, and Predictors of Clostridium difficile Infection in Lymphoma: A Nationwide Study. *South Med J* 2018;111:628–33. <https://doi.org/10.14423/SMJ.0000000000000872>.
- [80] Luo R, Greenberg A, Stone CD. Outcomes of Clostridium difficile infection in hospitalized leukemia patients: a nationwide analysis. *Infect Control Hosp Epidemiol* 2015;36:794–801. <https://doi.org/10.1017/ice.2015.54>.
- [81] Selvey LA, Slimings C, Joske DJL, Riley TV. Clostridium difficile Infections amongst Patients with Haematological Malignancies: A Data Linkage Study. *PloS One* 2016;11:e0157839. <https://doi.org/10.1371/journal.pone.0157839>.
- [82] Shargian-Alon L, Gafer-Gvili A, Ben-Zvi H, Wolach O, Yeshurun M, Raanani P, et al. Risk factors for mortality due to Acinetobacter baumannii bacteremia in patients with hematological malignancies - a retrospective study. *Leuk Lymphoma* 2019;60:2787–92. <https://doi.org/10.1080/10428194.2019.1599113>.
- [83] Tofas P, Samarkos M, Piperaki E-T, Kosmidis C, Triantafyllopoulou I-D, Kotsopoulou M, et al. Pseudomonas aeruginosa bacteraemia in patients with hematologic malignancies: risk factors, treatment and outcome. *Diagn Microbiol Infect Dis* 2017;88:335–41. <https://doi.org/10.1016/j.diagmicrobio.2017.05.003>.
- [84] Zhao Y, Lin Q, Liu L, Ma R, Chen J, Shen Y, et al. Risk Factors and Outcomes of Antibiotic-resistant Pseudomonas aeruginosa Bloodstream Infection in Adult Patients With Acute Leukemia. *Clin Infect Dis Off Publ Infect Dis Soc Am* 2020;71:S386–93. <https://doi.org/10.1093/cid/ciaa1522>.
- [85] Aitken SL, Sahasrabhojane PV, Kontoyiannis DP, Savidge TC, Arias CA, Ajami NJ, et al. Alterations of the Oral Microbiome and Cumulative Carbapenem Exposure Are Associated With Stenotrophomonas maltophilia Infection in Patients With Acute Myeloid Leukemia Receiving Chemotherapy. *Clin Infect Dis Off Publ Infect Dis Soc Am* 2021;72:1507–13. <https://doi.org/10.1093/cid/ciaa778>.
- [86] Kim S-H, Cho SY, Kang C-I, Seok H, Huh K, Ha YE, et al. Clinical predictors of Stenotrophomonas maltophilia bacteremia in adult patients with hematologic malignancy. *Ann Hematol* 2018;97:343–50. <https://doi.org/10.1007/s00277-017-3178-4>.
- [87] Cho S-Y, Lee D-G, Choi S-M, Park C, Chun H-S, Park Y-J, et al. Stenotrophomonas maltophilia bloodstream infection in patients with hematologic malignancies: a retrospective study and in vitro activities of antimicrobial combinations. *BMC Infect Dis* 2015;15:69. <https://doi.org/10.1186/s12879-015-0801-7>.
- [88] Kim S-H, Cha MK, Kang C-I, Ko J-H, Huh K, Cho SY, et al. Pathogenic significance of hemorrhagic pneumonia in hematologic malignancy patients with Stenotrophomonas maltophilia bacteremia: clinical and microbiological analysis. *Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol* 2019;38:285–95. <https://doi.org/10.1007/s10096-018-3425-1>.
- [89] Ford CD, Coombs J, Stofer MG, Lopansri BK, Webb BJ, Ostronoff F, et al. Decrease in vancomycin-resistant Enterococcus colonization associated with a reduction in carbapenem use as empiric therapy for febrile neutropenia in patients with acute

- leukemia. *Infect Control Hosp Epidemiol* 2019;40:774–9. <https://doi.org/10.1017/ice.2019.93>.
- [90] Ford CD, Lopansri BK, Haydoura S, Snow G, Dascomb KK, Asch J, et al. Frequency, risk factors, and outcomes of vancomycin-resistant *Enterococcus* colonization and infection in patients with newly diagnosed acute leukemia: different patterns in patients with acute myelogenous and acute lymphoblastic leukemia. *Infect Control Hosp Epidemiol* 2015;36:47–53. <https://doi.org/10.1017/ice.2014.3>.
- [91] Herc ES, Kauffman CA, Marini BL, Perissinotti AJ, Miceli MH. Daptomycin nonsusceptible vancomycin resistant *Enterococcus* bloodstream infections in patients with hematological malignancies: risk factors and outcomes. *Leuk Lymphoma* 2017;58:2852–8. <https://doi.org/10.1080/10428194.2017.1312665>.
- [92] Hefazi M, Damlaj M, Alkhateeb HB, Partain DK, Patel R, Razonable RR, et al. Vancomycin-resistant *Enterococcus* colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. *Transpl Infect Dis Off J Transplant Soc* 2016;18:913–20. <https://doi.org/10.1111/tid.12612>.
- [93] Heisel R, Sutton R, Mascara G, Winger D, Weber D, Lim S, et al. Vancomycin-resistant enterococci in acute myeloid leukemia and myelodysplastic syndrome patients undergoing induction chemotherapy with idarubicin and cytarabine. *Leuk Lymphoma* 2017;58. <https://doi.org/10.1080/10428194.2017.1306645>.
- [94] Klein E-M, Sauer S, Klein S, Tichy D, Benner A, Bertsch U, et al. Antibiotic Prophylaxis or Granulocyte-Colony Stimulating Factor Support in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. *Cancers* 2021;13:3439. <https://doi.org/10.3390/cancers13143439>.
- [95] Kamboj M, Cohen N, Huang Y-T, Kerpelev M, Jakubowski A, Sepkowitz KA, et al. Impact of Empiric Treatment for Vancomycin-Resistant *Enterococcus* in Colonized Patients Early after Allogeneic Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant* 2019;25:594–8. <https://doi.org/10.1016/j.bbmt.2018.11.008>.
- [96] Kirkizlar TA, Akalin H, Kirkizlar O, Ozkalemkas F, Ozkocaman V, Kazak E, et al. Vancomycin-resistant enterococci infection and predisposing factors for infection and mortality in patients with acute leukaemia and febrile neutropenia. *Leuk Res* 2020;99:106463. <https://doi.org/10.1016/j.leukres.2020.106463>.
- [97] Ornstein MC, Mukherjee S, Keng M, Elson P, Tiu RV, Sauntharajah Y, et al. Impact of vancomycin-resistant enterococcal bacteremia on outcome during acute myeloid leukemia induction therapy. *Leuk Lymphoma* 2015;56:2536–42. <https://doi.org/10.3109/10428194.2014.1003557>.
- [98] Papanicolaou GA, Ustun C, Young J-AH, Chen M, Kim S, Woo Ahn K, et al. Bloodstream Infection Due to Vancomycin-resistant *Enterococcus* Is Associated With Increased Mortality After Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome: A Multicenter, Retrospective Cohort Study. *Clin Infect Dis Off Publ Infect Dis Soc Am* 2019;69:1771–9. <https://doi.org/10.1093/cid/ciz031>.
- [99] Zhang P, Wang J, Hu H, Zhang S, Wei J, Yang Q, et al. Clinical Characteristics and Risk Factors for Bloodstream Infection Due to Carbapenem-Resistant *Klebsiella pneumoniae* in Patients with Hematologic Malignancies. *Infect Drug Resist* 2020;13:3233–42. <https://doi.org/10.2147/IDR.S272217>.
- [100] Micozzi A, Gentile G, Santilli S, Minotti C, Capria S, Moleti ML, et al. Reduced mortality from KPC-K.pneumoniae bloodstream infection in high-risk patients with hematological malignancies colonized by KPC-K.pneumoniae. *BMC Infect Dis* 2021;21:1079. <https://doi.org/10.1186/s12879-021-06747-8>.
- [101] Treçarichi EM, Pagano L, Martino B, Candoni A, Di Blasi R, Nadali G, et al. Bloodstream infections caused by *Klebsiella pneumoniae* in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. *Am J Hematol* 2016;91:1076–81. <https://doi.org/10.1002/ajh.24489>.

- [102] Micozzi A, Gentile G, Minotti C, Cartoni C, Capria S, Ballarò D, et al. Carbapenem-resistant *Klebsiella pneumoniae* in high-risk haematological patients: factors favouring spread, risk factors and outcome of carbapenem-resistant *Klebsiella pneumoniae* bacteremias. *BMC Infect Dis* 2017;17:203. <https://doi.org/10.1186/s12879-017-2297-9>.
- [103] Benanti GE, Brown ART, Shigle TL, Tarrand JJ, Bhatti MM, McDanel PM, et al. Carbapenem versus Cefepime or Piperacillin-Tazobactam for Empiric Treatment of Bacteremia Due to Extended-Spectrum- β -Lactamase-Producing *Escherichia coli* in Patients with Hematologic Malignancy. *Antimicrob Agents Chemother* 2019;63:e01813-18. <https://doi.org/10.1128/AAC.01813-18>.
- [104] Treçarichi EM, Giuliano G, Cattaneo C, Ballanti S, Criscuolo M, Candoni A, et al. Bloodstream infections caused by *Escherichia coli* in onco-haematological patients: Risk factors and mortality in an Italian prospective survey. *PLoS One* 2019;14:e0224465. <https://doi.org/10.1371/journal.pone.0224465>.
- [105] Heo ST, Tataara AM, Jiménez-Ortigosa C, Jiang Y, Lewis RE, Tarrand J, et al. Changes in In Vitro Susceptibility Patterns of *Aspergillus* to Triazoles and Correlation With Aspergillosis Outcome in a Tertiary Care Cancer Center, 1999-2015. *Clin Infect Dis Off Publ Infect Dis Soc Am* 2017;65:216–25. <https://doi.org/10.1093/cid/cix297>.
- [106] Magira E, Jiang Y, Economides M, Tarrand J, Kontoyiannis D. Mixed mold pulmonary infections in haematological cancer patients in a tertiary care cancer centre. *Mycoses* 2018;61. <https://doi.org/10.1111/myc.12830>.
- [107] Wang E, Farmakiotis D, Yang D, McCue DA, Kantarjian HM, Kontoyiannis DP, et al. The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality. *J Antimicrob Chemother* 2015;70:2362–8. <https://doi.org/10.1093/jac/dkv087>.
- [108] Folan SA, Marx KR, Tverdek FP, Raad I, Mulanovich VE, Tarrand JJ, et al. Clinical Outcomes Associated With Linezolid Resistance in Leukemia Patients With Linezolid-Resistant *Staphylococcus epidermidis* Bacteremia. *Open Forum Infect Dis* 2018;5:ofy167. <https://doi.org/10.1093/ofid/ofy167>.
- [109] Valcarcel B, De-la-Cruz-Ku G, Malpica L, Enriquez-Vera D. Clinical features and outcome of *Aeromonas sobria* bacteremia in pediatric and adult patients with hematologic malignancies: A single-center retrospective study in Peru. *PLoS One* 2021;16:e0255910. <https://doi.org/10.1371/journal.pone.0255910>.
- [110] Bastug A, Kayaaslan B, Kazancioglu S, But A, Aslaner H, Akinci E, et al. Emergence of multidrug resistant isolates and mortality predictors in patients with solid tumors or hematological malignancies. *J Infect Dev Ctries* 2015;9:1100–7. <https://doi.org/10.3855/jidc.6805>.
- [111] Chiang H-Y, Wu T-H, Hsu C-Y, Chao W-C. Association Between Positive Cultures During Admission and 1-Year Mortality in Patients With Cancer Receiving Perioperative Intensive Care. *Cancer Control J Moffitt Cancer Cent* 2018;25:1073274818794162. <https://doi.org/10.1177/1073274818794162>.
- [112] Freire MP, Pierrotti LC, Zerati AE, Benites L, da Motta-Leal Filho JM, Ibrahim KY, et al. Role of Lock Therapy for Long-Term Catheter-Related Infections by Multidrug-Resistant Bacteria. *Antimicrob Agents Chemother* 2018;62:e00569-18. <https://doi.org/10.1128/AAC.00569-18>.
- [113] Islas-Muñoz B, Volkow-Fernández P, Ibanes-Gutiérrez C, Villamar-Ramírez A, Vilar-Compte D, Cornejo-Juárez P. Bloodstream infections in cancer patients. Risk factors associated with mortality. *Int J Infect Dis IJID Off Publ Int Soc Infect Dis* 2018;71:59–64. <https://doi.org/10.1016/j.ijid.2018.03.022>.
- [114] Joncour A, Puyade M, Michaud A, Tourani J-M, Cazenave-Roblot F, Rammaert B. Is current initial empirical antibiotherapy appropriate to treat bloodstream infections in short-duration chemo-induced febrile neutropenia? *Support Care Cancer Off J Multinatl Assoc Support Care Cancer* 2020;28:3103–11. <https://doi.org/10.1007/s00520-019-05113-4>.

- [115] Marín M, Gudiol C, Ardanuy C, Garcia-Vidal C, Jimenez L, Domingo-Domenech E, et al. Factors influencing mortality in neutropenic patients with haematologic malignancies or solid tumours with bloodstream infection. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis* 2015;21:583–90. <https://doi.org/10.1016/j.cmi.2015.01.029>.
- [116] Martinez-Nadal G, Puerta-Alcalde P, Gudiol C, Cardozo C, Albasanz-Puig A, Marco F, et al. Inappropriate Empirical Antibiotic Treatment in High-risk Neutropenic Patients With Bacteremia in the Era of Multidrug Resistance. *Clin Infect Dis Off Publ Infect Dis Soc Am* 2020;70:1068–74. <https://doi.org/10.1093/cid/ciz319>.
- [117] Royo-Cebrecos C, Gudiol C, Ardanuy C, Pomares H, Calvo M, Carratalà J. A fresh look at polymicrobial bloodstream infection in cancer patients. *PloS One* 2017;12:e0185768. <https://doi.org/10.1371/journal.pone.0185768>.
- [118] Jiang A-M, Shi X, Liu N, Gao H, Ren M-D, Zheng X-Q, et al. Nosocomial infections due to multidrug-resistant bacteria in cancer patients: a six-year retrospective study of an oncology Center in Western China. *BMC Infect Dis* 2020;20:452. <https://doi.org/10.1186/s12879-020-05181-6>.
- [119] Puerta-Alcalde P, Ambrosioni J, Chumbita M, Hernández-Meneses M, Garcia-Pouton N, Cardozo C, et al. Clinical Characteristics and Outcome of Bloodstream Infections in HIV-Infected Patients with Cancer and Febrile Neutropenia: A Case-Control Study. *Infect Dis Ther* 2021;10:955–70. <https://doi.org/10.1007/s40121-021-00445-3>.
- [120] Costa P de O, Atta EH, Silva ARA da. Infection with multidrug-resistant gram-negative bacteria in a pediatric oncology intensive care unit: risk factors and outcomes. *J Pediatr (Rio J)* 2015;91:435–41. <https://doi.org/10.1016/j.jpeds.2014.11.009>.
- [121] Marini BL, Hough SM, Gregg KS, Abu-Seir H, Nagel JL. Risk factors for piperacillin/tazobactam-resistant Gram-negative infection in hematology/oncology patients with febrile neutropenia. *Support Care Cancer Off J Multinatl Assoc Support Care Cancer* 2015;23:2287–95. <https://doi.org/10.1007/s00520-014-2582-8>.
- [122] Tossey JC, El Boghdady Z, Reed EE, Dela-Pena J, Coe K, Williams SN, et al. Oral fluoroquinolones for definitive treatment of gram-negative bacteremia in cancer patients. *Support Care Cancer Off J Multinatl Assoc Support Care Cancer* 2021;29:5057–64. <https://doi.org/10.1007/s00520-021-06063-6>.
- [123] Kim Y, Jung S, Kang J, Ryoo S, Sohn S, Seo D, et al. Risk factors for extended-spectrum beta-lactamase-producing Enterobacteriaceae infection causing septic shock in cancer patients with chemotherapy-induced febrile neutropenia. *Intern Emerg Med* 2019;14. <https://doi.org/10.1007/s11739-018-02015-x>.
- [124] Refay SM, Ahmed EH, Abd ELzاهر AR, Morsy AM, Yasser MM, Mahmoud AM. Risk of Drug Resistance and Repeated Infection with *Klebsiella pneumoniae* and *Escherichia coli* in Intensive Care Unit Cancer Patients. *Comb Chem High Throughput Screen* 2022;25:324–34. <https://doi.org/10.2174/1386207324666210121104724>.
- [125] Medboua-Benbalagh C, Touati A, Kermas R, Gharout-Sait A, Brasme L, Mezhoud H, et al. Fecal Carriage of Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae Strains Is Associated with Worse Outcome in Patients Hospitalized in the Pediatric Oncology Unit of Beni-Messous Hospital in Algiers, Algeria. *Microb Drug Resist Larchmt N* 2017;23:757–63. <https://doi.org/10.1089/mdr.2016.0153>.
- [126] Ben-Chetrit E, Eldaim MA, Bar-Meir M, Dodin M, Katz DE. Associated factors and clinical outcomes of bloodstream infection due to extended-spectrum β -lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* during febrile neutropenia. *Int J Antimicrob Agents* 2019;53:423–8. <https://doi.org/10.1016/j.ijantimicag.2018.12.003>.
- [127] Ceken S, Iskender G, Gedik H, Duygu F, Mert D, Kaya AH, et al. Risk factors for bloodstream infections due to extended-spectrum β -lactamase producing Enterobacteriaceae in cancer patients. *J Infect Dev Ctries* 2018;12:265–72. <https://doi.org/10.3855/jidc.9720>.
- [128] Martínez-Valencia A, Gómez Martínez B, Montañez Ayala A, García K, Sánchez Pedraza SP, Jiménez Cetina L, et al. Development and validation of a scoring system

- for predicting cancer patients at risk of extended-spectrum b-lactamase-producing Enterobacteriaceae infections. *BMC Infect Dis* 2020;20. <https://doi.org/10.1186/s12879-020-05280-4>.
- [129] Abu-Sbeih H, Choi K, Tran CN, Wang X, Lum P, Shuttlesworth G, et al. Recurrent *Clostridium difficile* infection is associated with treatment failure and prolonged illness in cancer patients. *Eur J Gastroenterol Hepatol* 2019;31:128–34. <https://doi.org/10.1097/MEG.0000000000001288>.
- [130] Chang GY, Dembry LM, Banach DB. Epidemiology of *Clostridium difficile* infection in hospitalized oncology patients. *Am J Infect Control* 2016;44:1408–10. <https://doi.org/10.1016/j.ajic.2016.04.210>.
- [131] Daida A, Yoshihara H, Inai I, Hasegawa D, Ishida Y, Urayama KY, et al. Risk Factors for Hospital-acquired *Clostridium difficile* Infection Among Pediatric Patients With Cancer. *J Pediatr Hematol Oncol* 2017;39:e167–72. <https://doi.org/10.1097/MPH.0000000000000742>.
- [132] Fuereder T, Koni D, Gleiss A, Kundi M, Makristathis A, Zielinski C, et al. Risk factors for *Clostridium difficile* infection in hemato-oncological patients: A case control study in 144 patients. *Sci Rep* 2016;6:31498. <https://doi.org/10.1038/srep31498>.
- [133] Hebbard AIT, Slavin MA, Reed C, Trubiano JA, Teh BW, Haeusler GM, et al. Risks factors and outcomes of *Clostridium difficile* infection in patients with cancer: a matched case-control study. *Support Care Cancer Off J Multinatl Assoc Support Care Cancer* 2017;25:1923–30. <https://doi.org/10.1007/s00520-017-3606-y>.
- [134] Shoaee P, Shojaei H, Khorvash F, M Hosseini S, Ataei B, Esfandiari Z, et al. *Clostridium difficile* infection in cancer patients with hospital acquired diarrhea at the teaching hospitals in Iran: Multilocus sequence typing analysis (MLST) and Antimicrobial resistance pattern. *Ann Ig Med Prev E Comunita* 2019;31:365–73. <https://doi.org/10.7416/ai.2019.2298>.
- [135] Willis DN, Huang FS, Elward AM, Wu N, Magnusen B, Dubberke ER, et al. *Clostridioides difficile* Infections in Inpatient Pediatric Oncology Patients: A Cohort Study Evaluating Risk Factors and Associated Outcomes. *J Pediatr Infect Dis Soc* 2021;10:302–8. <https://doi.org/10.1093/jpids/piaa090>.
- [136] Willis ZI, Nicholson MR, Esbenshade AJ, Xu M, Slaughter JC, Friedman DL, et al. Intensity of Therapy for Malignancy and Risk for Recurrent and Complicated *Clostridium difficile* Infection in Children. *J Pediatr Hematol Oncol* 2019;41:442–7. <https://doi.org/10.1097/MPH.0000000000001411>.
- [137] Gupta A, Tariq R, Frank RD, Jean GW, Beg MS, Pardi DS, et al. Trends in the Incidence and Outcomes of Hospitalized Cancer Patients With *Clostridium difficile* Infection: A Nationwide Analysis. *J Natl Compr Cancer Netw JNCCN* 2017;15:466–72. <https://doi.org/10.6004/jnccn.2017.0046>.
- [138] Delgado A, Reveles IA, Cabello FT, Reveles KR. Poorer outcomes among cancer patients diagnosed with *Clostridium difficile* infections in United States community hospitals. *BMC Infect Dis* 2017;17:448. <https://doi.org/10.1186/s12879-017-2553-z>.
- [139] Siddiqui NS, Khan Z, Khan MS, Khan Z, Haq KF, Solanki SD, et al. Trends in Incidence and Outcomes of *Clostridium difficile* Colitis in Hospitalized Patients of Febrile Neutropenia: A Nationwide Analysis. *J Clin Gastroenterol* 2019;53:e376–81. <https://doi.org/10.1097/MCG.0000000000001171>.
- [140] Fan L, Wang Z, Wang Q, Xiong Z, Xu Y, Li D, et al. Increasing rates of *Acinetobacter baumannii* infection and resistance in an oncology department. *J Cancer Res Ther* 2018;14:68–71. https://doi.org/10.4103/jcrt.JCRT_737_17.
- [141] Cornejo-Juárez P, Cevallos MA, Castro-Jaimes S, Castillo-Ramírez S, Velázquez-Acosta C, Martínez-Oliva D, et al. High mortality in an outbreak of multidrug resistant *Acinetobacter baumannii* infection introduced to an oncological hospital by a patient transferred from a general hospital. *PloS One* 2020;15:e0234684. <https://doi.org/10.1371/journal.pone.0234684>.
- [142] Freire MP, de Oliveira Garcia D, Garcia CP, Campagnari Bueno MF, Camargo CH, Kono Magri ASG, et al. Bloodstream infection caused by extensively drug-resistant

- Acinetobacter baumannii in cancer patients: high mortality associated with delayed treatment rather than with the degree of neutropenia. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis* 2016;22:352–8. <https://doi.org/10.1016/j.cmi.2015.12.010>.
- [143] Namendys-Silva SA, Correa-García P, García-Guillén FJ, González-Herrera MO, Pérez-Alonso A, Texcocano-Becerra J, et al. Outcomes of critically ill cancer patients with *Acinetobacter baumannii* infection. *World J Crit Care Med* 2015;4:258–64. <https://doi.org/10.5492/wjccm.v4.i3.258>.
- [144] Gudiol C, Albasanz-Puig A, Laporte-Amargós J, Pallarès N, Mussetti A, Ruiz-Camps I, et al. Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2020;64:e02494-19. <https://doi.org/10.1128/AAC.02494-19>.
- [145] Smith ZR, Tajchman SK, Dee BM, Bruno JJ, Qiao W, Tverdek FP. Development of a combination antibiogram for *Pseudomonas aeruginosa* bacteremia in an oncology population. *J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract* 2016;22:409–15. <https://doi.org/10.1177/1078155215586081>.
- [146] Velázquez-Acosta C, Zarco-Márquez S, Jiménez-Andrade MC, Volkow-Fernández P, Cornejo-Juárez P. *Stenotrophomonas maltophilia* bacteremia and pneumonia at a tertiary-care oncology center: a review of 16 years. *Support Care Cancer Off J Multinatl Assoc Support Care Cancer* 2018;26:1953–60. <https://doi.org/10.1007/s00520-017-4032-x>.
- [147] Aktürk H, Sütçü M, Somer A, Karaman S, Acar M, Ünüvar A, et al. Results of Four-Year Rectal Vancomycin-Resistant Enterococci Surveillance in a Pediatric Hematology-Oncology Ward: From Colonization to Infection. *Turk J Haematol Off J Turk Soc Haematol* 2016;33. <https://doi.org/10.4274/tjh.2015.0368>.
- [148] Akhtar N, Sultan F, Nizamuddin S, Zafar W. Risk factors and clinical outcomes for vancomycin-resistant enterococcus bacteraemia in hospitalised cancer patients in Pakistan: A case-control study. *JPMA J Pak Med Assoc* 2016;66:829–36.
- [149] Di Domenico EG, Cavallo I, Sivori F, Marchesi F, Prignano G, Pimpinelli F, et al. Biofilm Production by Carbapenem-Resistant *Klebsiella pneumoniae* Significantly Increases the Risk of Death in Oncological Patients. *Front Cell Infect Microbiol* 2020;10:561741. <https://doi.org/10.3389/fcimb.2020.561741>.
- [150] Freire MP, Pierrotti LC, Filho HHC, Ibrahim KY, Magri ASGK, Bonazzi PR, et al. Infection with *Klebsiella pneumoniae* carbapenemase (KPC)-producing *Klebsiella pneumoniae* in cancer patients. *Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol* 2015;34:277–86. <https://doi.org/10.1007/s10096-014-2233-5>.
- [151] Nham E, Huh K, Cho SY, Chung DR, Peck KR, Lee NY, et al. Characteristics and Clinical Outcomes of Extended-Spectrum beta-lactamase-producing *Klebsiella pneumoniae* Bacteremia in Cancer Patients. *Infect Chemother* 2020;52:59–69. <https://doi.org/10.3947/ic.2020.52.1.59>.
- [152] Bello-Chavolla OY, Bahena-Lopez JP, Garciadiego-Fosass P, Volkow P, Garcia-Horton A, Velazquez-Acosta C, et al. Bloodstream infection caused by *S. aureus* in patients with cancer: a 10-year longitudinal single-center study. *Support Care Cancer Off J Multinatl Assoc Support Care Cancer* 2018;26:4057–65. <https://doi.org/10.1007/s00520-018-4275-1>.
- [153] Khanzada MJ, Zianab I, Samreen A. A RESEARCH STUDY ON BACTERAEEMIA PRODUCED THROUGH *ESCHERICHIA COLI* IN TUMOR PATIENTS AT THE SPECIFIC CENTER IN OUR COUNTRY. *INDO Am J Pharm Sci* 2019;06:5367–72. <https://doi.org/10.5281/zenodo.2593737>.
- [154] Zhang Q, Zhang W, Li Z, Bai C, Li D, Zheng S, et al. Bacteraemia due to AmpC β -lactamase-producing *Escherichia coli* in hospitalized cancer patients: risk factors, antibiotic therapy, and outcomes. *Diagn Microbiol Infect Dis* 2017;88:247–51. <https://doi.org/10.1016/j.diagmicrobio.2017.04.006>.

- [155] Parveen A, Sultan F, Raza A, Zafar W, Nizamuddin S, Mahboob A, et al. Bacteraemia caused by *Escherichia coli* in cancer patients at a specialist center in Pakistan. *JPMA J Pak Med Assoc* 2015;65:1271–6.
- [156] Zhang Q, Gao H-Y, Li D, Li Z, Qi S-S, Zheng S, et al. Clinical outcome of *Escherichia coli* bloodstream infection in cancer patients with/without biofilm formation: a single-center retrospective study. *Infect Drug Resist* 2019;12:359–71. <https://doi.org/10.2147/IDR.S192072>.
- [157] Farmakiotis D, Kyvernitakis A, Tarrand JJ, Kontoyiannis DP. Early initiation of appropriate treatment is associated with increased survival in cancer patients with *Candida glabrata* fungaemia: a potential benefit from infectious disease consultation. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis* 2015;21:79–86. <https://doi.org/10.1016/j.cmi.2014.07.006>.
- [158] Jung DS, Farmakiotis D, Jiang Y, Tarrand JJ, Kontoyiannis DP. Uncommon *Candida* Species Fungemia among Cancer Patients, Houston, Texas, USA. *Emerg Infect Dis* 2015;21:1942–50. <https://doi.org/10.3201/eid2111.150404>.
- [159] Le A, Farmakiotis D, Tarrand JJ, Kontoyiannis DP. Initial Treatment of Cancer Patients with Fluconazole-Susceptible Dose-Dependent *Candida glabrata* Fungemia: Better Outcome with an Echinocandin or Polyene Compared to an Azole? *Antimicrob Agents Chemother* 2017;61:e00631-17. <https://doi.org/10.1128/AAC.00631-17>.
- [160] Paixao de Sousa da Silva AM, de Moraes-Pinto MI, Teofilo Pignati L, Barbosa Teixeira B, Cordeiro Lima AP, Costa Pimentel Germano P, et al. *Candida* spp bloodstream infections in a Latin American Pediatric Oncology Reference Center: Epidemiology and associated factors. *Mycoses* 2020;63:812–22. <https://doi.org/10.1111/myc.13106>.
- [161] Puig-Asensio M, Ruiz-Camps I, Fernández-Ruiz M, Aguado JM, Muñoz P, Valerio M, et al. Epidemiology and outcome of candidaemia in patients with oncological and haematological malignancies: results from a population-based surveillance in Spain. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis* 2015;21:491.e1-10. <https://doi.org/10.1016/j.cmi.2014.12.027>.
- [162] Raza A, Zafar W, Mahboob A, Nizamuddin S, Rashid N, Sultan F. Clinical features and outcomes of Candidaemia in cancer patients: Results from Pakistan. *JPMA J Pak Med Assoc* 2016;66:584–9.
- [163] Sun M, Chen C, Xiao W, Chang Y, Liu C, Xu Q. Increase in *Candida Parapsilosis* Candidemia in Cancer Patients. *Mediterr J Hematol Infect Dis* 2019;11:e2019012. <https://doi.org/10.4084/MJHID.2019.012>.
- [164] Ko J-H, Kang C-I, Lee WJ, Huh K, Yoo JR, Kim K, et al. Clinical features and risk factors for development of *Bacillus* bacteremia among adult patients with cancer: a case-control study. *Support Care Cancer Off J Multinatl Assoc Support Care Cancer* 2015;23:377–84. <https://doi.org/10.1007/s00520-014-2382-1>.
- [165] Fontana NS, Ibrahim KY, Bonazzi PR, Rossi F, Almeida SCG, Tengan FM, et al. Fluoroquinolone treatment as a protective factor for 10-day mortality in *Streptococcus pneumoniae* bacteremia in cancer patients. *Sci Rep* 2021;11:3699. <https://doi.org/10.1038/s41598-021-81415-0>.
- [166] Altman DG. Systematic reviews of evaluations of prognostic variables. *BMJ* 2001;323:224–8. <https://doi.org/10.1136/bmj.323.7306.224>.
- [167] Alevizakos M, Gaitanidis A, Andreatos N, Arunachalam K, Flokas ME, Mylonakis E. Bloodstream infections due to extended-spectrum β -lactamase-producing Enterobacteriaceae among patients with malignancy: a systematic review and meta-analysis. *Int J Antimicrob Agents* 2017;50:657–63. <https://doi.org/10.1016/j.ijantimicag.2017.07.003>.
- [168] Alevizakos M, Gaitanidis A, Nasioudis D, Tori K, Flokas ME, Mylonakis E. Colonization With Vancomycin-Resistant Enterococci and Risk for Bloodstream Infection Among Patients With Malignancy: A Systematic Review and Meta-Analysis. *Open Forum Infect Dis* 2017;4:ofw246. <https://doi.org/10.1093/ofid/ofw246>.

- [169] Li Z, Zhuang H, Wang G, Wang H, Dong Y. Prevalence, predictors, and mortality of bloodstream infections due to methicillin-resistant *Staphylococcus aureus* in patients with malignancy: systemic review and meta-analysis. *BMC Infect Dis* 2021;21:74. <https://doi.org/10.1186/s12879-021-05763-y>.
- [170] Montassier E, Batard E, Gastinne T, Potel G, de La Cochetière MF. Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. *Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol* 2013;32:841–50. <https://doi.org/10.1007/s10096-013-1819-7>.
- [171] Choeyprasert W, Hongeng S, Anurathapan U, Pakakasama S. Bacteremia during neutropenic episodes in children undergoing hematopoietic stem cell transplantation with ciprofloxacin and penicillin prophylaxis. *Int J Hematol* 2017;105:213–20. <https://doi.org/10.1007/s12185-016-2113-0>.
- [172] Kaveh M, Bazargani A, Ramzi M, Sedigh Ebrahim-Saraie H, Heidari H. Colonization Rate and Risk Factors of Vancomycin-Resistant Enterococci among Patients Received Hematopoietic Stem Cell Transplantation in Shiraz, Southern Iran. *Int J Organ Transplant Med* 2016;7:197–205.
- [173] Fentie A, Wondimeneh Y, Balcha A, Amsalu A, Adankie BT. Bacterial profile, antibiotic resistance pattern and associated factors among cancer patients at University of Gondar Hospital, Northwest Ethiopia. *Infect Drug Resist* 2018;11:2169–78. <https://doi.org/10.2147/IDR.S183283>.
- [174] Arega B, Woldeamanuel Y, Adane K, Sherif AA, Asrat D. Microbial spectrum and drug-resistance profile of isolates causing bloodstream infections in febrile cancer patients at a referral hospital in Addis Ababa, Ethiopia. *Infect Drug Resist* 2018;11:1511–9. <https://doi.org/10.2147/IDR.S168867>.
- [175] Ali AA, Alabden SSZ, Zaman NA. Prevalence of some Gram-Negative Bacteria and Adenovirus in Breast Cancer Patients in Kirkuk City. *Int J Pharm Qual Assur* 2020;11:224–7. <https://doi.org/10.25258/ijpqa.11.2.5>.
- [176] Lochan H, Moodley C, Rip D, Bamford C, Hendricks M, Davidson A, et al. Emergence of vancomycin-resistant Enterococcus at a tertiary paediatric hospital in South Africa. *South Afr Med J Suid-Afr Tydskr Vir Geneeskde* 2016;106:39–43. <https://doi.org/10.7196/SAMJ.2016.v106i6.10858>.
- [177] Bender R, Lange S. Adjusting for multiple testing--when and how? *J Clin Epidemiol* 2001;54:343–9. [https://doi.org/10.1016/s0895-4356\(00\)00314-0](https://doi.org/10.1016/s0895-4356(00)00314-0).
- [178] Greenland S, Mansournia MA, Altman DG. Sparse data bias: a problem hiding in plain sight. *BMJ* 2016;352:i1981. <https://doi.org/10.1136/bmj.i1981>.
- [179] Ioannidis JPA. Why Most Discovered True Associations Are Inflated. *Epidemiology* 2008;19:640–8. <https://doi.org/10.1097/EDE.0b013e31818131e7>.
- [180] Hayden JA, Côté P, Bombardier C. Evaluation of the Quality of Prognosis Studies in Systematic Reviews. *Ann Intern Med* 2006;144:427–37. <https://doi.org/10.7326/0003-4819-144-6-200603210-00010>.
- [181] Wolff RF, Moons KGM, Riley RD, Whiting PF, Westwood M, Collins GS, et al. PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies. *Ann Intern Med* 2019;170:51–8. <https://doi.org/10.7326/M18-1376>.
- [182] Smith G. Step away from stepwise. *J Big Data* 2018;5:32. <https://doi.org/10.1186/s40537-018-0143-6>.
- [183] Sun G-W, Shook TL, Kay GL. Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. *J Clin Epidemiol* 1996;49:907–16. [https://doi.org/10.1016/0895-4356\(96\)00025-X](https://doi.org/10.1016/0895-4356(96)00025-X).
- [184] Hernán MA, Robins JM. *Causal Inference: What If*. Boca Raton: Chapman & Hall/CRC; 2020.

Supplementary material 1

First search

Database: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations, Daily and Versions(R) <1946 to June 21, 2021>

Date: 22.06.21

Hits: 6878

| | | |
|---|---|---------|
| 1 | exp Neoplasms/ | 3485612 |
| 2 | (tumor? or tumour? or cancer? or neoplas* or paraneoplastic or precancer* or cyst? or malignanc* or carcinogenes#s or oncogenes#s or tumorigenes#s or cocarcinogenes#s or metastas#s or metastatic or incidentaloma?).tw,kf. | 3441687 |
| 3 | 1 or 2 | 4533774 |
| 4 | exp Drug Resistance, Microbial/ or exp Drug Resistance, Bacterial/ | 170727 |
| 5 | ((antibacterial or bacterial or bacterium or antibiotic or antimicrobial or microbial or multidrug or multiple drug) adj2 (resistance or resistant)) or antibiotic non-susceptibility or antibiotic nonsusceptibility).tw,kf. | 136901 |
| 6 | 4 or 5 | 254631 |
| 7 | 3 and 6 | 22036 |
| 8 | limit 7 to (danish or english or interlingua or multilingual or norwegian or spanish or swedish) | 20721 |
| 9 | limit 8 to yr="2015 -Current" | 6878 |

Database: Embase <1974 to 2021 June 22>

Date: 23.06.21

Hits: 7314

| | | |
|---|--|---------|
| 1 | exp neoplasm/ | 4730064 |
| 2 | (tumor? or tumour? or cancer? or neoplas* or paraneoplastic or precancer* or cyst? or malignanc* or carcinogenes#s or oncogenes#s or tumorigenes#s or cocarcinogenes#s or metastas#s or metastatic or incidentaloma?).tw,kw. | 4525726 |

| | | |
|----|---|---------|
| 3 | 1 or 2 | 5821589 |
| 4 | exp antibiotic resistance/ | 177653 |
| 5 | ((antibacterial or bacterial or bacterium or antibiotic or antimicrobial or microbial or multidrug or multiple drug) adj2 (resistance or resistant)) or antibiotic non-susceptibility or antibiotic nonsusceptibility).tw,kw. | 167050 |
| 6 | 4 or 5 | 267257 |
| 7 | 3 and 6 | 28672 |
| 8 | limit 7 to (danish or english or norwegian or polyglot or spanish or swedish) | 26746 |
| 9 | limit 8 to yr="2015 -Current" | 9903 |
| 10 | limit 9 to embase | 7314 |

Database: Web of Science (Science Citation Index Expanded (SCI-EXPANDED) --1987-present, Social Sciences Citation Index (SSCI) --1987-present, Arts & Humanities Citation Index (A&HCI) --1987-present, Emerging Sources Citation Index (ESCI) --2015-present)

Date: 24.06.21

Hits: 11,302

| | | |
|---|---|-----------|
| 1 | TS=("tumor\$" or "tumour\$" or "cancer\$" or "neoplas*" or "paraneoplastic" or "precancer*" or "cyst\$" or "malignanc*" or "carcinogenes?s" or "oncogenes?s" or "tumorigenes?s" or "cocarcinogenes?s" or "metastas?s" or "metastatic" or "incidentaloma\$") | 3,746,108 |
| 2 | TS=(((antibacterial" or "bacterial" or "bacterium" or "antibiotic " or "antimicrobial" or "microbial" or "multidrug" or "multiple drug") NEAR/1 ("resistance" or "resistant")) or "antibiotic non-susceptibility" or "antibiotic nonsusceptibility") | 172,855 |
| 3 | (#2 AND #1) AND LANGUAGE: (English OR Danish OR Multiple Languages OR | 11,302 |

| | | |
|--|----------------------------------|--|
| | Norwegian OR Spanish OR Swedish) | |
|--|----------------------------------|--|

Supplementary material 2

Second search

Database: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations, Daily and Versions(R) <1946 to November 18, 2021>

Date: 19.11.21

Hits: 12 478

| | | |
|---|---|---------|
| 1 | exp Neoplasms/ | 3573100 |
| 2 | (tumor? or tumour? or cancer* or neoplas* or paraneoplas* or preneoplas* or precancer* or premalign* or malign* or carcinogenes#s or oncogenes#s or tumorigenes#s or cocarcinogenes#s or metastas#s or metastatic or incidentaloma? or leukemia? or leucemia? or lymphoma? or sarcoma? or carcinoma* or melanoma? or glioma ? or blastoma?).tw,kf. | 3958905 |
| 3 | 1 or 2 | 4744972 |
| 4 | exp Drug Resistance, Microbial/ or exp Drug Resistance, Bacterial/ | 174771 |
| 5 | ((antibacterial or bacterial or bacterium or antibiotic or antifungal or antimicrobial or microbial or multidrug or multiple drug or multiple antibiotics or penicillin or meth#cillin? or met#cillin? or cephalosporin* or cephalosporanic acid? or cefepim? or cefuroxime or cefotaxim? or ceftazidime or ceftriaxon? or cefixime or ceftaroline or carbapenem? or aminoglycoside? or gentam#cin? or amikacin? or fluoroquinolone? or linezolid? or vancomycin? or echinocandin? or azole? or colistin? or colimycin? or polymyxin e or intrinsic* or penicillin or macrolide or tobramycin? or fluconazol? or voricanazole or posaconazole or caspofungin or anidulafungin or micafungin or ciproflo* or ciproxin or levofloxacin or clindamycin? or dalacin or clarithromycin or CLAR or erythromycin or azt?reonam or azactam) adj4 (resistance or resistant or nonsusceptib* or insusceptib* or non-susceptib* or susceptibity)).tw,kf. | 235262 |
| 6 | (piperacillin adj3 tazobactam adj4 resistant).tw,kf. | 202 |
| 7 | beta-Lactamases/ or Methicillin-Resistant Staphylococcus aureus/ or Vancomycin-Resistant Enterococci/ or Vancomycin-Resistant Staphylococcus aureus/ | 40508 |
| 8 | (b*-lactamase? or "ec 3.5.2.6" or beta lactam?hydrolase or cefinase or ESBL or carbapenemase? or biofilm or non-fermenting).tw,kf. | 88504 |
| 9 | Pseudomonas aeruginosa/ or (pseudomonas aeruginosa or "P. aeruginosa").tw,kf. | 74856 |

| | | |
|----|--|--------|
| 10 | Acinetobacter/ or (acinetobacter* or "A. baumannii").tw,kf. | 20486 |
| 11 | Stenotrophomonas Maltophilia/ or ((Stenotrophomonas or Pseudomonas or Xanthomonas) adj malt#philia).tw,kf. | 3477 |
| 12 | Clostridioides difficile/ or ((clostridium or clostridioides) adj difficil*).tw,kf. | 17332 |
| 13 | Enterococcus faecium/ or ((enterococcus or streptococcus) adj faecium).tw,kf. | 7433 |
| 14 | (candida adj1 (non albicans or auris)).tw,kf. | 1779 |
| 15 | Aspergillus fumigatus/ or ((aspergillus or neosartorya) adj fumigat*).tw,kf. | 12302 |
| 16 | or/4-15 | 456787 |
| 17 | 3 and 16 | 35096 |
| 18 | limit 17 to (danish or english or interlingua or multilingual or norwegian or spanish or swedish) | 32942 |
| 19 | limit 18 to yr="2015 -Current" | 12478 |

Database: Embase <1974 to 2021 November 17>

Date: 19.11.21

Hits: 16471

| | | |
|---|--|---------|
| 1 | exp Neoplasm/ | 4853484 |
| 2 | (tumor? or tumour? or cancer* or neoplas* or paraneoplas* or preneoplas* or precancer* or premalign* or malign* or carcinogenes#s or oncogenes#s or tumorigenes#s or cocarcinogenes#s or metastas#s or metastatic or incidentaloma? or leukemia? or leucemia? or lymphoma? or sarcoma? or carcinoma* or melanoma? or glioma ? or blastoma?).tw,kf. | 5177268 |
| 3 | 1 or 2 | 6060075 |
| 4 | exp Antibiotic Resistance/ or Antifungal resistance/ or Antifungal susceptibility/ or Multidrug resistance/ or Extensive Drug Resistance/ or Antifungal susceptibility/ | 229586 |
| 5 | ((antibacterial or bacterial or bacterium or antibiotic or antifungal or antimicrobial or microbial or multidrug or multiple drug or multiple antibiotics or penicillin or meth#cillin? or met#cillin? or cephalosporin* or cephalosporanic acid? or cefepim? or cefuroxime or cefotaxim? or ceftazidime or ceftriaxon? or cefixime or ceftaroline or carbapenem? or | 287384 |

| | | |
|----|--|--------|
| | aminoglycoside? or gentam#cin? or amikacin? or fluoroquinolone? or linezolid? or vancomycin? or echinocandin? or azole? or colistin? or colimycin? or polymyxin e or intrinsic* or penicillin or macrolide or tobramycin? or fluconazol? or voriconazole or posaconazole or caspofungin or anidulafungin or micafungin or ciproflo* or ciproxin or levofloxacin or clindamycin? or dalacin or clarithromycin or CLAR or erythromycin or azt?reonam or azactam) adj4 (resistance or resistant or nonsusceptib* or insusceptib* or non-susceptib* or susceptibility)).tw,kf. | |
| 6 | (piperacillin adj3 tazobactam adj4 resistant).tw,kf. | 334 |
| 7 | beta-Lactamase/ or Extended Spectrum Beta Lactamase/ or Carbapenemase/ or Carbapenemase Producing Enterobacteriaceae/ or Carbapenem resistance/ or Methicillin Resistant Staphylococcus aureus/ or Vancomycin-Resistant Enterococcus/ or Vancomycin Resistant Staphylococcus aureus/ | 85966 |
| 8 | (b*-lactamase? or "ec 3.5.2.6" or beta lactam?hydrolase or cefinase or ESBL or carbapenemase? or biofilm or non-fermenting).tw,kf. | 105594 |
| 9 | Pseudomonas aeruginosa/ or (pseudomonas aeruginosa or "P. aeruginosa").tw,kf. | 122215 |
| 10 | Acinetobacter/ or (acinetobacter* or "A. baumannii").tw,kf. | 29911 |
| 11 | Stenotrophomonas Maltophilia/ or ((Stenotrophomonas or Pseudomonas or Xanthomonas) adj malt#philia).tw,kf. | 7160 |
| 12 | Clostridioides difficile/ or ((clostridium or clostridioides) adj difficil*).tw,kf. | 24295 |
| 13 | Enterococcus faecium/ or ((enterococcus or streptococcus) adj faecium).tw,kf. | 12422 |
| 14 | Candida auris/ or (candida adj1 (non albicans or auris)).tw,kf. | 2531 |
| 15 | Aspergillus fumigatus/ or ((aspergillus or neosartorya) adj fumigat*).tw,kf. | 20302 |
| 16 | or/4-15 | 575608 |
| 17 | 3 and 16 | 57855 |
| 18 | limit 17 to (danish or english or norwegian or polyglot or spanish or swedish) | 54246 |
| 19 | limit 18 to yr="2015 -Current" | 23248 |
| 20 | limit 19 to embase | 16471 |

Database: Web of Science Core Collection: Science Citation Index Expanded (SCI-EXPANDED) -1987-present, Social Sciences Citation Index (SSCI) --1987-present, Arts & Humanities Citation Index (A&HCI) --1987-present, Emerging Sources Citation Index (ESCI) --2015-present

Date: 19.11.21

Hits: 19 369

| | | |
|----|---|---------|
| 14 | (#13) AND LA=(English OR Danish OR Multiple Languages OR Norwegian OR Spanish OR Swedish) | 19,369 |
| 13 | (#12) AND PY=(2015-2021) | 19,528 |
| 12 | #1 and #11 | 46,063 |
| 11 | #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 | 454,205 |
| 10 | TS=(("aspergillus" or "neosartorya") NEAR/0 "fumigat*") | 13,687 |
| 9 | TS=("candida" NEAR/0 ("non albicans" or "auris")) | 1,906 |
| 8 | TS=(("enterococcus" or "streptococcus") NEAR/0 "faecium") | 8,677 |
| 7 | TS=(("clostridium" or "clostridioides") NEAR/0 "difficil*") | 20,940 |
| 6 | TS=(("Stenotrophomonas" or "Pseudomonas" or "Xanthomonas") NEAR/0 "malt?philia") | 4,062 |
| 5 | TS=("acinetobacter*" or "A. baumannii") | 23,475 |
| 4 | TS=("pseudomonas aeruginosa" or "P. aeruginosa") | 88,969 |
| 3 | TS=(("b*-lactamase\$" or "ec 3.5.2.6" or "beta lactam hydrolase" or "beta lactamhydrolase" or "cefinae" or "ESBL" or "carbapenemase\$" or "biofilm" or "non-fermenting") | 118,459 |
| 2 | TS=(("antibacterial" or "bacterial" or "bacterium" or "antibiotic\$" or "antifungal" or "antimicrobial" or "microbial" or "multidrug" or "multiple drug" or "multiple antibiotics" or "penicillin" or "meth?cillin\$" or "met?cillin\$" or "cephalosporin*" or "cephalosporanic acid\$" or "cefepim\$" or "cefuroxime" or "cefotaxim\$" or "ceftazidime" or "ceftriaxon\$" or "cefixime" or "ceftaroline" or "carbapenem\$" or "aminoglycoside\$" or "gentam?cin\$" or "amikacin\$" or "fluoroquinolone\$" or "linezolid\$" or "vancomycin\$" or "echinocandin\$" or "azole\$" or "colistin\$" or "colimycin\$" or "antibacterial" or "bacterial" or "bacterium" or "antibiotic" or "antifungal" or "antimicrobial" or "microbial" or "multidrug" or "multiple drug" or "multiple antibiotics" or "penicillin" or "meth?cillin\$" or "met?cillin\$" or "cephalosporin*" or "cephalosporanic acid\$" or "cefepim\$" or "cefuroxime" or "cefotaxim\$" or "ceftazidime" or "ceftriaxon\$" or "cefixime" or "ceftaroline" or "carbapenem\$" or "aminoglycoside\$" or "gentam?cin\$" or "amikacin\$" or "fluoroquinolone\$" or "linezolid\$" or "vancomycin\$" or "echinocandin\$" or "azole\$" or | 274,926 |

| | | |
|---|--|-----------|
| | <p>"colistin\$" or "colimycin\$" or "polymyxin e" or "intrinsic*" or "penicillin" or "macrolide" or "tobramycin\$" or "fluconazol\$" or "voriconazole" or "posaconazole" or "caspofungin" or "anidulafungin" or "micafungin" or "ciproflo*" or "ciproxin" or "levofloxacin" or "clindamycin\$" or "dalacin" or "clarithromycin" or "CLAR" or "erythromycin" or "aztreonam" or "azactam" or "polymyxin e" or "intrinsic*" or "penicillin" or "macrolide" or "tobramycin\$" or "fluconazol\$" or "voriconazole" or "posaconazole" or "caspofungin" or "anidulafungin" or "micafungin" or "ciproflo*" or "ciproxin" or "levofloxacin" or "clindamycin\$" or "dalacin" or "clarithromycin" or "CLAR" or "erythromycin" or "aztreonam" or "azactam") NEAR/3 ("resistance" or "resistant" or "nonsusceptib*" or "insusceptib*" or "non-susceptib*" or "susceptibility"))</p> | |
| 1 | <p>TS=("tumor\$" or "tumour\$" or "cancer\$" or "neoplas*" or "paraneoplas*" or "preneoplas*" or "precancer*" or "prealign*" or "malign*" or "carcinogenes?s" or "oncogenes?s" or "tumorigenes?s" or "cocarcinogenes?s" or "metastas?s" or "metastatic" or "incidentaloma\$" or "leukemia\$" or "leucemia\$" or "lymphoma\$" or "sarcoma\$" or "carcinoma*" or "melanoma\$" or "glioma\$" or "blastoma\$")</p> | 4,410,329 |

Supplementary material 3

Table S3 - All included articles in the systematic review with an infection/colonisation outcome

| Year | Title | Authors | Number of patients | Number of events in the final (and largest) model | Country/setting | Study aim statement | Patient population | Factors included in the final model | Microbial etiology and resistance | Risk of bias grading (NIH tool) | Bivariable screening/stepwise regression | Events per variable in the final (and largest) model | Number of variables included in the tested/screened/initial model | Number of variables included in the final (and largest) model | Comments |
|------|---|---|--------------------|---|-----------------|---|---|--|-------------------------------------|---------------------------------|--|--|---|---|--|
| 2019 | Recurrent <i>Clostridium difficile</i> infection is associated with treatment failure and prolonged illness in cancer patients | Abu-Sbeih, Choi, Tran et al [129] | 170 | 270 | USA | To describe patient characteristics associated with RCDI, severe CDI disease, and treatment resistant RCDI. | Adult cancer patients who had both NAAT and EIA results positive for <i>C. difficile</i> were identified in our institutional laboratory database from January 2015 to May 2017 | Antibiotic use, Comorbidities, NSAID use, PPI use, Immunosuppressant use, Chemotherapy, Organ transplantation, Gastrointestinal GVHD, Previous hospitalisation, Haematological malignancy, Mean length of CDI treatment, CDI treatment failure, Severe/fulminant CDI disease | <i>Clostridioides difficile</i> | Low | + | 38,6 | 13 | 7 | Authors concluded that the risk factors for RCDI they found in cancer patients were the same as one can otherwise find in non-cancer patients (previous antibiotic use, NSAID, comorbidities, and immunosuppressant use), except for the risk use of chemotherapeutic therapy. |
| 2020 | Alterations of the oral microbiome and cumulative carbapenem exposure are associated with <i>Stenotrophomonas maltophilia</i> infection in patients with acute myeloid leukemia | Aitken, Sahasrabhojane, Kontoyiannis et al [85] | 90 | 8 | USA | To characterize cumulative antibiotic exposure and the relative abundance of <i>S. maltophilia</i> in patients with AML in order to identify patients at increased risk for <i>S. maltophilia</i> infections. | Patients with a new diagnosis of AML who were receiving remission-induction chemotherapy (RIC) between 9/2013 and 8/2015. | Ciprofloxacin, Levofloxacin, Meropenem, <i>S. maltophilia</i> oral abundance | <i>Stenotrophomonas maltophilia</i> | Low | - | 2,0 | 8 | 4 | Authors found that the abundance of <i>S. maltophilia</i> in the oral microbiome, in addition to fluoroquinolone use, is associated with <i>S. maltophilia</i> infection. |

| | | | | | | | | | | | | | | | |
|------|--|----------------------------------|-----|-----|--------|--|--|--|----------------------------------|--------|---|------|----|----|--|
| | receiving chemotherapy | | | | | | | | | | | | | | |
| 2016 | Results of Four-Year Rectal Vancomycin-Resistant Enterococci Surveillance in a Pediatric Hematology-Oncology Ward: From Colonization to Infection | Akturk, Sutcu, Somer et al [147] | 72 | 7 | Turkey | To investigate the clinical impact of vancomycin resistant enterococci (VRE) colonization in patients with hematologic malignancies and associated risk factors | All patients admitted to the paediatric haematology/oncology ward with a documented Vancomycin-resistant enterococci colonisation 48-72 h after admission. | Severe neutropenia (<100/mm ³), Previous bacteremia with another pathogen | Vancomycin-resistant enterococci | Medium | + | 3,5 | 10 | 2 | A brief report investigating the risk factors for progression from vancomycin-resistant enterococci colonisation to infection, which they find is associated with severe neutropenia and previous bacteraemia. |
| 2017 | A multicenter, retrospective, case-cohort study of the epidemiology and risk factors for <i>Clostridium difficile</i> infection among cord blood transplant recipients | Alonso, Braun, Patel et al [69] | 226 | 226 | USA | To retrospectively evaluate the local epidemiology of CDI across three institutions, to describe novel risk-factors for development of CDI in UCBT recipients in the first 100 days after UCBT, and to describe the clinical spectrum of CDI in this population so as to better determine whether infection is linked to adverse secondary clinical outcomes | Adult Umbilical cord blood transplant (UCBT) recipients at the three Boston centres from January 1, 2003 to December 31, 2012 | Age, BMI, Conditioning regimen, Antipseudomonal penicillin, Bacterial infection post- UCBT | <i>Clostridioides difficile</i> | Low | + | 45,2 | 21 | 5 | Authors identified having had a bacterial infection post-transplant as a risk factor of CDI, without considering the treatment of the bacterial infection. |
| 2016 | Retrospective analysis of the microbiological spectrum of pneumonia in Turkish patients with lung cancer | Avcı, Hartavi, Kaçan et al [43] | 119 | 22 | Turkey | To investigate the potential correlates of pneumonia in patients with lung tumours | Patients with lung cancer and pneumonia between 2010 and 2011 | Male sex, Age, Diabetes mellitus, COPD, Histology, Tumour stage, Tumour localisation, Surgical treatment, Pleural effusion, Hospital-acquired pneumonia, Chemotherapy dose modifications, Respiratory failure, Febrile neutropenia, Development of | <i>Aspergillus fumigatus</i> | Medium | - | 1,6 | 14 | 14 | Authors found that febrile neutropenia and pneumonia within the first 10 days of admission may increase the risk of <i>A. fumigatus</i> pneumonia. |

| | | | | | | | | | | | | | | | |
|------|---|-------------------------------------|-----|----|---------|--|---|--|--|--------|---|------|----|---|---|
| | | | | | | | | pneumonia within the first 10 days | | | | | | | |
| 2020 | Use of carbapenems and glycopeptides increases risk for <i>Clostridioides difficile</i> infections in acute myeloid leukemia patients undergoing intensive induction chemotherapy | Ballo, Kreisel, Eladly et al [70] | 415 | 37 | Germany | To analyze the incidence of CDI at the University Hospital Frankfurt and its impact on the clinical course of induction chemotherapy and (b) to identify factors associated with CDI | All patients with AML who underwent intensive induction chemotherapy between 2007 and 2019. | Cumulative glycopeptide exposure | <i>Clostridioides difficile</i> | Low | + | 7,4 | 8 | 5 | Authors found an association between cumulative exposure to some antibiotics and <i>C. difficile</i> infection |
| 2021 | Bacterial bile duct colonization in perihilar cholangiocarcinoma and its clinical significance | Bednarsch, Czigany, Heij et al [22] | 95 | 52 | Germany | To investigate bacterial bile duct colonization in a large European cohort of pCCA patients and determine its impact on the postoperative outcome focusing on abdominal infections | All surgically treated patients with localised pCCA with available information on bile duct colonisation from intraoperative sampling | Portal vein embolization, Susceptibility to applied perioperative antibiotics | 47 species identified, top 5 most common: <i>Enterococcus faecalis</i> , <i>Enterococcus faecium</i> , <i>Enterobacter cloacae</i> , <i>Escherichia coli</i> , <i>Kebsiella pneumoniae</i> | Medium | + | 26,0 | 26 | 2 | Authors found that portal vein embolization and susceptibility to perioperative antibiotics is associated with postoperative abdominal infections after excluding a number of variables |
| 2016 | Epidemiology of <i>Clostridium difficile</i> infection in hospitalized oncology patients | Chang, Dembry, Banach et al [130] | 229 | 77 | USA | To identify demographic and clinical risk factors associated with CDI among oncology inpatients | Adult patients admitted to oncology units, those with <i>C. difficile</i> infection were cases. | Age, Prior history of <i>Clostridioides difficile</i> , Blood transfusion, β -lactam/ β -lactamase inhibitor, Cephalosporin, Metronidazole | <i>Clostridioides difficile</i> | Medium | + | 12,8 | 32 | 6 | Authors found a very strong association between a history of <i>C. difficile</i> infection and current <i>C. difficile</i> infection, in addition to a selection of antibiotics. |
| 2017 | Risk Factors for Hospital-acquired <i>Clostridium difficile</i> Infection Among Pediatric Patients With Cancer | Daida, Yoshihara, Inai et al [131] | 145 | 51 | Japan | To provide a descriptive account of hospital-acquired CDI and its recurrence rate in a general pediatrics ward, as well as to identify major risk factors for this infection in the hospital setting | Paediatric patients with cancer admitted to the hospital between July 2003 and September 2012, CDI cases matched to controls | Age, Male (vs. female), Same ward, Duration of neutropenia | <i>Clostridioides difficile</i> | Low | + | 10,2 | 9 | 5 | Antibiotics use is omitted from the final model due to collinearity with duration of neutropenia, which is associated with an increased odds of CDI |

| | | | | | | | | | | | | | | | |
|------|---|---|------|----|--------|--|--|--|--|--------|---|------|----|---|---|
| 2015 | Infection with multidrug-resistant gram-negative bacteria in a pediatric oncology intensive care unit: risk factors and outcomes | de Oliveira Costa, Atta, da Silva [120] | 76 | 47 | Brazil | To evaluate the risk factors and outcomes associated with MDR-GNB infections in children with cancer and/or hematologic diseases | Infection episodes related to GNB that occurred between January 1, 2009 and December 31, 2012 in PICU patients, aged between 0 months and 18 years, who were hospitalised for more than 24 h in a tertiary oncology public hospital. | Healthcare-associated infection, Hematologic diseases, Length of neutropenia ≥ 3 days, Length of ICU stay > 3 days, Previous antibiotic therapy | Multidrug-resistant Gram-negative bacteria | Medium | + | 9,4 | 14 | 5 | The authors found that there is a higher odds of a MDR-GNB infection compared to a non-MDR-GNB infection if the infection was healthcare-associated and the patient had a haematological cancer |
| 2018 | Increasing rates of <i>Acinetobacter baumannii</i> infection and resistance in an oncology department | Fan, Wang, Wang et al [140] | 6154 | 60 | China | To determine the relationship between <i>A. baumannii</i> infections in patients and antibiotic use as well as other risk factors | Cancer patients with nosocomial infections in a general teaching hospital from January 2010 to December 2015 | Gender, Age, Hematologic malignancy, Radiation, Hospitalisation time, Operation, Prior antibiotic use | <i>Acinetobacter baumannii</i> | Medium | - | 8,6 | 7 | 7 | Authors found that there is an association between prior antibiotic use and <i>A. baumannii</i> infection |
| 2018 | Clinical Outcomes Associated With Linezolid Resistance in Leukemia Patients With Linezolid-Resistant <i>Staphylococcus epidermidis</i> Bacteremia | Folan, Marx, Tverdek et al [108] | 82 | 33 | USA | To test the hypotheses that LRSE bacteremia empirically treated with linezolid would have worse clinical outcomes in comparison with patients infected by linezolid-sensitive strains | All adult leukaemia patients with <i>S. epidermidis</i> bacteremia treated with empiric linezolid between 2012 and 2015. | Linezolid-resistant <i>S. epidermidis</i> , Age, AML, Prior HSCT, Presence of CVC | <i>Staphylococcus epidermidis</i> , linezolid-resistance | Low | + | 8,3 | 12 | 4 | The infection outcome was persistent <i>S. epidermidis</i> bacteraemia, which the authors found was more common in patients that were infected by linezolid-resistant bacteria |
| 2019 | Decrease in vancomycin-resistant Enterococcus colonization associated with a reduction in carbapenem use as empiric therapy for febrile neutropenia in patients with acute leukemia | Ford, Coombs, Stofer et al [89] | 342 | 79 | USA | The authors report the results of [changing empirical antibiotics] on the incidence of hospital acquired VRE colonization. They also investigated the effects on BSI rates, the gastrointestinal (GI) microbiome, dominant VRE | Patients admitted with newly diagnosed acute myelogenous leukaemia (AML), acute lymphoblastic leukaemia (ALL), biphenotypic leukaemia (BPL), or chronic myelogenous leukaemia in blast phase (CML-BP) | Age, Days of empiric antibiotics, LOS, Cycling vs carbapenem period, Days of carbapenem, Days of cefepime or piperacillin/tazobactam | Vancomycin-resistant enterococci | Low | - | 13,2 | 6 | 6 | The infection outcome is VRE colonisation. The authors found that after the hospital changed policies to use less carbapenems, the VRE colonisation rates declined. |

| | | | | | | | | | | | | | | | |
|------|---|-------------------------------------|-----|-----|---------|--|--|---|----------------------------------|--------|---|------|----|----|---|
| | | | | | | strains on the unit, and patient outcomes | between September 2011 and August 2017 | | | | | | | | |
| 2015 | Frequency, Risk Factors, and Outcomes of Vancomycin-Resistant Enterococcus Colonization and Infection in Patients with Newly Diagnosed Acute Leukemia: Different Patterns in Patients with Acute Myelogenous and Acute Lymphoblastic Leukemia | Ford, Lopansri, Haydoura et al [90] | 214 | 15 | USA | To describe the frequency of, risk factors for, and outcomes associated with VRE colonization and BSI in patients admitted with newly diagnosed acute leukemia | Patients with newly diagnosed acute leukaemia between 2006 and 2012 | Severe neutropenia, Number of stools/day | Vancomycin-resistant enterococci | Low | + | 7,5 | 7 | 2 | Data extracted from the model with bloodstream infection as the infection outcome. Authors find that such infections are associated with prolonged neutropenia and diarrhoea. |
| 2018 | <i>Clostridioides difficile</i> colonization and infection in patients with newly diagnosed acute leukemia: Incidence, risk factors, and patient outcomes | Ford, Lopansri, Webb et al [71] | 509 | 31 | USA | The authors describe a single-center experience with a large consecutive population of patients admitted with newly diagnosed AL | Patients with AL admitted between 2006 and 2017 | Age, Gender female, Diabetes, Hospitalisation prior 2 mo, Antibiotics prior 3 mo, Karnofsky performance Status, Admit serum albumin, Severe neutropenia, Antibiotics (no.), Antibiotics (d) | <i>Clostridioides difficile</i> | Low | - | 3,1 | 10 | 10 | CDI during hospitalisation was found in 31 patients - more often in those who had recently been hospitalised or had recently been put on antibiotics |
| 2016 | Risk factors for <i>Clostridium difficile</i> infection in hemato-oncological patients: A case control study in 144 patients | Fuereder, Koni, Gleiss et al [132] | 288 | 144 | Austria | To to investigate risk factors for CDI in a large cohort of hemato-oncological patients with microbiologically confirmed CDI | Patients that had a histologically or cytologically confirmed hemato-oncological disease diagnosed between 1st January 2004 and 31st December 2014. Cases were patients that had received chemotherapy during the course of their disease and suffered from CDI positive diarrhoea, controls were those with | Intervall chemotherapy to diarrhoea, Antibiotic therapy within 30 days | <i>Clostridioides difficile</i> | Medium | - | 72,0 | 2 | 2 | The authors found that chemotherapy is not associated with CDI positive diarrhoea, but that antimicrobial therapy is. |

| | | | | | | | | | | | | | | | |
|------|---|--|------|-----|----------------------------|---|--|--|--|-----|-----------------------------------|------|----|---|--|
| | | | | | | | CDI negative diarrhoea. | | | | | | | | |
| 2017 | Consequences of Increases in Antibiotic Resistance Pattern on Outcome of Pancreatic Resection for Cancer | Gianotti, Tamini, Gavazzi et al [23] | 517 | 99 | Italy | To explore the potential correlation between the occurrence of multidrug-susceptible, multidrug-resistant, extensively drug-resistant, and pan-drug-resistant bacterial infections developing during the postoperative course and the rate of non-infectious complications occurring after the onset of infection | Adult patients who underwent elective pancreatic resections for cancer from January 1, 2013 to December 31, 2015, with an available sample of biological fluid. | Type of operation (pancreatoduodenectomy vs. others), Operation time, Estimated blood loss, Preoperative biliary stenting (yes vs. no) | Several bacteria, tested for resistance towards several antibiotics | Low | - | 24,8 | 4 | 4 | The authors found that there is an association between preoperative biliary stenting and multidrug or extensively drug resistant infectious complications |
| 2019 | Colonization by fecal extended-spectrum beta-lactamase-producing <i>Enterobacteriaceae</i> and surgical site infections in patients with cancer undergoing gastrointestinal and gynecologic surgery | Golzari, Silva-Sanchez, Cornejo-Juarez et al [38] | 171 | 25 | Mexico | To describe the prevalence of ESBL-PE fecal carriage in cancer patients prior to surgery (at time of admission) and during their hospital stay, and whether carriers have a major risk of infectious complications | Adult patients, with gynaecological or gastrointestinal malignancies, who were admitted to the hospital for elective abdominal and pelvic surgical procedures from September 2014 to December 2015 | ESBL-PE. Adjusted for the following confounders: age, sex, albumin, and type of malignancy. | Extended-spectrum beta-lactamase-producing <i>Enterobacteriaceae</i> | Low | + (with fixed set of confounders) | 3,6 | 13 | 7 | The risk ratio of several infectious outcomes in carriage ESBL-producing <i>Enterobacteriaceae</i> vs non-carriers are modelled, after adjusting for confounders. The authors found that the risk of surgical site infection and blood stream infection is increased by such carriage, but not pneumonia and urinary tract infection. |
| 2020 | Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to <i>Pseudomonas aeruginosa</i> | Gudiol, Albasanz-Puig, Laporte-Amargos et al [144] | 1217 | 309 | 34 centres in 12 countries | To assess the rate and evolution of multidrug resistance among <i>P. aeruginosa</i> isolates causing BSI in neutropenic cancer patients over recent years and to develop a clinical prediction model to estimate the probability of | Adult neutropenic onco haematological patients diagnosed with at least one episode of <i>P. aeruginosa</i> BSI from 1 January 2006 to 31 May 2018. | Prior piperacillin-tazobactam therapy (within 1 mo), Prior fluoroquinolone prophylaxis (within 1 mo), Urinary catheter, Prior antipseudomonal carbapenem therapy (within 1 mo), Haematological disease | <i>Pseudomonas aeruginosa</i> , multidrug resistant | Low | - | 51,5 | 32 | 6 | The authors constructed a clinical prediction model to predict resistance in <i>P. aeruginosa</i> bloodstream infections in onco haematological patients, achieving an area under the curve of 0.72 (0.63, 0.80) in internal validation. A risk score calculator of this model is available on https://ubidi.shinyapps.io |

| | | | | | | | | | | | | | | | |
|------|---|---|-----|----|----------|---|--|--|--|--------|---|-----|----|----|---|
| | syndrome patients undergoing induction chemotherapy with idarubicin and cytarabine | | | | | cohort of AML and MDS patients undergoing intensive induction chemotherapy in our institution | cytarabine and idarubicin for newly diagnosed AML or MDS from January 2012 to December 2015 | | | | | | | | |
| 2017 | Changes in In Vitro Susceptibility Patterns of <i>Aspergillus</i> to Triazoles and Correlation With Aspergillosis Outcome in a Tertiary Care Cancer Center, 1999–2015 | Heo, Tatara, Jimenez-Ortigosa et al [105] | 107 | 19 | USA | To determine if any changes in susceptibility were species-, triazole-, and/or host-dependent, and their clinical implications | A case-control study of patients with haematological malignancy comparing azole-resistant strains is nested within a cohort of all <i>Aspergillus</i> species clinical isolates recovered from respiratory sources in patients treated at a cancer centre between January 1999 and December 2015 | Asian race, Culture specimen–BAL fluid, Previous azole exposure history | Four <i>Aspergillus</i> species (<i>fumigatus</i> , <i>flavus</i> , <i>terreus</i> , <i>niger</i>), azole-resistance | Low | + | 6,3 | 58 | 3 | The authors concluded that there are three independent risk factors of invasive pulmonary aspergillosis caused by <i>Aspergilli</i> with a non-wild type azole MIC - asian race, bronchoalveolar lavage fluid culture and a history of azole exposure. There is also a univariate analysis of mortality in the article. |
| 2017 | Daptomycin nonsusceptible vancomycin resistant <i>Enterococcus</i> bloodstream infections in patients with hematological malignancies: risk factors and outcomes | Herc, Kauffman, Marini et al [91] | 60 | 20 | USA | An increase in bloodstream infections due to daptomycin non susceptible VRE among patients in the Hematology and HCT Units, prompted the authors to identify risk factors, assess treatment strategies and characterize outcomes in these populations | Adult patients treated on an inpatient haematology service from January 2011 to December 2015 with a haematological malignancy and a blood culture positive for an enterococcus species. | Congestive heart failure, Typhilitis, Gastrointestinal bleeding, Daptomycin, Cefepime received within 90 days, Cumulative Daptomycin days within 90 days, Cumulative Fluoroquinolone days within 90 days, Prior enterococcal infection, Hospital LOS prior to positive culture., Stage of malignancy, Number induction chemotherapy regimens, Clofarabine within 30 days | <i>Enterococcus</i> , vancomycin and daptomycin resistance | Medium | + | 1,4 | 46 | 14 | The authors found that the only risk factor associated with a daptomycin-resistant VRE infection is daptomycin exposure within 90 days |
| 2019 | A RESEARCH STUDY ON BACTERAEMIA | Khonzada, Zianab, Samreen | 229 | 99 | Pakistan | To examine anti-microbial vulnerability | Cancer patients with <i>E. coli</i> bacteremia from | Man sex, Age fewer than 19 years, Haematological | <i>Escherichia coli</i> , multidrug-resistant | High | - | 7,1 | 14 | 14 | The authors find that multidrug-resistant <i>E. coli</i> bacteraemia was |

| | | | | | | | | | | | | | | | |
|------|---|-----------------------------|-----|-----|-------------|---|---|--|---|--------|---|------|----|---|--|
| | PRODUCED THROUGH ESCHERICHIA COLI IN TUMOR PATIENTS AT THE SPECIFIC CENTER IN OUR COUNTRY | [153] | | | | designs of <i>E. coli</i> bacteremia amongst tumor patients, also to measure danger issues also consequences of MDR <i>E. coli</i> bacteremia | October 2014 to September 2015 | distortion, Hospitalization inside 1 month before contagion, ICU admission, Carlson score, Dominant intravenous tube use, Previous chemotherapy inside 1 month, Previous surgery inside 1 month, Preceding fallout inside 1 month, ANC less than 110 cells/mm ³ , Usage of quinolones inside 95 days of catalogue sample, Usage of third group cephalosporins inside 95 days of index sample, Usage of Piperacilin/Tazobactam within 95 days of index sampling, Usage of carbapenems inside 95 days of index sample | | | | | | | associated with young age, central venous catheter, and piperacillin/tazobactam exposure within 95 days of infection |
| 2018 | Clinical predictors of <i>Stenotrophomonas maltophilia</i> bacteremia in adult patients with hematologic malignancy | Kim, Cho, Kang et al [86] | 236 | 118 | South Korea | To identify clinical predictors of <i>S. maltophilia</i> bacteremia in adult patients with hematologic malignancy compared with other GNB | Cases were <i>S. maltophilia</i> bacteremia in adult patients with hematologic malignancy. Controls were other Gram-negative (<i>Escherichia coli</i> , <i>Klebsiella</i> species, <i>Acinetobacter</i> species, <i>Pseudomonas</i> species, and Enterobacter species) bacteraemias. | Polymicrobial infection, Previous <i>S. maltophilia</i> isolation, Breakthrough infection during carbapenem therapy, No. of previous antibiotic use ≥ 3 , Previous TMP/SMX use | <i>Stenotrophomonas maltophilia</i> | Medium | + | 23,6 | 18 | 5 | The authors concluded that all independent variables included in the final multivariable model were associated with <i>S. maltophilia</i> bacteraemia. |
| 2019 | Risk factors for extended spectrum beta lactamase | Kim, Jung, Kang et al [123] | 179 | 32 | South Korea | To identify risk factors suggestive of ESBL-PE | Adult (≥ 18 years) patients with chemotherapy. | Profound neutropenia | Enterobacteriaceae, extended-spectrum beta- | Low | - | 6,4 | 5 | 5 | After adjustment, the authors found that only profound neutropenia was associated with |

| | | | | | | | | | | | | | | | | |
|------|--|------------------------------------|-----|----|-------------|--|--|--|--|--------|---|------|----|---|--|---|
| | producing Enterobacteriaceae infection causing septic shock in cancer patients with chemotherapy induced febrile neutropenia | | | | | infection in septic shock patients with chemotherapy-induced FN to guide appropriate antibiotic therapy. | induced febrile neutropenia admitted to an emergency department with septic shock | | lactamase | | | | | | | ESBL-PE infection |
| 2021 | Antibiotic Prophylaxis or Granulocyte-Colony Stimulating Factor Support in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation | Klein, Sauer, Klein et al [94] | 298 | 25 | Germany | To compare antibiotic prophylaxis with ciprofloxacin or cotrimoxazole versus G-CSF support, with respect to blood count recovery, infectious complications, and emerging MDR bacteria in patients with MM, undergoing HDT/ASCT | Multiple myeloma inpatients who received high-dose therapy with melphalan followed by autologous stem cell transplantation at a hospital between March 2016 and July 2011 | Antibiotic prophylaxis (vs. G-CSF support), No prophylaxis (vs. G-CSF support), Age (per ten years), ASCT at relapse (vs. first-line treatment), \geq VGPR before ASCT (vs. \leq PR), Stem cell amount ≥ 2.5 * (vs. < 2.5) | Enterococcus faecium, vancomycin-resistant | Medium | - | 4,2 | 6 | 6 | | The article includes analyses of several microbes, but the assessed model investigates the association between the listed risk factors and VRE detection. Authors concluded that Granulocyte-Colony Stimulating Factor instead of antibiotic prophylaxis is associated with a fewer detected VRE cases. |
| 2015 | Clinical features and risk factors for development of Bacillus bacteremia among adult patients with cancer: a case-control study | Ko, Kang, Lee et al [164] | 258 | 86 | South Korea | To evaluate the risk factors related to the development of Bacillus bacteremia and its prognosis in cancer patients | Cases were adult patients with cancer who were diagnosed with Bacillus bacteremia during the period of January 1995 through December 2012. Controls were patients with bacteraemia due to other pathogens. | Hospital stay of longer than 14 days, History of HSCT, Presence of a CVC, Hematologic malignancy, Diarrhoea at presentation, Prior use of extended-spectrum cephalosporin, Prior use of glycopeptides | <i>Bacillus spp.</i> | Low | - | 9,6 | 9 | 9 | | The authors found that in addition to a central venous catheter, the use of cephalosporins within a month of admission was associated with Bacillus bacteraemia |
| 2016 | Risk factors for the development of <i>Clostridium difficile</i> infection in adult allogeneic hematopoietic stem cell transplant recipients: A single-center study in Québec, | Lavallee, Labbe, Talbot et al [72] | 188 | 65 | Canada | To describe the risk factors associated with CDI during the first year following allo-HSCT, including those specifically | Adults allo-HSCT recipients. Cases were CDI positive, controls were CDI negative. | Mucositis, CMV reactivation, Herpesviridae reactivation other than CMV, Antibiotic use within 30 days before transplantation (No antibiotic, Any antibiotic except TMP-SMX, TMP-SMX) | <i>Clostridioides difficile</i> | Low | + | 13,0 | 30 | 5 | | The authors concluded that reactivation of CMV and other Herpesviridae was associated with CDI. There is also a multivariable model stratified on the time of CDI positivity, which shows that high-risk antibiotics were associated with CDI late in the treatment. |

| | | | | | | | | | | | | | | | |
|------|---|----------------------------------|-----|----|-------------|---|---|---|--|--------|---|---------------|---------------|---------------|---|
| | Canada | | | | | associated with early and late CDI | | | | | | | | | |
| 2015 | Risk factors for acquisition of multidrug-resistant bacteria in patients with anastomotic leakage after colorectal cancer surgery | Lee, Ryu, Chung et al [24] | 143 | 46 | South Korea | To identify independent risk factors for the acquisition of MDR pathogens at the time of diagnosis of anastomotic leakage after colorectal cancer surgery. We also evaluated risk factors for MDR bacterial acquisition in the early phase of leakage to improve early antibiotic therapy after diagnosis of leakage. We compared the outcomes of patients with MDR pathogens to patients without MDR pathogens | Patients with colorectal cancer that underwent surgery and had anastomotic leakage and a subsequent positive blood or intra abdominal fluid culture from January 2009 to April 2013 | Diabetes mellitus, The total length of antibiotic administration for more than 5 days before diagnosis of anastomosis site leakage. Adjustment variables indeterminate. | Several bacteria and fungi, tested for resistance towards several antimicrobials | Medium | + | Indeterminate | Indeterminate | Indeterminate | The authors found that compared to non-MDR pathogens, diabetes mellitus and the total length of antibiotic administration for more than 5 days before diagnosis of anastomosis site leakage were associated with acquisition of a MDR pathogen. |
| 2017 | Post-operative MRSA infections in head and neck surgery | Lin, Melki, Lisgaris et al [42] | 113 | 24 | USA | To identify patients with MRSA SSIs Following any head and neck procedure | Patients who were >18 years of age and underwent major head and/or neck surgery between January 1, 2008 and January 1, 2014, and were found to have a documented surgical site infection during their postoperative hospitalisation | Indeterminate | <i>Staphylococcus aureus</i> , methicillin-resistance | Medium | - | Indeterminate | Indeterminate | Indeterminate | The authors describe a multivariable model in the methods chapter, but we were unable to locate a regression table. Nonetheless, the authors conclude that hospital exposure prior to the procedure, a history of chemotherapy, or immunosuppression were risk factors for developing a MRSA SSI. |
| 2015 | Risk for <i>Clostridium difficile</i> infection after radical cystectomy for bladder cancer. | Liu, Shatagopam, Monn et al [39] | 552 | 49 | USA | To determine the incidence of CDI in a contemporary cohort undergoing RC at a high-volume tertiary | Patients undergoing radical cystectomy between January 2010 and December 2013 for | Diversion type (Ileal conduit, Indiana pouch, Orthotopic neobladder), Preoperative haemoglobin, | <i>Clostridioides difficile</i> | Low | + | 8,2 | 22 | 6 | The authors found that chronic antacid therapy and long duration of antibiotic exposure in the perioperative setting were associated with a |

| | | | | | | | | | | | | | | | |
|------|---|---------------------------------------|-----|----|-----|--|--|--|---|--------|---------------------------------|----------------|----|----------------|---|
| | Analysis of a contemporary series | | | | | referral center and to identify the perioperative risk factors for development CDI in patients undergoing RC. | bladder cancer | Preoperative antacid use, Days of antibiotics received (1 day or less, 2-7 days, Greater than 7 days) | | | | | | | <i>C. difficile</i> infection in these patients |
| 2018 | Mixed mold pulmonary infections in haematological cancer patients in a tertiary care cancer centre | Magira, Jiang, Economides et al [106] | 54 | 27 | USA | To evaluate the incidence, clinical and mycological characteristics, risk factors, and outcome of patients with haematological cancer who developed MMPIs. | Cases were adult (>18 years old) patients with haematological malignancy who had proven or probable pulmonary infection with >1 mould grown concurrently in sputum or bronchoalveolar lavage (BAL) cultures, controls were patients with haematological cancer (from the same time period) with IPA caused by <i>Aspergillus fumigatus</i> . | Significant use of corticosteroids, culture from sputum specimens | Mixed moulds, <i>Aspergillus fumigatus</i> | Medium | + | Indeterminable | 29 | Indeterminable | We were unable to locate a printed regression table, but the authors concluded that there is an association between use of corticosteroids and sputum samples, and mixed moulds instead of <i>A. fumigatus</i> infection |
| 2015 | Risk factors for piperacillin/tazobactam-resistant Gram-negative infection in hematology/oncology patients with febrile neutropenia | Marini, Hough, Gregg et al [121] | 171 | 25 | USA | To determine risk factors for PTZ-resistant (PTZ-R) isolates in hematology/oncology patients with FN | Adult haematology/oncology patients with a diagnosis of FN and any culture positive for a Gram-negative rod from November 2007 to November 2013 | Demographic model: Unit ICU, Source of positive culture (Respiratory). Resistance model: History of PTZ-R, Antibiotic use previous 90 days (Antibiotic therapy >14 days), Specific antibiotics previous 90 days (PTZ, Vancomycin), LOS >14 days prior to culture, Healthcare exposures previous 90 days (ICU admission), Transfer from outside hospital, Urinary catheter at culture. Haematology/oncology model: Stage of disease | Gram-negative bacilli, Piperacillin/tazobactam resistance | Medium | + (collinear variables removed) | Indeterminable | 69 | Indeterminable | There are three models - one with demographic variables, one with resistance variables, and one with haematology/oncology-specific variables. A final model with variables from all these models are described and the area under the curve of this model is reported, but a regression table is not printed. The authors concluded that prolonged antibiotic use and critical illness increase the risk of piperacillin/tazobactam resistance. |

| | | | | | | | | | | | | | | | |
|------|---|--|-----|-----|----------|--|--|---|----------------------------------|-----|---|------|----------------|---|--|
| | | | | | | | | (Hematologic malignancy–newly diagnosed, Hematologic malignancy– continuation/consolidation), Oncology treatment previous 90 days (Rituximab, Clofarabine). | | | | | | | |
| 2020 | Development and validation of a scoring system for predicting cancer patients at risk of extended-spectrum b-lactamase-producing Enterobacteriaceae infections | Martinez-Valencia, Martinez, Ayala et al [128] | 710 | 265 | Colombia | To develop and validate a reliable and easy-to-use clinical scoring system to identify patients with solid or hematologic malignancies with a high risk of ESBL-PE infections at the National Cancer Institute of Colombia | Cancer patients with documented microbiological isolation during hospitalisation at a national cancer institute | Prolonged hospitalisation (≥7 days), Hospitalisation during previous year, Immunosuppressive therapy, Neutropenia, Beta-lactams during the previous month, Invasive devices at the time of culture, Neoplasia in remission, No chemotherapy | <i>Enterobacteriaceae</i> , ESBL | Low | + | 33,1 | 39 | 8 | The authors did develop a clinical prediction model, which is validated in a separate cohort and assessed with an area under the curve. The variable selection in the prediction model is based on the statistical significance of the candidate predictors in a stepwise regression. The authors translated the model into a scoring system, with prolonged hospitalisation and previous hospitalisation the last year as the highest scores. |
| 2019 | Oral Vancomycin Prophylaxis as Secondary Prevention Against <i>Clostridium difficile</i> Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population | Morrisette, Van Matre, Miller et al [73] | 50 | 11 | USA | To evaluate the effectiveness and safety of an oral vancomycin prophylaxis (OVP) protocol for secondary prevention of CDI in a retrospective cohort of adult autologous/allogeneic HSCT recipients and patients with Hematologic Malignancy who did not undergo HSCT with a first CDI episode treated with | Patients aged >18 years with a history of autologous or allogeneic HSCT and patients with HM who did not undergo HSCT, who have been treated for the initial episode of CDI first with planned oral vancomycin monotherapy and must have been receiving a broad-spectrum antibiotic at the time of CDI diagnosis and/or during the course of CDI | Oral vancomycin prophylaxis, Outpatient CDI diagnosis. | <i>Clostridioides difficile</i> | Low | + | 5,5 | Indeterminable | 2 | The infection outcome here is recurrent CDI infection, which the authors found was associated with no oral vancomycin prophylaxis and an inpatient CDI diagnosis. |

| | | | | | | | | | | | | | | | |
|------|---|--|--------|------|-----|--|---|---|---------------------------------|--------|---|-------|----------------|----|--|
| | | | | | | concomitant broad-spectrum antibiotics (BSA) | treatment/prophylaxis. | | | | | | | | |
| 2019 | Antimicrobial de-escalation in adult hematopoietic cell transplantation recipients with febrile neutropenia of unknown origin | Petteys, Kachur, Pillinger et al [74] | 107 | 3 | USA | To evaluate the outcomes associated with early de-escalation of Broad Spectrum Antibiotics prior to hematopoietic recovery in autologous and allogeneic HCT recipients with FN of unknown origin. | Adult HCT recipients with FN at an academic teaching hospital between March 2014 and April 2018. | Early de-escalation vs hematopoietic recovery de-escalation, Gender, Race, Age | <i>Clostridioides difficile</i> | Medium | - | 0,8 | 4 | 4 | The authors did not find that the early de-escalation of broad-spectrum antibiotics was associated with a <i>Clostridioides difficile</i> infection |
| 2017 | Moxifloxacin versus levofloxacin or ciprofloxacin prophylaxis in acute myeloid leukemia patients receiving chemotherapy | Przybylski & Reeves [75] | 141 | 141 | USA | To provide more insight into the use of moxifloxacin as a prophylactic antibiotic in immunocompromised patients with prolonged neutropenia, specifically compared with levofloxacin or ciprofloxacin | Adult patients admitted to the hospital with a diagnosis of AML who received induction or reinduction chemotherapy from January 2008 to June 2015 | Prophylactic antibiotherapy received, treatment antibiotic duration, mucositis, proton pump inhibitor, neutropenic days | <i>Clostridioides difficile</i> | Medium | - | 28,2 | Indeterminable | 5 | Authors found that treatment antibiotic duration was the only statistically significant association with <i>C. difficile</i> infection |
| 2019 | Risk, Outcomes, and Trends of <i>Clostridium Difficile</i> Infection in Multiple Myeloma Patients from a Nationwide Analysis | Ran-Castillo, Oluwole, Abuaisha et al [76] | 114249 | 3549 | USA | To determine the risk of <i>Clostridium difficile</i> infection (CDI) in hospitalization with multiple myeloma (MM), as well as its outcomes and trends, using a nationally representative database | Patients with a diagnosis of MM between 2010 and September 2015 | Year (2010, 2011, 2012, 2013, 2014, 2015), Age categories (18-49, 50-59, 60-69, 70-79, ≥ 80), Race/Ethnicity (White, Black, Hispanic, Others), Female, Obesity, Peripheral vascular disease, Chronic renal disease, Atrial fibrillation, Stem cell transplantation, | <i>Clostridioides difficile</i> | Medium | - | 177,5 | 20 | 20 | The authors balanced multiple myeloma patients with non-multiple myeloma using propensity scores, then modelled the risk of CDI and of mortality given CDI. The unadjusted OR for mortality is also reported. They found several risk factors for CDI, e.g. neutropenia. |

| | | | | | | | | | | | | | | | |
|------|---|--|-----|----|-------|---|--|--|---|------------|---|-----|---|---|---|
| | | | | | | | | Neutropenia, Chemotherapy, Inflammatory bowel disease, Congestive heart failure, Hypertension, Chronic liver failure, Elixhauser score (0, 1-3, \geq 4), Hospital bed size (Small, Medium, Large), Hospital teaching status (Rural, Urban non-teaching, Urban teaching), Expected primary payer (Medicare, Medicaid, Private, Others), Median household income in quartile (1st, 2nd, 3rd, 4th). | | | | | | | |
| 2021 | Risk of Drug Resistance and Repeated Infection with <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i> in Intensive Care Unit Cancer Patients | Refay, Ahmed, ELzaher et al [124] | 107 | 38 | Egypt | To identify predictors of repeat infections of <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> and drug resistance in cancer patients admitted to the intensive care unit (ICU) in Upper Egypt | Cancer patients who were treated at either the Paediatric Oncology or the Medical Oncology ICU with an initial infection or repeated infection with either <i>K. pneumoniae</i> or <i>E. coli</i> from February 2017 to May 2018 | Age at diagnosis, Type of Malignancy, Type of Organism, Total prior Hospital Stay, Total Prior Admission in ICU, Prior Mechanical Ventilation, Prior Urinary Catheterization, Peripheral or Central CVP Line, Infection | <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i> , tested for resistance towards several antibiotics | Low | - | 4,8 | 9 | 8 | The infection outcome is drug resistance in the previous infection. A ROC curve is printed to show predictive accuracy. The authors conclude that restricting unnecessary antibiotic prescriptions is important to prevent the emergence of multidrug- resistance in these infections |
| 2015 | Risk factors associated with <i>Clostridium difficile</i> infection in adult oncology patients | Rodriguez Garzotto, Merida Garcia, Munoz Unceta et al [40] | 225 | 39 | Spain | To better ascertain the incidence, susceptibility, and risk factors for CDI in cancer patients receiving chemotherapy at our hospital | Hospitalised cancer patient with diarrhoea between January 2009 through April 2013 | Gastrointestinal cancer, Breast cancer, Lung cancer, Age (>65), Antibiotic exposure, Corticosteroid use, PP inhibitor use | <i>Clostridioides difficile</i> | Mediu m | - | 9,8 | 4 | 4 | The authors stratified three tables based on cancer types and include 4 previously identified risk factors. They concluded that antibiotic exposure was associated with CDI |

| | | | | | | | | | | | | | | | | |
|------|---|---|-----|----|------|---|--|--|---|--------|---|------|----|---|---|-----------|
| | | | | | | | | | | | | | | | | infection |
| 2016 | Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies | Satlin, Cohen, Ma et al [64] | 301 | 43 | USA | To determine the prevalence, risk factors, treatments, and outcomes of bloodstream infections (BSIs) due to carbapenem-resistant Enterobacteriaceae (CRE) in adult neutropenic patients with hematologic malignancies | Cases were adult neutropenic patients with hematological malignancies with carbapenem-resistant Enterobacteriaceae bacteraemias. Primary control group was patients with bacteraemias caused by pathogens other than carbapenem-resistant Gram-negative bacteria, and the secondary control group was patients with carbapenem-susceptible Gram-negative bacteria. | b-lactam/b-lactamase inhibitor within previous 30 days, Carbapenem within previous 30 days, Receiving TMP-SMX at BSI onset, Receiving glucocorticoids at BSI onset, Prior CRE at any site within the previous 90 days, ICU stay within previous 30 days, Receiving cephalosporin at BSI onset, Receiving fluoroquinolone at BSI onset, Renal disease | Enterobacteriaceae, carbapenem-resistance | Medium | + | 4,8 | 81 | 9 | The infection outcome here was bacteraemia. The authors find that previous CRE infection and antibiotic exposure was associated with CRE bacteraemia | |
| 2017 | Risk factors and impact of Clostridium difficile recurrence on haematology patients | Scappaticci, Perissinotti, Nagel et al [77] | 100 | 41 | USA | To identify risk factors for recurrent CDI (rCDI) and to determine the impact of rCDI on adult patients with a haematological malignancy | Adult (age >18 years) patients with an active haematological malignancy and CDI from June 2010 to December 2014 | Demographic and traditional model: Severe CDI, salvage lymphoma. Longitudinal model: Hospitalised (days), Antibiotic exposure (ceftriaxone, fluoroquinolones, piperacillin/tazobactam, other (daptomycin), other (vancomycin IV), number of antibiotic exposures), Haematological risk factors (neutropenia (days), chemotherapy exposure, decitabine, CHOP, salvage lymphoma) | Clostridioides difficile | Medium | + | 20,5 | 40 | 2 | The infection outcome is recurring CDI, and there is one model containing demographical and traditional risk factors, and one containing longitudinal risk factors. Data are extracted from the "traditional" model. The authors found that exposure to a number of antibiotics were associated with recurrent CDI. | |
| 2019 | Clostridium difficile infection in cancer patients with hospital acquired diarrhea | Shoaei, Shojaei, Khorvash et al [134] | 67 | 19 | Iran | To investigate the phenotype and genotype characterization of Clostridium | Adult (>18 years old) cancer patients with presence of hospital-acquired | Chronic renal diseases, Gastroenteritis diseases, Previous surgery | Clostridioides difficile | Low | + | 6,3 | 14 | 3 | The authors found that patients with gastrointestinal diseases had an association with lower CDI incidence | |

| | | | | | | | | | | | | | | | |
|------|--|---------------------------------------|-----|----|-------|--|---|--|--|--------|---|------|----|---|--|
| | at the teaching hospitals in Iran: Multilocus sequence typing analysis (MLST) and Antimicrobial resistance pattern | | | | | <i>difficile</i> isolates among cancer patients with hospital-acquired diarrhea in 4 teaching hospitals in Isfahan, Iran | diarrhea at major teaching hospitals between April 2015 and May 2017 | | | | | | | | |
| 2015 | Development of a combination antibiogram for <i>Pseudomonas aeruginosa</i> bacteremia in an oncology population | Smith, Tajchman, Dee et al [145] | 123 | 36 | USA | To develop a combination antibiogram to aid clinicians in the empiric management of presumed <i>P. aeruginosa</i> bacteremia in a cancer population; To identify risk factors for MDR <i>P. aeruginosa</i> bacteremia; To develop a combination antibiogram specifically for ICU and hematologic malignancy patients, and to determine the impact of empiric antibiotics on survival to hospital discharge | <i>Pseudomonas aeruginosa</i> isolates from an oncology population at least 18 years of age who were hospitalised between 1 January 2012 and 31 December 2012 | Prophylactic antibiotic (None, Fluoroquinolone, Cefpodoxime, Amoxicillin-clavulanate), LOS prior to culture (<5 days, >5 days), IV antibiotics in previous 90 day, Hemodialysis in previous 30 day | <i>Pseudomonas aeruginosa</i> , multidrug resistant | Low | + | 9,0 | 5 | 4 | The authors did develop an antibiogram for multidrug-resistant <i>P. aeruginosa</i> . In multivariable analysis they found that such bacteraemias were associated with receiving IV antibiotics 90 days prior |
| 2019 | Significance of bile culture surveillance for postoperative management of pancreatoduodenectomy | Sugimachi, Iguchi, Mano et al [36] | 69 | 43 | Japan | To determine the significance of preoperative surveillance bile culture in perioperative management of pancreatoduodenectomy | Patients who underwent pancreatoduodenectomy at a single institute between the years 2014 and 2017 | Smoking history (+ vs -), Pancreatic texture (soft vs hard) | <i>Enterobacter</i> spp., <i>Staphylococcus aureus</i> , <i>Pseudomonas</i> spp., multidrug-resistance | Medium | + | 21,5 | 8 | 2 | The authors do not find that having a multidrug-resistant bacteria in the preoperative bile culture was associated with surgical site infection following a pancreatoduodenectomy, and as such did not include it in the multivariable model |
| 2019 | Risk factors for recurrent percutaneous nephrostomy catheter-related infections | Szvalb, El Haddad, Rolston et al [25] | 81 | 10 | USA | To identify the risk factors leading to recurrent percutaneous nephrostomy related infections | Patients who had undergone an initial percutaneous nephrostomy catheter placement at the hospital | Concurrent antibiotics use for PCN infection, PCN exchange within 4 days of infection | Several bacteria | Medium | + | 5,0 | 10 | 2 | The infection outcome here is recurrent catheter-related infection. The authors did not find any association between |

| | | | | | | | | | | | | | | | | |
|------|---|---|-----|-----|----------|--|---|---|----------------------------------|--------|---|------|----------------|---|--|--|
| | | | | | | (PCNI) in cancer patient | between July 2014 and February 2017 | | | | | | | | | intrinsically resistant pathogens and recurrent infections |
| 2019 | Oral Candida colonization in xerostomic postradiotherapy head and neck cancer patients | Tarapan, Matangaso mbut, Trachootham et al [44] | 72 | 72 | Thailand | To evaluate oral colonization of Candida species, especially for non-albicans Candida species (NACS), in xerostomic postradiotherapy head and neck cancer patients and risk factors affecting their colonization | Xerostomic post radiotherapy head and neck cancer patients, aged from 30 to 70 years old, who finished radiotherapy for at least 1 month and/or chemotherapy for at least 2 weeks, from 3 Thai institutes | Sex, denture, antifungals, objective dry mouth scores, NACS (?) | <i>C. albicans, Candida spp.</i> | Medium | + | 14,4 | 8 | 5 | Authors found that increased signs of dry mouth, female sex and dental prostheses may promote NACS colonization. | |
| 2021 | <i>Clostridioides difficile</i> Infections in Inpatient Pediatric Oncology Patients: A Cohort Study Evaluating Risk Factors and Associated Outcomes | Willis, Huang, Elward et al [135] | 952 | 109 | USA | To evaluate the prevalence and risk factors for CDI in inpatient pediatric oncology patients and to assess their associated outcomes compared to pediatric oncology patients without CDI at a large academic pediatric hospital. | Paediatric patient with malignancies admitted at St Louis hospital between July 2009 and February 2018 | Model 1 Risk for CDI: Length of stay before CDI, Leukaemia, Lymphoma, Autologous transplant, Allogeneic transplant, CDI exposure, Antibiotic exposure prior to CDI ; Model 2 outcomes linked to CDI : LOS, Chemotherapy delay OR and mean difference. | <i>Clostridioides difficile</i> | Low | + | 15,6 | 16 | 7 | Leukaemia, Lymphoma, autologous transplant, antibiotic exposure, CDI exposure were associated with CDI. The authors also showed that LOS and chemotherapy delay were outcomes linked to CDI. | |
| 2019 | Intensity of Therapy for Malignancy and Risk for Recurrent and Complicated <i>Clostridium difficile</i> Infection in Children | Willis, Nicholson, Esbenshade et al [136] | 122 | 122 | USA | We sought to determine whether intensity of cancer therapy was associated with risk of recurrent CDI and other adverse outcomes | Children >12 months and <18 years of age undergoing treatment for cancer and diagnosed with CDI between August 1st, 2008 and May 1st, 2015 | Level 2 of patient's Intensity of Treatment Rating Scale, level 3 with HCST, level 3 without HCST and the HCST status | <i>Clostridioides difficile</i> | Low | - | 30,5 | Indeterminable | 4 | The authors concluded that they did not manage to find which paediatric oncology patients were at increased risk of CDI recurrence. | |
| 2015 | Monitoring antibiotic-resistant enterobacteria faecal levels is helpful in predicting | Woerther, Micol, Angebault et al [65] | 104 | 16 | France | To determine the predictive values of testing patients for BSBL-RE carriage in forecasting the susceptibility to BSBLs of the | Patient with neutropenia, haematological malignancies and EB-BSI from a probable intestinal origin | Death during neutropenia, non beta lactam antibiotic previous exposure, Carbapenem previous exposure, empirical treatment | Enterobacteria, BSBL or ESBL | Low | + | 2,0 | 20 | 8 | The authors showed that to have a BSBL-RE carriage increased risk to have BSBL-RE in blood cultures. | |

| | | | | | | | | | | | | | | | |
|------|---|-----------------------------|-----|-----|-------|--|--|---|--|--------|-------------------------------------|------|----|----|--|
| | antibiotic susceptibility of bacteraemia isolates in patients with haematological malignancies | | | | | bacterial strains responsible for EB-BSI and the impact of semiquantitative assessment of BSBL-RE carriage levels on the performances of the test | | of EB-BSI with carbapenems, empirical treatment with antibiotics combination, presence of BSBL-Resistant EnteroBacteria, ESBL-EB, and non E. coli EB in blood cultures | | | | | | | |
| 2020 | Clinical Characteristics and Risk Factors for Bloodstream Infection Due to Carbapenem-Resistant <i>Klebsiella pneumoniae</i> (CRKP) in Patients with Hematologic Malignancies | Zhang, Wang, Hu et al [99] | 734 | 22 | China | To examine the clinical characteristics and risk factors for bloodstream infection (BSI) due to carbapenem-resistant <i>Klebsiella pneumoniae</i> (CRKP) in patients with hematologic malignancies | Patients with haematological malignancies, hospitalised for more than 7 days between January 2017 and January 2018 | CRKP rectal colonisation, Severe neutropenia,IMV. | <i>Klebsiella pneumoniae</i> , carbapenem-resistance | Medium | + (+ clinically relevant variables) | 7,3 | 42 | 3 | Variables with p<0.2 in the bivariable screening were included in the multivariable model, but also variables that were "clinically significant", which were not disclosed. The authors concluded that rectal colonisation with carbapenem-resistant <i>K. pneumoniae</i> increases the risk of such bloodstream infections. |
| 2017 | <i>Clostridium difficile</i> colonization in preoperative colorectal cancer patients | Zheng, Luo, Lv et al [41] | 205 | 33 | China | To reveal the rate of <i>C. difficile</i> colonization and its correlation to clinical characteristics in preoperative CRC patients | Consecutive preoperative CRC patients who were scheduled to accept radical cancer resection in a hospital in China, October, 2014 and August, 2015. | Age (<60 vs >60), Site (Colon vs Rectum), Morphology (Ulcerative vs Exophytic), Differentiation (Poor vs Well), T stage (Non-T4 vs T4), N stage (LNM neg. Vs LN pos.), Albumin (<35 vs >35), FBG (>7 vs <7), BMI, Triglyceride, Total cholesterol, HDL, Haemoglobin, OB | <i>Clostridioides difficile</i> | Medium | - | 2,4 | 14 | 14 | The authors concluded that colorectal cancer patients in China with large tumours or metastases were associated with a higher risk of <i>C. difficile</i> infections. |
| 2020 | Distribution, diagnosis, and analysis of related risk factors of multidrug-resistant organism in patients with malignant | Zhou, Yang, Yang et al [26] | 278 | 128 | China | To investigate the distribution characteristics, early diagnosis, and related risk factors of multidrug-resistant organism (MDRO) in patients with malignant | Patients aged >18 years old and <75 years old with malignant tumour, positive bacterial culture during hospitalisation at Zhujia Hospital from January 2017 to December 2019 | Length of hospitalisation, Fever days, Invasive operation, Excessive bed rest, Hypoproteinemia, Procalcitonin, C Reactive Protein, Serum Amyloid | MDRO, non MDRO | Medium | + | 16,0 | 13 | 8 | Variables with p<0.001 in the bivariable screening were included in the multivariable model, except for excessive bedstay (p=0.002). The authors found that invasive operation, excessive bedstay, |

Supplementary material 4

Table S4 - All included articles in the systematic review with a mortality outcome

| Year | Title | Authors | Number of patients | Number of events in the final (and largest) model | Country/setting | Study aim statement | Patient population | Factors included in the final model | Microbial etiology and resistance | Risk of bias grading (NIH tool) | Bivariable screening/stepwise regression | Events per variable in the final (and largest) model | Number of variables included in the tested/screened/initial model | Number of variables included in the final (and largest) model | Comments |
|------|--|---|--------------------|---|-----------------|---|--|---|--|---------------------------------|--|--|---|---|---|
| 2016 | Risk factors and clinical outcomes for vancomycin-resistant enterococcus bacteraemia in hospitalised cancer patients in Pakistan: A case-control study | Akhtar, Sultan, Nizamuddin et al. [148] | 111 | 57 | Pakistan | To identify the risk factors and outcomes for VRE bacteraemia among cancer patients | Cancer patients whose blood culture grew either vancomycin-sensitive or resistant enterococcus (VSE or VRE) from January 2012 to December 2014 | Paediatric (Compared to adults), sex, type of malignancies, location in hospital at onset of bacteraemia, inpatient, others(OPD/ ER), APACHE-II score at onset of bacteraemia, length of hospital stay in days before onset of bacteraemia, shock at onset of bacteraemia), disseminated Intravascular Coagulation (DIC) score, received vancomycin within 4 weeks prior to bacteraemia | <i>Enterococcus spp.</i> , vancomycin-resistance | Medium | No | 5.2 | 11 | 11 | The only risk factor that seems to be of importance for the mortality of patients with VRE vs VSE bacteraemia is shock at onset of bacteraemia. |
| 2019 | <i>Clostridium difficile</i> Infections in patients with AML or MDS undergoing allogeneic hematopoietic stem cell transplantation identify high risk for adverse outcome | Amberge, Kramer, Schröttner et al [78] | 727 | Indeterminable | Germany | To study the effect of CDI and CD colonization on the outcome in patients with AML/MDS undergoing alloHCT | All patients with acute myeloid leukaemia or myelodysplastic syndrome who underwent allogeneic hematopoietic stem cell transplant at the institution between January 1st 2004 and March 31st 2015. | <i>Clostridium difficile</i> status (no infection/asymptomatic/symptomatic), donor type (related/unrelated), human Leukocyte Antigen compatibility (match/mismatch), disease risk (favourable/intermediate/high), age, meropenem exposition (yes/no) | <i>Clostridioides difficile</i> | Low | No | #VALUE! | 6 | 6 | The study indicated symptomatic <i>C. difficile</i> infection increases the risk of death |
| 2015 | Mortality burden related to infection with carbapenem- | Andria, Henig, Kotler et al | 330 | 95 | Israel | To estimate the mortality burden of | Adult patients with Gram-negative | Dependent functional capacity at baseline, pulmonary disease, liver disease, | Carbapenem-resistant Gram-negative | Medium | Yes | 5.6 | 28 | 9 | The authors found that a bacteraemia with |

| | | | | | | | | | | | | | | | |
|------|--|---|-----|-----|---------|--|--|---|-------------------------------|--------|-----|------|----|----|---|
| | resistant Gram-negative bacteria among haematological cancer patients: a retrospective cohort study | [58] | | | | CRGNB among haematological cancer patients receiving chemotherapy | aerobic bacteraemia hospitalised in the haematological/bone marrow transplantation departments actively treated for their malignancy between 2008-2014 | haematological stem cell transplant comorbidities index, renal failure, admission-days before bacteraemia, type of the last chemotherapy treatment, functional capacity at bacteraemia onset, urinary catheter, nasogastric tube, type of bacteria, polymicrobial bacteraemia, appropriate empirical antibiotic treatment, CRGNB, systolic blood pressure, diastolic blood pressure, septic shock | bacteria | | | | | | a Carbapenem-resistant Gram-negative bacteria increases the risk of death, but the propensity score for resistance did not. |
| 2019 | Current etiology, clinical features and outcomes of bacteremia in older patients with solid tumors | Antonio, Gudiol, Royo-Cebrecos et al [27] | 217 | 77 | Spain | To assess the etiology, clinical features, and outcomes among older patients with solid tumors who developed bacteremia in the era of widespread antimicrobial resistance. | All consecutive patients with solid tumours hospitalised with one or more episodes of bacteremia from January 2006 to November 2015. | Age years, lung cancer, prostate cancer, advance neoplasm, comorbidities, current corticosteroid therapy, bacteremia origin (healthcare/nosocomial), clinical manifestations (Low grade fever (<38 °C/ Shock at presentation), source of bacteraemia (Urinary tract), inadequate empirical antibiotic therapy | Multidrug-resistant organisms | Low | Yes | 6.4 | 23 | 8 | There is both a model for early case-fatality (at 7 days) and 30-day mortality. The risk factors in this table is from the final 30-day mortality model, in which the author did not include resistant pathogens due to automatic variable selection. |
| 2019 | Colonization with multidrug resistant organisms determines the clinical course of patients with acute myeloid leukemia undergoing intensive induction chemotherapy | Ballo, Tarazzit, Stratmann et al [45] | 220 | 104 | Germany | The authors hypothesized that colonization with a MDRO affects the clinical course of AML patients undergoing intensive induction chemotherapy | All patients with acute myeloid leukaemia who underwent intensive induction chemotherapy between 2007 and 2015. | Age >60, adverse genetic group acute myeloid leukaemia, day 15 bone marrow blast clearance, stem cell transplantation as consolidation therapy, colonisation with carbapenem resistant enterococci | Multidrug-resistant organisms | Medium | Yes | 20.8 | 9 | 6 | Finds an increased risk of dying for AML patients colonised with carbapenem-resistant <i>enterobacteriaceae</i> |
| 2015 | Emergence of multidrug resistant isolates and | Bastug, Kayaaslan, Kazancioglu | 205 | 48 | Turkey | To identify the recent epidemiology | Patients admitted to hemato- | Age > 65 years, prior haematologic stem cell transplant, prolonged | Multidrug-resistant organisms | Medium | Yes | 4.8 | 10 | 10 | Finds an increased risk of dying among |

| | | | | | | | | | | | | | | | |
|------|--|---|-----|-----|--------|--|--|--|--|--------|-----|-----|----|----|---|
| | mortality predictors in patients with solid tumors or hematological malignancies | u et al [110] | | | | y of infections and mortality risk factors in infected neutropenic and non-neutropenic patients with hematological malignancies | oncology wards of the 1,140-bed tertiary care hospital between 2008 and 2013. | neutropenia prior to infection, inadequate initial antibiotic treatment, gram-negative bacterial infection, infection with coagulase negative Staphylococci, infection with <i>Acinetobacter baumannii</i> , infection with <i>Klebsiella spp.</i> , infection with extended spectrum beta lactamase-producing bacteria, infection with Gram-negative multi drug resistant bacteria | | | | | | | patients with predominantly haematological malignancies when infected with either <i>A. baumannii</i> or <i>Klebsiella spp.</i> |
| 2018 | The relationship between mortality and microbiological parameters in febrile neutropenic patients with hematological malignancies | Çalık, Arı Bilgir et al [57] | 106 | 58 | Turkey | To determine effective risk factors on mortality in febrile neutropenic cases with hematologic malignancy | Patients diagnosed with hematologic malignancies | Absolute neutrophil count, duration of neutropenia (days), catheterization focus of infection, central catheterization, isolation of Gram + bacteria in culture, isolation of Gram - bacteria in culture, extended spectrum beta lactamase <i>Enterobacteriaceae</i> , carbapenem resistance, imipenem empirical antibiotic regimen, bacterial growth during antibiotic treatment, administration of appropriate antibiotic treatment for minimum 72 hours, septic shock | Several bacterias, tested for sensitivity to all major classes of antibiotics. | Medium | Yes | 4.8 | 18 | 12 | Does not find an association between the resistant bacteria and mortality. |
| 2016 | Emerging resistant bacteria strains in bloodstream infections of acute leukaemia patients: results of a prospective study by the Rete Ematologica Lombarda (Rel) | Cattaneo, Zappasodi, Mancini et al [46] | 433 | 37 | Italy | To Describe the specific epidemiological scenario of bacterial infections and antibiotic resistance in AL patients during treatment, often affected by severe neutropaenia | All febrile/infectious episodes were recorded in patients with acute leukaemia from December 2012 to December 2014 | Complete remission, relapsed/refractory disease, central venous catheter-related bloodstream infection (BSI), multi-resistant Gram-negative BSI, pneumonia | Several bacteria and fungi, tested for various antibiotics | Medium | Yes | 7.4 | 20 | 4 | Authors found that multi-resistant Gram-negative bloodstream infections are associated with higher mortality |
| 2021 | A practical update on the | Chen, Lin, Li et al [47] | 725 | 171 | China | To characterize | Patients with haematologic | Age>45, Hospital length of | Several bacteria and fungi, some | Medium | Yes | 6.3 | 27 | 27 | The authors found that the |

| | | | | | | | | | | | | | | | |
|------|---|-----------------------------|-----|-----|-------------|--|---|--|---|--------|-----|------|----|----|---|
| | epidemiology and risk factors for the emergence and mortality of bloodstream infections from real-world data of 3014 hematological malignancy patients receiving chemotherapy | | | | | HM BSI and identify risk factors for BSI emergence and mortality | all malignancies, between 2013 and 2016 | stay, Duration of neutropenia before blood culture, Hemograms of bloodstream infections (white blood cell, Haemoglobin, platelet), Disease status, Use of antibiotics (≥3 agents), Co-infections (respiratory), Numbers of co-infected locations, Pathogens for bloodstream infections (among them 11 bacterias, fungi, polymicrobial and other), gram negative organisms, gram positive organisms, polyorganisms, and fungi | intrinsically resistant | | | | | | intrinsically resistant bacteria <i>S. maltophilia</i> and <i>A. baumannii</i> is associated with an increased hazard for mortality |
| 2018 | Association Between Positive Cultures During Admission and 1-Year Mortality in Patients With Cancer Receiving Perioperative Intensive Care | Chiang, Wu, Hsu et al [111] | 638 | 134 | Taiwan | To address the long-term impact of having positive cultures during admission on 1-year mortality among patients with cancer who received perioperative intensive care by using both data in cancer registry and electronic medical records | All adult patients who were registered in the hospital cancer registry and had at least one intensive care unit admission to an from 2011 through 2016 following their cancer diagnosis | Age, male gender, type II diabetes mellitus, cerebrovascular disease, congestive heart failure, metastatic cancer, emergent surgery, APACHE II, mechanical ventilation, positive culture of multi drug resistant organism, positive culture in blood/respiratory tract/urinary tract/skin and soft tissue | Several bacteria and fungi are studied, including MDROs (methicillin-resistant <i>Staphylococcus aureus</i> , vancomycin-resistant Enterococci, and carbapenem-resistant Gram-negative bacilli) | Medium | No | 12.2 | 11 | 11 | After adjusting for other factors, the authors did not find that MDROs were associated with a higher hazard of death. |
| 2015 | <i>Stenotrophomonas maltophilia</i> bloodstream | Cho, Lee, Choi et al [87] | 31 | 20 | South Korea | To investigate the clinical | All consecutive episodes of | Neutropenia at the onset of bloodstream infection, severe neutropenia at the onset of | <i>Stenotrophomonas maltophilia</i> | Medium | Yes | 6.7 | 9 | 3 | The authors found that shock, neutropenia and |

| | | | | | | | | | | | | | | | |
|------|--|---|-----|----|--------|---|---|---|--|--------|-----|-----|---|---|--|
| | infection in patients with hematologic malignancies: a retrospective study and in vitro activities of antimicrobial combinations | | | | | characteristics and outcomes related to <i>S. maltophilia</i> BSIs in patients with hematologic malignancies | <i>S. maltophilia</i> bloodstream infections in adult patients with hematologic malignancies from June 2009 to May 2014. | bloodstream infection (<100/mm ³), duration of neutropenia >21 days, hospital stay >30 days, SAPS II score >40, Source of infection (Pneumonia), polymicrobial bloodstream infection, shock | | | | | | | combined <i>S. maltophilia</i> pneumonia are associated with mortality in these patients. |
| 2020 | High mortality in an outbreak of multidrug resistant <i>Acinetobacter baumannii</i> infection introduced to an oncological hospital by a patient transferred from a general hospital | Cornejo-Juarez, Cevallos, Castro-Jaimes et al [141] | 106 | 53 | Mexico | To identify the epidemiology of the outbreak and to describe the clinical evolution and risk factors for adverse outcomes of patients during the outbreak of MDR <i>A. baumannii</i> | Patients with multi drug resistant <i>A. baumannii</i> in a tertiary care oncology hospital from January 2011 to December 2015 | Age <60, colonised/Infected, solid tumour/Hematologic malignancy, recent diagnosis (vs relapse), no recent chemotherapy (vs recent), appropriate treatment/Non-appropriate treatment, SOFA score <10/>10 | Multidrug-resistant <i>Acinetobacter baumannii</i> | Low | Yes | 7.6 | 7 | 7 | In this outbreak analysis, the authors found that haematological cancer patients had a higher risk of death than solid tumour patients |
| 2019 | Fungaemia in haematological malignancies: SEIFEM 2015 survey | Criscuolo, Marchesi, Candoni et al [63] | 215 | 82 | Italy | We focused on epidemiology of fungal BSI in patients affected by either myeloid or lymphoid HM admitted over the past 5 years to 34 Italian Hematology centres participating to the SEIFEM consortium | Hospitalised patients with haematological malignancies in which a documented fungaemia was diagnosed between January 2011 and December 2015 | Performance status >2, chronic kidney disease, steroid administration, gastrointestinal symptoms, respiratory symptoms, septic shock, multiorgan failure, concurrent bacterial sepsis, central venous catheter removal, neutrophil recovery, albicans vs non albicans | Several fungi, including intrinsically resistant | Low | Yes | 9.1 | 9 | 7 | In a univariate analysis, authors found that non-albicans candidaemias had a higher odds of death, but the factor is not retained in the final model |
| 2020 | Biofilm Production by Carbapenem-Resistant | Di Domenico, Cavallo, | 53 | 19 | Italy | To analyze the impact of different | Oncological patients colonised or | Biofilm (strong vs weak), colistin resistance, fungal infection, phenotype, site | Carbapenem-resistant <i>Klebsiella</i> | Medium | No | 3.8 | 5 | 5 | The authors did find that the production of |

| | | | | | | | | | | | | | | | |
|------|--|---|-----|----|-------|---|---|--|---|--------|-----|-----|----|---|--|
| | <i>Klebsiella pneumoniae</i> Significantly Increases the Risk of Death in Oncological Patients | Sivori et al [149] | | | | CRKP virulence determinants to assess their predictivity in supporting clinical decision-making in high-risk oncological patients | infected with carbapenem resistant <i>K. pneumoniae</i> | (respiratory vs other) | <i>pneumoniae</i> | | | | | | biofilm in carbapenem-resistant <i>K. pneumoniae</i> is associated with a higher hazard of death |
| 2021 | The Impact of Bacterial Biofilms on End-Organ Disease and Mortality in Patients with Hematologic Malignancies Developing a Bloodstream Infection | Di Domenico, Marchesi, Cavallo et al [48] | 96 | 8 | Italy | To explore putative risk factors for the development of BSIs and mortality caused by MDR and biofilm-growing bacteria in a cohort of patients with HMs | All consecutive adult patients (aged >18 years) affected by haematological malignancies and experiencing a bloodstream infection as detected from April 2016 through April 2019 | Antimicrobial prophylaxis, multi drug resistant (MDR) vs non-MDR bloodstream infection (BSI), initial antimicrobial failure, <i>P. aeruginosa</i> vs other BSI, strong vs weak biofilm-producer, septic shock, end organ disease | Several bacteria, including intrinsically resistant tested for resistance towards several antibiotics | Medium | Yes | 1.1 | 16 | 6 | The authors found that a multidrug-resistant bloodstream infection is associated with a higher hazard of death in these patients |
| 2021 | Clinical characteristics and outcome of 125 polymicrobial bloodstream infections in hematological patients: an 11 year epidemiologic survey | Facchin, Candoni, Lazzarotto et al [49] | 125 | 19 | Italy | To investigate the clinical microbiological characteristics and outcome of pBSI that were consecutively observed in hematological patients admitted to our Hematology Department to receive intensive | Patients affected by haematological neoplasms with a documented polymicrobial bloodstream infection | Age, infection related mortality, septic shock rate, multi drug resistant-polymicrobial bloodstream infections mortality | Several bacteria tested for resistance towards several antibiotics | Medium | Yes | 4.8 | 13 | 4 | The authors found that in these patients, having a multidrug-resistant bacteria as part of a polymicrobial bloodstream infection is associated with a higher odds of death |

| | | | | | | | | | | | | | | | |
|------|---|---|-----|----|--------|---|--|--|---|--------|-----|-----|----|----|--|
| | | | | | | chemotherapy or stem cell transplantation (SCT) | | | | | | | | | |
| 2015 | Early initiation of appropriate treatment is associated with increased survival in cancer patients with <i>Candida glabrata</i> fungaemia: a potential benefit from infectious disease consultation | Farmakiotis, Kyvernitakis, Tarr et al [157] | 146 | 58 | USA | To investigate the correlation of clinical outcomes with early initiation of appropriate treatment and ID consultation, in a contemporary cohort of cancer patients with <i>C. glabrata</i> fungaemia | Patients with at least one blood culture(s) positive for <i>C. Glabrata</i> at a cancer centre between March 2005 and September 2013 | Intensive care unit stay, monocytopenia, APACHE II score, mechanical ventilation, septic shock, acute kidney infection or acute renal failure, fever, corticosteroids, catheter-related candidemia, mixed bloodstream infection, caspofungin resistance, echinocandin pre-exposure, central venous catheter removal within 48 h after blood culture collection, appropriate treatment within 48 h after blood culture collection | <i>Candida glabrata</i> | Medium | Yes | 4.1 | 18 | 7 | The authors concluded that patients with a blood culture positive for <i>C. glabrata</i> should consult an ID specialist within 48 hours |
| 2021 | Fluoroquinolone treatment as a protective factor for 10 day mortality in <i>Streptococcus pneumoniae</i> bacteremia in cancer patients | Fontana, Ibrahim, Bonazzi et al [165] | 161 | 34 | Brazil | To evaluate prognostic factors in cancer patients in episodes of pneumococcal bacteremia and to describe the epidemiological, clinical and microbiological data, the phenotypic characteristics of the collected specimens (serotypes and antimicrobial resistance) and to correlate the S. | Patients attended between January 2009 and July 2015 at a cancer institute with haematological malignancies and / or solid tumours, over 18 years of age, and who had at least one episode of <i>S. pneumoniae</i> bacteremia during the referred period | Ethnicity, diabetes Mellitus, neutropenia past month, current neutropenia, severe neutropenia past month, current severe neutropenia, febrile neutropenia, SOFA score, polymicrobial bacteremia, vaccine serotype VPV23, 3rd and 4th generation cephalosporins, fluoroquinolones. | <i>Streptococcus pneumoniae</i> , tested for resistance against several antibiotics | Low | Yes | 2.8 | 53 | 21 | While the authors test for association between antimicrobial susceptibility and mortality, they conclude that there is no association and do not include it in the final model |

| | | | | | | | | | | | | | | | |
|------|---|---|-----|-----|--------|--|--|---|---|-----|-----|------|----|----|---|
| | | | | | | pneumoniae serotypes with available vaccine coverage | | | | | | | | | |
| 2016 | Bloodstream infection caused by extensively drug-resistant <i>Acinetobacter baumannii</i> in cancer patients: high mortality associated with delayed treatment rather than with the degree of neutropenia | Freire, de Oliveira Garcia, Garcia et al. [142] | 92 | 77 | Brazil | To describe severe infections with XDR <i>Acinetobacter baumannii</i> -calcoacetikus complex (XDR-ABC), as well as to investigate risk factors for mortality, in cancer patients | All patients diagnosed with extensively drug resistant <i>A. baumannii</i> bacteraemia, acquired during hospitalisation in the intensive care unit at a cancer institute | Serum albumin, septic shock at diagnosis of XDR-ABC bacteraemia (extended drug resistant), SOFA score at diagnosis, received appropriate therapy for XDR-ABC bacteraemia, combination therapy, days from 1st positive culture to initial treatment, removal of invasive devices within the first 48 h | <i>Acinetobacter baumannii</i> , extensively drug resistance | Low | Yes | 11.0 | 20 | 6 | The authors found that 68% of all healthcare-associated bacteraemias are caused by extensively drug resistant <i>A. baumannii</i> , which is associated with a 30-day mortality of more than 80%. The authors concluded that the only risk factor of importance was appropriate antibiotic treatment. |
| 2018 | Role of Lock Therapy for Long-Term Catheter-Related Infections by Multidrug-Resistant Bacteria | Freire, Pierotti, Zerati et al [112] | 212 | 212 | Brazil | To analyze LTCVC-associated infections in terms of risk factors for unfavorable outcomes and the impact of ALT, including infection by MDR bacteria | All LTCVC-associated infections diagnosed at the a cancer institute between January 2009 and December 2016 | Haematological malignancies, Palliative care, SOFA score, MDR bacteria, Adherence to protocol, Antibiotic lock therapy | Several bacteria and fungi, tested for resistance towards several antibiotics | Low | + | 15,1 | 28 | 14 | The authors found that there is an increased hazard of death when the patient is infected by multidrug-resistant bacteria, but that antibiotic lock therapy is associated with a decrease in death. |
| 2015 | Infection with <i>Klebsiella pneumoniae</i> carbapenemase (KPC)-producing <i>Klebsiella pneumoniae</i> in cancer patients | Freire, Pierrotti, Filho et al [150] | 83 | 49 | Brazil | To describe HAIs due to KPC-Kp in patients with solid tumors and hematologic malignancies. In addition, we | All patients diagnosed with an healthcare associated infection due to <i>Klebsiella</i> producing carbapenemase- <i>Klebsiella pneumoniae</i> | Serum albumin, concomitant infection, bloodstream infection, urinary tract infection, SOFA score at healthcare associated infection (HAI) diagnosis, removal of invasive device or control deep infection, received effective therapy for <i>Klebsiella</i> producing carbapenemase-Kp infection, intensive care unit | <i>Klebsiella pneumoniae</i> , carbapenemase-producing | Low | Yes | 4.5 | 27 | 11 | The authors concluded that there is high mortality in patients with KPC-Kp infection, and that mortality is associated with the severity of the infection rather than the |

| | | | | | | | | | | | | | | | |
|------|--|---|------------|----------------|-------|--|---|--|---|--------|-----|----------------|----------------|----------------|--|
| | | | | | | attempted to identify the risk factors associated with mortality in such cases | acquired during hospitalisation at a cancer institute between January 2009 and July 2013 | admission for healthcare associated infection (HAI), mechanical ventilation, acute kidney injury within 30 days after HAI diagnosis | | | | | | | underlying disease |
| 2018 | Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance | Garcia-Vidal, Cardozo-Espinola, Puerta-Alcalde et al [50] | 589 | 87 | Spain | To describe the current epidemiology and its changes during the different cycles of chemotherapy of BSI in a large current cohort of patients with AL. The authors also assessed the risk factors for BSI mortality and the risk factors for BSI caused by MDR- <i>Pseudomonas aeruginosa</i> (MDR-PA) | All consecutive episodes of bloodstream infection occurring in patients with acute leukaemia from July 2004 to February 2016. | Older age (>65 years old), diabetes mellitus, chronic lung disease, chronic liver disease, prolonged neutropenia, mucositis, fatal prognosis according to McCabe index, community site of acquisition, catheter as a source of bacteremia, pulmonary source of infection, intra abdominal source of infection, cONs, <i>E.coli</i> , <i>P.aeruginosa</i> , shock at onset, inappropriate antibiotic therapy for multi drug resistant strains, inappropriate antibiotic therapy for multi drug resistant <i>P. aeruginosa</i> | Several bacteria and fungi, tested for resistance towards several antibiotics. A special focus on multidrug-resistant <i>Pseudomonas aeruginosa</i> . | Low | Yes | 5.1 | 34 | 17 | The authors found an association between multidrug-resistant <i>P. aeruginosa</i> and mortality, after adjusting for some other confounders and risk factors. |
| 2017 | Trends in the Incidence and Outcomes of Hospitalized Cancer Patients With Clostridium difficile Infection: A Nationwide Analysis | Gupta, Tariq, Frank et al [137] | 20,100,000 | Indeterminable | USA | To evaluate the incidence of CDI in patients with both solid organ and hematologic cancers, incidence trends over time, and outcomes in these | Cancer hospitalizations in a national cancer database from 2001 to 2010. | <i>C. difficile</i> infection, age, sex, admission status, and comorbidities. | <i>Clostridioides difficile</i> | Medium | No | Indeterminable | Indeterminable | Indeterminable | The authors found that CDI is associated with a higher mortality among cancer patients. It was not clear how many factors variables were included in this model but we assumed 12 confounders and 2 factors (CDI and dismissal to care |

| | | | | | | | | | | | | | | | |
|------|---|---|-----|---------------|---------|--|--|--|--|--------|-----|---------------|----|---|---|
| | | | | | | patients compared with those with cancer without CDI | | | | | | | | | facility) |
| 2021 | Colonization with multidrug resistant organisms impairs survival in patients with hepatocellular carcinoma | Himmelsbach, Knabe, Ferstl et al [28] | 954 | 476 | Germany | To determine the incidence of MDRO-colonization in HCC patients and to evaluate its impact on the clinical course | Patients with confirmed hepatocellular carcinoma presenting between January 2008 and December 2017 | Age, sex, underlying cirrhosis, Child-Pugh class C vs. A or B, BCLC stage C or D vs. A or B, ALBI grade 3 vs. grade 1 or 2, Alpha-fetoprotein > 400 ng/ml, sorafenib treatment, resection as hepatocellular carcinoma treatment, multi drug resistant organism-colonization | Several bacteria, tested for resistance towards several antibiotics | Medium | Yes | 95.2 | 10 | 5 | In this study, the authors concluded that there is an association between colonisation with a multidrug-resistant organism and mortality in patients with hepatocellular carcinoma. |
| 2018 | Bloodstream infections in cancer patients. Risk factors associated with mortality | Islas-Muñoz, Volkow-Fernández, Ibanes-Gutiérrez et al [113] | 496 | 109 | Mexico | To evaluate the clinical epidemiological characteristics and risk factors associated with mortality in cancer patients with BSI, with special emphasis on MDR bacteria | From August 2016 to July 2017, all positive blood cultures detected at the Microbiology Laboratory at a cancer centre were recorded, and all episodes confirmed as bloodstream infection were included in the study. | Age <60 years vs. Age >60 years, Solid tumour vs Haematological, Recent diagnosis or remission vs Progression/relapse, Gram-positive vs Gram-negative, Monomicrobial vs Polymicrobial, Appropriate treatment vs Inappropriate treatment, Non-multidrug resistant (MDR) vs MDR and/or extended spectrum beta lactamase, Neutrophils >500 vs Neutrophils 500 | Several bacteria, tested for resistance towards several antibiotics | Low | No | 13.6 | 8 | 8 | Authors included every variable of the univariate in the multivariate despite it being written that inclusion depended on p<0.5. The authors concluded that there was an association in the 30-day mortality among the cancer patients and bloodstream infection with multidrug-resistant Gram-negative bacteria, particularly if it was inappropriately treated. |
| 2020 | Nosocomial Infections in Gastrointestinal Cancer Patients: Bacterial Profile, Antibiotic Resistance Pattern, and Prognostic | Jiang, Liu, Said et al [29] | 428 | Indeterminate | China | To explore the bacterial profile, antibiotic resistance pattern, and prognostic factors of nosocomial | Hospitalised gastrointestinal cancer patients with nosocomial infections at a cancer treatment centre from | Gram negative bacteria, <i>E.coli</i> , <i>K. pneumoniae</i> , <i>Enterobacter</i> spp, Fungi, <i>C. albicans</i> . <i>Candida</i> spp, enterococcus | Several bacteria and fungi, tested for resistance towards several antimicrobials | Medium | Yes | Indeterminate | 24 | 8 | There are three full multivariable models in this article that all estimate the OR for mortality associated with different factors; a demographic/clinical |

| | | | | | | | | | | | | | | | |
|------|---|-----------------------------|-----|----|-------|--|---|---|---|-----|-----|-----|----|----|--|
| | Factors | | | | | infections in hospitalized GI cancer patients | August 2013 to June 2019 | | | | | | | | cal model, an infection-related model, and a causative pathogens model. Only the causative pathogens model is assessed as the other models don't explicitly include antimicrobial resistance. One is about resistant pathogens. The authors concluded that Gram-negative bacteria were most common. |
| 2020 | Nosocomial infections due to multidrug-resistant bacteria in cancer patients: a six-year retrospective study of an oncology Center in Western China | Jiang, Shi, Liu et al [118] | 257 | 28 | China | To evaluate the characteristics, antibiotic resistance patterns, and prognosis of nosocomial infections due to multidrug-resistant (MDR) bacteria in cancer patients | Cancer patients with nosocomial infections due to multi drug resistant bacteria who received medical care during hospitalisation from August 2013 to May 2019 | Clinical model: Demographic data (age), Smoking history (Never smoker/Former smoker/Current smoker), ECOG performance status (0,1/2,3,4), Existence of distant metastasis, Comorbidities (Liver disease), Charlson comorbidity index CCI (1-2), CCI≥3, Surgery, Chemotherapy, Intrapleural/abdominal infusion (within 30 days), Presence of indwelling urinary catheters, presence of Drains postoperative, Infection-related model: Sample type (Urine/Blood culture), Primary sites of infection (Respiratory tract/Urinary tract/BSI), Length of hospitalisation (≥21.0), Septic shock, Laboratory examination results | Methicillin resistant <i>S. aureus</i> (MRSA), Extended spectrum beta lactamase producing <i>Enterobacteriaceae</i> (ESBL-PE), multi drug resistant (MDR) <i>Pseudomonas aeruginosa</i> , <i>Acinetobacter baumannii</i> , <i>Stenotrophomonas maltophilia</i> , Carbapenem-resistant <i>Enterobacteriaceae</i> | Low | Yes | 2.5 | 40 | 11 | There are two full multivariable models in this article that both are assessed, as both have antimicrobial resistance as factors. Numbers are extracted from the nested model with the less variables tested, hence the highest number of events by variable in theory. Authors explained they included variables from univariate in MVA when p<0.1 but they included other factors as well. The most common bacteria were ESBL-PE, and the authors conclude that former smokers, intrapleural/abdominal infusion history within 30 days, presence of indwelling urinary |

| | | | | | | | | | | | | | | | | |
|------|---|--------------------------------------|----|----|--------|---|---|--|---|--------|-----|-----|----|---|--|---|
| | | | | | | | | (Haemoglobin g/L <110.0, Platelet count ×10 ⁹ /L <100.0, Lymphocytes count ×10 ⁹ /L <1.0, PCT ng/mL ≥1.0, Albumin g/L <30.0) | | | | | | | | catheters, and anaemia were independent risk factors for in-hospital mortality of nosocomial infections caused by MDR bacteria. |
| 2020 | Is current initial empirical antibiotherapy appropriate to treat bloodstream infections in short-duration chemotherapy-induced febrile neutropenia? | Joncour, Puyade, Michaud et al [114] | 27 | 13 | France | To assess the appropriateness of antibiotherapy and the outcome of bloodstream infections (BSI) in patients with expected neutropenia of short duration | Febrile neutropenic patients at a hospital undergoing chemotherapy for solid tumours or malignant haemopathy with expected duration of neutropenia ≤7 days from 1 January 2015 to 31 December 2016. | Signs of severity, documented clinical source, qSOFA score ≥2 | Several bacteria, tested for resistance towards several antibiotics | Medium | Yes | 4.3 | 18 | 3 | The authors found that the only risk factor associated with mortality was the qSOFA score, and found no association between mortality and a history of infection/colonisation with MDR <i>P. aeruginosa</i> . Numbers are extracted from the model table in Supplementary material | |
| 2015 | Uncommon Candida Species Fungemia among Cancer Patients, Houston, Texas, USA | Jung, Farmakiotis, Jiang et al [158] | 66 | 40 | USA | The authors aimed to investigate the epidemiology, antifungal use, susceptibility patterns, and factors associated with all-cause death among | Patients ≥18 years of age hospitalised in the cancer centre during January 1998–September 2013. | Underlying leukaemia, steroid exposure, intensive care unit admission, intubation, persistent neutropenia, APACHE II score ≥19, hypoalbuminemia, breakthrough fungemia | <i>Candida</i> spp. | Medium | Yes | 5.0 | 9 | 8 | The authors showed that ICU, neutropenia and high APACHE score, were the strongest risk factors for mortality. | |

| | | | | | | | | | | | | | | | |
|------|--|---------------------------------|------|----|-------------------------------|---|---|--|---|--------|-----|------|----|---|--|
| | | | | | | cancer patients in whom uncommon <i>Candida</i> spp. were diagnosed at a cancer treatment center | | | | | | | | | |
| 2019 | Impact of empiric treatment for vancomycin-resistant <i>Enterococcus</i> (VRE) in colonized patients early after allogeneic hematopoietic stem cell transplantation | Kamboj, Cohen, Huang et al [95] | 95 | 5 | USA | To compare all-cause mortality at 30 days in patients who received empiric versus (vs) directed VRE therapy | Adults 18 years and older who underwent allo-hematologic stem cell transplantation and developed vancomycin resistant enterococcus bacteremia between January 1, 2005 and December 31, 2014, at the cancer centre | T cell depletion, prior vancomycin resistant enterococcus bacteremia (VREB), hypotension (<90/50), persistent VREB >48 hours | <i>Enterococcus</i> spp., vancomycin-resistance | Medium | Yes | 1.3 | 13 | 4 | The authors found there is no association with higher mortality at day 30 and any of tested variables in VREB cancer patients |
| 2019 | Contribution of specific pathogens to bloodstream infection mortality in neutropenic patients with hematologic malignancies: Results from a multicentric surveillance cohort study | Kern, Roth, Bertz et al [54] | 1424 | 36 | Germany, Austria, Switzerland | The authors analyzed early and late mortality rates after BSI as well as its predictors | Patients with bloodstream infection during neutropenia subsequent to high dose chemotherapy for acute leukaemia (HDC) or autologous or allogeneic hematopoietic stem cell transplantation | Mortality 30 days model : Auto hematologic stem cell transplant treatment, CoNS (coagulase negative staphylococci). Mortality 7 days model: coNS | Several bacteria, tested for resistance towards several antibiotics | Low | Yes | 18.0 | 5 | 2 | There are 2 mortality models in Annex, and one model about ICU admission which we did not assess. Numbers are extracted from the mortality 30 days model. In this relatively large cohort, the authors found that there is an association between the infecting pathogen |

| | | | | | | | | | | | | | | | |
|------|--|---|-----|----|-------------|--|--|---|--|--------|-----|-----|----|----|---|
| | | | | | | | (auto HSCT or allo HSCT) from the beginning of 2002 through April 2015 | | | | | | | | and 7 day mortality after BSI - particularly <i>Klebsiella</i> , <i>Enterobacter</i> , <i>Serratia</i> , and <i>Pseudomonas</i> . |
| 2019 | Pathogenic significance of hemorrhagic pneumonia in hematologic malignancy patients with <i>Stenotrophomonas maltophilia</i> bacteremia: clinical and microbiological analysis | Kim, Cha, Kang et al [88] | 118 | 72 | South Korea | To evaluate the risk factors for mortality in hematologic malignancy patients with SMB and to analyze clinical and microbiological characteristics of HP associated with SMB and CRBSI | Patients ≥18 years of age with hematologic malignancy who were diagnosed with <i>S. maltophilia</i> bacteremia | Age, hospital stay, polymicrobial infection, previous isolation of <i>S. maltophilia</i> , Focus of infection catheter related infection (CRI), focus of infection hemorrhagic, CRI non hemorrhagic, leukaemia, lymphoma, refractory or recurrent disease, Charlson comorbidity index >3, neutropenia, intensive care unit stay, mechanical ventilation, renal Replacement Therapy, initial SOFA score, platelet count, previous antibiotics <3, early empirical TMP/SMX antibiotic use within 72 h | <i>Stenotrophomonas maltophilia</i> | Low | Yes | 3.8 | 27 | 19 | The authors also included clinically relevant variables in the MVA. The authors concluded that the mortality of haematological malignancy patients with <i>S. maltophilia</i> bacteraemia is high, and that hemorrhagic pneumonia is associated with an increased mortality |
| 2020 | Vancomycin-resistant enterococci infection and predisposing factors for infection and mortality in patients with acute leukaemia and febrile neutropenia | Kirkizlar, Akalin, Kirkizlar et al [96] | 179 | 17 | Turkey | To analyse the incidence of VRE infections and mortality rates in VRE colonized adult acute leukemia patients with febrile neutropenia (FN) | Adult acute leukaemia patients with vancomycin resistant enterococcus colonised who had febrile neutropenia | Age, sex, primary disease acute myeloid leukemia, remission, previous hospitalisation, previous colonization, exposure to empirical antibiotics, mucositis, central venous catheter, invasive procedures, < 0,5x10 ⁹ /L neutrophil count while vancomycin resistant enterococcus (VRE) +, coinfection, acute kidney injury, >15 days VRE | <i>Enterococcus</i> spp. , vancomycin-resistance | Low | No | 1.2 | 14 | 14 | Apart from age and gender, the authors found an association between in-hospital mortality in VRE-colonised patients and low neutrophil count and coinfection |
| 2017 | Initial Treatment of Cancer Patients with Fluconazole- | Le, Farmakiotis, Tarrand et al [159] | 68 | 26 | USA | The authors performed a retrospective review of | Patients with <i>C. glabrata</i> fungemia caused by | APACHE II score, absolute monocyte count<100, intensive care unit, azole monotherapy | <i>Candida glabrata</i> | Medium | Yes | 2.9 | 17 | 9 | The authors found that azole monotherapy was associated with |

| | | | | | | | | | | | | | | | |
|------|---|------------------------------------|-----|----------------|-------|--|---|---|---|--------|-----|----------------|----------------|----------------|--|
| | Susceptible Dose-Dependent <i>Candida glabrata</i> Fungemia: Better Outcome with an Echinocandin or Polyene Compared to an Azole? | | | | | clinical and laboratory data for patients with <i>C. glabrata</i> fungemia caused by strains with dose-dependent in vitro susceptibility to fluconazole | strains with dose-dependent in vitro susceptibility to fluconazole at a cancer centre between March 2005 and September 2013. | | | | | | | | higher mortality than compared to the addition of an echinocandin or polyene in these patients |
| 2021 | Epidemiology, Risk Factors, and Clinical Outcomes of Bloodstream Infection due to Extended-Spectrum Beta-Lactamase-Producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> in Hematologic Malignancy: A Retrospective Study from Central South China | Liang, Xu, Cheng et al [66] | 449 | Indeterminable | China | To determine the epidemiology, risk factors, and prognosis of extended-spectrum beta-lactamase (ESBL)-producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> bloodstream infections (BSIs) among hematologic malignancy (HM) patients in China | Patients with hematologic malignancies who were diagnosed with extended spectrum beta lactamase (ESBL)-producing and non-ESBL-producing <i>E. coli</i> and <i>K. pneumoniae</i> bacteremia between January 2010 and July 2018 | Myelodysplastic syndrome, MASCC score <21, Charlson Comorbidity index>3 | <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> , ESBL | Medium | Yes | Indeterminable | Indeterminable | Indeterminable | The authors did not find a difference in overall mortality between the ESBL and non-ESBL groups, but they do find that the Charlson Comorbidity Index and the MASCC score were associated with an increased mortality in the ESBL-group. Number of deaths extracted from supplementary material. |
| 2015 | Factors influencing mortality in neutropenic patients with haematologic malignancies or solid tumours with bloodstream infection | Marin, Gudiol, Ardanuy et al [115] | 510 | 61 | Spain | To identify factors influencing mortality in neutropenic patients with haematologic malignancies or solid tumours with bloodstream | Hospitalised adult neutropenic cancer patients with at least one episode of bloodstream infection | Haematological malignancies: age, sex, advanced neoplasm, MASCC score <21, corticosteroid therapy, coagulase-negative staphylococci, multi drug resistant gram negative bacteria, Empirical antibiotic combination therapy, intensive care unit admission. Solid tumours: age, sex, advanced neoplasm, corticosteroid | Several bacteria, tested for resistance towards several antibiotics | Low | Yes | 6.8 | 40 | 9 | The authors used stepwise regression but also included some clinically relevant variables. The authors stratified the population and made one model for haematological malignancies and |

| | | | | | | | | | | | | | | | |
|------|---|--|-----|----|-------|---|---|--|---|-----|-----|------|----------------|---|---|
| | | | | | | infection (BSI) | | therapy, septic shock. | | | | | | | one model for solid tumours. The numbers were extracted from the hematologic model, with a higher number of events. They only found an association between antimicrobial resistance and mortality among haematological cancer patients |
| 2019 | Bloodstream infection in patients with head and neck cancer: a major challenge in the cetuximab era | Marin, Gudiol, Castet et al [30] | 51 | 7 | Spain | To assess the impact of bloodstream infection (BSI) in patients with head and neck cancer (HNC) | Consecutive episodes of bloodstream infection occurring in patients with head and neck cancer and bloodstream infection from January 2006 to April 2017 | Early case fatality: age, sex, Charlson scoring system, median albumin level, corticosteroid therapy. Overall case fatality: age, sex, Charlson scoring system, comorbidities, median Albumin level, corticosteroid therapy. | Several bacteria and fungi, tested for resistance towards several antimicrobials | Low | Yes | 1.2 | 39 | 6 | The authors used stepwise regression but also included some clinically relevant variables. Both models investigating fatality include antimicrobial resistance as a factor, but it is removed after the bivariable screening. Numbers were extracted from the early fatality model. There is also a matched case-control study investigating the risk factors of all BSIs but it does not include any resistance. |
| 2020 | Inappropriate Empirical Antibiotic Treatment in High-risk Neutropenic Patients With Bacteremia in the Era of Multidrug Resistance | Martinez-Nadal, Puerta-Alcalde, Gudiol et al [116] | 251 | 87 | Spain | To describe the current rates of inappropriate empirical antibiotic treatment (IEAT) in oncohematological | All consecutive episodes of bacteremia in patients with high-risk febrile neutropenia from January 2006 to | Inappropriate empirical antibiotic therapy, septic shock at onset, pneumonia | Several bacteria tested for resistance towards several antibiotics. The model is on <i>Pseudomonas aeruginosa</i> . | Low | Yes | 29.0 | Indeterminable | 3 | The authors found that inappropriate empirical antibiotic therapy, septic shock and pneumonia is associated with mortality among patients with <i>P. aeruginosa</i> |

| | | | | | | | | | | | | | | | |
|------|---|---|-----|-----|---------|--|--|--|---|--------|-----|----------------|----------------|----------------|---|
| | | | | | | patients with febrile neutropenia (FN) and its impact on mortality | January 2017 | | | | | | | | bloodstream infection. The area under the curve of this model is printed. |
| 2018 | Postoperative empyema following lung cancer surgery | Matsutani, Yoshiya, Chida et al [31] | 43 | 5 | Japan | The authors investigated the risk factors for developing postoperative empyema following lung cancer surgery and its prognosis | Patients who underwent thoracic surgery to treat primary lung cancer and had empyema between January, 2008 and December, 2012, from 9 institutions | Exacerbation of interstitial pneumonia, bronchial stump fistula, administration of steroid, interstitial pneumonia, histology with or without squamous cells, microbiology with or without non-fermenting Gram(-) bacilli | Several bacteria, tested for resistance towards several antibiotics | Medium | Yes | 0.8 | 35 | 6 | The authors used stepwise regression but it is unclear whether they used p-value<0.05 to include factors of the univariate in the final model. they exclude one significant factor with no observation in one group. No association with poor prognosis in empyema patients after lung cancer surgery were found through the multivariable model. |
| 2017 | Fecal Carriage of Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae Strains Is Associated with Worse Outcome in Patients Hospitalized in the Pediatric Oncology Unit of Beni-Messous Hospital in Algiers, Algeria | Medboua-Benbalagh, Touati, Kermas et al [125] | 171 | 28 | Algeria | To investigate extended-spectrum β -lactamase-producing <i>Enterobacteriaceae</i> (ESBL-E) fecal carriage in children with different cancers admitted in the pediatric oncology unit of Beni-Messous Hospital (Algiers, Algeria) | Paediatric oncology patients from February 2012 to May 2013 | Age, gender, previous hospital admission, haematological malignancies, antibiotic treatment for the last 3 months before admission, haematological malignancies, Nephroblastoma, neuroblastoma, sarcomas, extended spectrum beta lactamase enterobacteria (ESBL-E) | <i>Enterobacteriaceae</i> , ESBL | Medium | Yes | Indeterminable | Indeterminable | Indeterminable | No regression table is printed, but the variables that the authors report to be associated with the two outcomes are reported here. During screening, the authors find that more than half of the patients are carriers of ESBL-producing <i>Enterobacteriaceae</i> . |
| 2021 | Secondary | Mei, Yang, | 777 | 174 | China | To assess | Patients with | Performance status score, | Several bacteria | Medium | Yes | 19.3 | 21 | 9 | The authors used |

| | | | | | | | | | | | | | | | |
|------|---|---|-----|----|--------|---|---|--|--|--------|-----|-----|----|----|--|
| | Infections After Diagnosis of Severe Radiation Pneumonitis (SRP) Among Patients With Non-Small Cell Lung Cancer: Pathogen Distributions, Choice of Empirical Antibiotics, and the Value of Empirical Antifungal Treatment | Yu et al [32] | | | | pathogen distributions and antimicrobial sensitivity characteristics in patients with non-small cell lung cancer (NSCLC) with severe radiation pneumonitis (SRP) and secondary infections | severe radiation pneumonitis treated at a hospital between January 2009 and December 2020 with non-small cell lung cancer, who were infected after at least 48 hours of hospitalisation and received at least 1 antibiotic before susceptibility testing. | chronic obstructive pulmonary disease, diabetes, hypertension, radiotherapy dose in Gy, multiple bacterial infections, bacteria/fungal coinfections, appropriate antibiotic, empirical antifungal | and fungi, tested for resistance towards several antimicrobials | m | | | | | stepwise regression but it is unclear if the authors used a p-value < 0.05 to include the factors tested in the univariate in the final model. The authors did not find that there is any association between intrinsically resistant bacteria and infection-related mortality |
| 2021 | Predictive factors associated with induction related death in acute myeloid leukemia in a resource constrained setting | Mendes, da Silva, da Costa, Bandeira de Melo et al [55] | 206 | 53 | Brazil | To comprehensively explore which baseline clinical and laboratory features are associated with induction mortality in a LMIC center and to verify whether different prophylactic strategies employed throughout the years have impacted on this outcome | Patients aged ≥ 16 years with newly diagnosed acute myeloid leukaemia who started any regimen of intensive treatment | ECOG score binary, sex, age, intensive care unit entrance, Charlson comorbidities index (CCI), colonisation by <i>Klebsiella</i> producing carbapenemase, colonisation by <i>Acinetobacter</i> , colonisation by <i>Pseudomonas</i> , DM, tumor lysis, pre-chemo infection, Albumin to Globulin Ratio, monocytic acute myeloid leukaemia, monocytes, C reactive protein, prothrombin activity, D-Dimer, creatinin, albumin, alkaline phosphatase, total bilirubine, aciclovir, antibiotic prophylaxis, anthracycline | Several bacteria and fungi, tested for resistance towards several antimicrobials | Low | Yes | 2.1 | 56 | 25 | The authors used stepwise regression but excluded ECOG in the stepwise approach due to the high missing rate found during the chart reviewing. The final multivariable model showed that age > 60 years, Gram-negative colonisation, monocytic AML, CRP > 15 mg/dL, and an adverse risk in the genetic stratification were independently associated with early mortality in AML patients |
| 2021 | Reduced mortality from KPC- <i>K.pneumoniae</i> | Micozzi, Gentile, Santilli et al | 34 | 10 | Italy | The authors evaluated the impact | Patients with haematological | Model 1: <i>Klebsiella</i> producing carbapenemase-K <i>pneumoniae</i> (KPC-KP) | <i>Klebsiella pneumoniae</i> , carbapenemase- | Medium | Yes | 2.5 | 22 | 4 | The numbers were extracted from the Model 1. |

| | | | | | | | | | | | | | | | |
|------|---|---|-----|----|-------------|--|---|---|-------------------------------------|--------|-----|-----|----|---|--|
| | bloodstream infection in high-risk patients with hematological malignancies colonized by KPC- <i>K.pneumoniae</i> | [100] | | | | on KPC-KpBSI mortality of the preemptive use of antibiotics active against KPC- <i>K.pneumoniae</i> , as opposed to inactive or standard empiric antibiotics, for the empiric treatment of febrile neutropenia episodes in patients with hematological malignancy identified as KPC- <i>K.pneumoniae</i> intestinal carriers | malignancies identified as Klebsiella producing carbapenemase - <i>K.pneumoniae</i> carriers attending a haematology department between March 2012-December 2013 (Period 1) and January 2017-October 2018 (Period 2). | bloodstream infection (BSI) developing during inactive antibiotic treatment, acute myeloid leukaemia, shock, intensive chemotherapy. Model 2: Initial active treatment, KPC-KP BSI developing during inactive antibiotic treatment, acute myeloid leukaemia, shock, intensive chemotherapy. | producing | | | | | | It is unclear if authors used stepwise with p-value<0.05 to include factors of the univariate in the final model, and it is also unclear which factors are included or kept in the model. The authors found that 3 of 10 patients that died were put on initially active treatment |
| 2015 | Outcomes of critically ill cancer patients with <i>Acinetobacter baumannii</i> infection | Ñamendys-Silva, Correa-García, García-Guillén et al [143] | 23 | 6 | Mexico | To describe the ICU outcomes of critically ill cancer patients with AB infection | Cancer patients who acquired <i>Acinetobacter baumannii</i> infections during their stay at the intensive care unit of a cancer institute | Length of hospital stay, duration of vasopressors, blood lactate level (mmol/L), number of organ dysfunction, creatinine, | <i>Acinetobacter baumannii</i> | Medium | Yes | 1.2 | 14 | 5 | The authors found that the blood lactate level was associated with mortality in these patients |
| 2020 | Characteristics and Clinical Outcomes of Extended-Spectrum beta-lactamase-producing <i>Klebsiella</i> | Nham, Huh, Cho et al [151] | 267 | 46 | South Korea | To evaluate possible risk factors and outcomes of extended-spectrum beta-lactamase | Patients above the age of eighteen with cancer who had an episode of <i>K.pneumoniae</i> | 30-day mortality model: Neutropenia, foley catheter, nasogastric tube, mechanical ventilation, hemodialysis, catheter related infection, 14-day mortality model: solid tumour, extended spectrum beta lactamase, chronic liver | <i>Klebsiella pneumoniae</i> , ESBL | Medium | Yes | 7.7 | 51 | 6 | There are two models, one on 14 days mortality and one about 30 days mortality. Numbers were extracted from the 30 day mortality |

| | | | | | | | | | | | | | | | |
|------|--|--|------|------|--------|---|---|---|---|------------|----------------|-------|----------------|----|---|
| | <i>pneumoniae</i> Bacteremia in Cancer Patients | | | | | producing <i>Klebsiella pneumoniae</i> (ESBL-KP) bacteremia in cancer patients | bacteremia between 2010 and 2012 | disease, mechanical ventilation, hemodialysis, catheter related infection, PITT bacteremia score, carbapenem empirical therapy, vancomycin empirical therapy | | | | | | | model. The authors found that in these patients and with this statistical approach, there was an association between ESBL- production and 14-day mortality, but not with 30- day mortality |
| 2015 | Impact of vancomycin- resistant enterococcal bacteremia on outcome during acute myeloid leukemia induction therapy | Omstein, Mukherjee, Keng et al [97] | 350 | 84 | USA | To determine the rates of VRE bacteremia in patients with AML receiving IC, and whether VRE bacteremia is an independent predictor of inferior overall outcome in these patients | Patients with de novo and secondary acute myeloid leukaemia who received cytarabine- based induction chemotherapy at Cleveland Clinic between 1 January 2000 and 1 April 2008 | Age (>60 vs. <60), cytology Poor vs. Favourable, cytology Poor vs. Intermediate, cytology Poor vs. Unknown, VRE bacteremia, other bloodstream infections, aetiology (secondary vs. de novo), white blood cell at diagnosis, year of diagnosis | <i>Enterococcus</i> spp., vancomycin- resistance | Mediu m | Yes | 9.3 | 14 | 9 | The authors included factors which were significant in the univariate analysis plus blood cell count, year of diagnosis and non VRE BSI. conclude that the survival is poorer in AML patients who had a VRE bacteraemia. |
| 2020 | <i>Candida</i> spp bloodstream infections in a Latin American Pediatric Oncology Reference Center: Epidemiology and associated factors | Paixao de Sousa da Silva, de Moraes- Pinto, Teofilo Pignati et al [160] | 90 | 90 | Brazil | To characterize <i>Candida</i> spp bloodstream infections (BSI) in a reference centre for paediatric oncology and to describe the most prevalent risk factors associated with candida infections | Paediatric patients admitted to a paediatric oncology institute who presented with <i>Candida</i> spp. BSI from January 2004 to December 2016. | Age, Hospitalisation, ICU, Corticosteroid, Prior antifungal use, Skin lesion, Dissemination, <i>Candida</i> spp Species (<i>C parapsilosis</i> , <i>C</i> <i>tropicalis</i> , Others). | <i>Candida</i> spp. | Low | + | 9,0 | 28 | 10 | The authors find that a <i>Candida</i> <i>parapsilosis</i> infection was associated with a lower mortality, while there was no association between <i>Candida</i> <i>tropicalis</i> and mortality. |
| 2019 | Bloodstream | Papanicola | 7128 | 2774 | 450 | To | Patients who | Vancomycin resistant | <i>Enterococcus</i> | Low | Indeterminable | 277.4 | Indeterminable | 10 | The overall |

| | | | | | | | | | | | | | | | |
|------|--|--|-----|----|------------------------------|---|---|--|--|--------|-----|------|----------------|---|---|
| | Infection Due to Vancomycin-resistant <i>Enterococcus</i> Is Associated With Increased Mortality After Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome: A Multicenter, Retrospective Cohort Study | ou, Ustun, Young et al [98] | | | transplant centres worldwide | investigate the impact of VRE BSI within the first 100 days post HCT on overall survival (OS), nonrelapse mortality (NRM), and relapse at 1 year following HCT | received their first allogeneic hematologic cell transplantation for acute myelogenous leukaemia (AML), acute lymphoblastic leukaemia (ALL), or myelodysplastic syndrome (MDS) between January 2008 and December 2012 | enterococcus bloodstream infection, age (21-40, 41-50, 51-60, >60), AML/ALL intermediate, AML/ALL/MDS advanced, MDS advanced, Cord blood allograft, Human leukocyte antigen 7/8, Karnofsky performance scale <90, cytomegalovirus donor or receptor positive, hematologic cell transplant during 2010-2012 | spp. , vancomycin-resistance | | | | | | survival model was examined here. We were unable to determine the method used for variable selection, other than that several variables were "examined" in a multivariable model. The authors conclude that VRE BSI was associated with mortality. |
| 2019 | Infections Due to Multidrug-Resistant Bacteria in Oncological Patients: Insights from a Five-Year Epidemiological and Clinical Analysis | Perdikouri, Arvaniti, Lathyris et al [37] | 73 | 22 | Greece | To describe the current epidemiology of MDR infections and identify outcomes and risk factors associated with mortality in a cohort of patients with solid tumors | All cancer patients aged 18 years and older who presented an infection due to multi drug resistant bacteria from 1 January 2013 to 31 December 2017. | Model 1: neutropenia, C reactive protein (CRP). Model 2: creatinine, CRP. Model 3: guided antibiotics, duration of guided antibiotics. Model 4: empirical antibiotics, guided antibiotics. Model 5: CRP, guided antibiotics. Model 6: duration of empirical antibiotics, days of hospitalisation. Model 7: guided antibiotics, effective empirical antibiotics (there are 34 models overall, more models are in the Supplementary table) | <i>E. coli</i> , <i>Pseudomonas aeruginosa</i> , <i>Klebsiella pneumoniae</i> , <i>Acinetobacter baumannii</i> , <i>Enterococcus faecium</i> , <i>Staphylococcus aureus</i> , multidrug-, vancomycin- or oxacillin-resistant | Low | Yes | 11.0 | 37 | 2 | 34 models with each time 2 different variables included were tested. The authors selected some variables thanks to those significant in the univariate but also based on previous literature. In univariate analyses they found several associations with death, but none of these held up in multivariable analysis. |
| 2021 | Clinical Characteristics and Outcome of Bloodstream Infections in HIV-Infected Patients with Cancer and Febrile Neutropenia: A Case-Control Study | Puerta-Alcalde, Ambrosioni, Chumbita et al [119] | 180 | 43 | Spain | To compare the clinical characteristics and outcomes of bloodstream infections (BSI) in cancer patients presenting | All episodes of febrile neutropenia following chemotherapy occurring in patients with cancer and HIV from January 1997 to March | Hodgkin's lymphoma, Myelodysplastic syndrome, Solid neoplasia, Pulmonary source, Abdominal source, Shock, Candidemia, HIV-infection. Adjusted for: chronic liver disease, diabetes mellitus, chronic renal failure, HIV, corticosteroid use, catheter-related source, inappropriate empirical antibiotic treatment, | Several bacteria and fungi, tested for resistance towards several antimicrobials | Medium | Yes | 5.4 | Indeterminable | 8 | The authors did not find any association between resistant microbes and mortality, other than candidemia, but include CoNS and S. pneumoniae as adjustment |

| | | | | | | | | | | | | | | | | |
|------|--|--|-----|----|-------|---|---|--|--|--------|-----|-----|----|---|--|----------|
| | | | | | | febrile neutropenia with and without HIV infection, and analyze the prognostic factors for mortality | 2018. | coagulase-negative staphylococci bacteremia, <i>S. pneumoniae</i> bacteremia, intensive care unit requirement. | | | | | | | | factors. |
| 2017 | Ultrasonography-driven combination antibiotic therapy with tigecycline significantly increases survival among patients with neutropenic enterocolitis following cytarabine-containing chemotherapy for the remission induction of acute myeloid leukemia | Pugliese, Salvatore, Iula et al [56] | 100 | 23 | Italy | To identify the predictors of outcome within 30 days of NEC onset | Adult patients with newly diagnosed with acute myeloid leukaemia hospitalised at a haematological department from 1 January 2002 to 31 December 2012 in order to receive cytotoxic agent induction courses for haematological remission | High-dose cytarabine-containing chemotherapy, standard dose cytarabine chemotherapy, ultrasonography-driven necrotising enterocolitis NEC therapy with antibiotic regimens including tigecycline. | <i>Escherichia coli</i> , <i>Klebsiella pneumoniae</i> , <i>Enterococcus</i> spp., <i>Pseudomonas aeruginosa</i> , <i>Candida albicans</i> | Medium | Yes | 7.7 | 24 | 3 | It was unclear which variables were included in the final model. The authors did not find that mortality was associated with the different microbes | |
| 2015 | Epidemiology and outcome of candidaemia in patients with oncological and haematological malignancies: results from a population-based surveillance in Spain | Puig-Asensio, Ruiz-Camps, Fernandez-Ruiz et al [161] | 193 | 22 | Spain | To describe the distribution and susceptibility pattern of <i>Candida</i> species, and to evaluate risk factors for mortality in patients with oncological (solid tumours) and haematological | <i>Candida</i> bloodstream infection episodes in adult patients (>16 years) with underlying solid organ tumours or haematological malignancies | Charlson index, primary source of infection, catheter related source of infection, septic shock, <i>C. tropicalis</i> , central venous catheter removal within 48 hours, adequate combined treatment within 48 hours | <i>Candida</i> spp. | Low | Yes | 3.1 | 27 | 7 | The authors found that more than 1/4 of all <i>Candida</i> spp. isolates were non-susceptible to fluconazole, and that removal of the catheter and adequate antifungal treatment were associated with lower mortality. | |

| | | | | | | | | | | | | | | | |
|------|---|--|-----|-----|----------|--|--|--|--|-----|-----|------|----|----|---|
| | | | | | | malignancies | | | | | | | | | |
| 2016 | Clinical features and outcomes of Candidaemia in cancer patients: Results from Pakistan | Raza, Zafar, Mahboob et al [162] | 311 | 166 | Pakistan | To evaluate clinical risk factors and outcomes among cancer patients with candidaemia at a large cancer treatment centre | Cancer patients with a positive blood culture for <i>Candida</i> species between January 1995 and December 2013 | Time period (1996-2005, 2006-2009, 2010-2013), Age group (18-59 year, Younger than 18 years, 60 years or older), sex, haematological malignancy (Compared to solid tumours), <i>Candida albicans</i> (Compared to non- <i>C.albicans</i> or mixed), bacteraemia, shock, receiving chemotherapy, receiving total parenteral nutrition, receiving steroids, absolute neutrophil count 500 or more, duration of stay in hospital, receiving Amphotericin B (Compared to those not receiving), empirically, after positive culture | <i>Candida</i> spp. | Low | No | 10.4 | 16 | 16 | The authors wrote that the model was developed through forward selection, but do not report a stop criterion. We were unable to find the number of deaths. The authors did not find an association between death and different <i>Candida</i> species. |
| 2017 | A fresh look at polymicrobial bloodstream infection in cancer patients | Royo-Cebrecos, Gudiol, Ardanuy et al [117] | 194 | 62 | Spain | To assess the current incidence, clinical features, risk factors, aetiology, antimicrobial resistance and outcomes of polymicrobial bloodstream infection (PBSI) in patients with cancer | Consecutive episodes of primary bloodstream infections occurring in patients with cancer, including haematopoietic stem cell transplant recipients, from January 2006 to December 2015 | Sex, age, solid tumor, MASCC risk score < 21, corticosteroid therapy, persistent bacteremia, respiratory source, septic Shock, malignancy-related complications | Several bacteria and fungi, tested for resistance towards several antimicrobials | Low | Yes | 6.9 | 11 | 9 | The authors used stepwise regression but also included clinically relevant variables in the final model regardless if they were significant or not in the univariate model. There is another model in this article with more patients analysing risk factors for polymicrobial bloodstream infections, which we did not consider to be intrinsically resistant. In the mortality model, the authors did not find that multidrug-resistant bacteria factor met the criterion in the univariable analysis to be included in the |

| | | | | | | | | | | | | | | | |
|------|---|--|-----|----|---------|--|---|---|---|--------|-----|------|----------------|-----|---|
| | | | | | | | | | | | | | | | multivariable model. |
| 2017 | Characteristics, aetiology, antimicrobial resistance and outcomes of bacteraemic cholangitis in patients with solid tumours: A prospective cohort study | Royo-Cebrecos, Gudiol, Garcia et al [33] | 170 | 45 | Spain | To assess the clinical features, aetiology, antimicrobial resistance and outcomes of bacteraemic cholangitis in patients with solid tumours (ST) | All consecutive episodes of bacteraemic cholangitis occurring in patients with solid tumours from January 2006 to September 2015 | Sex, age, pancreatic tumour, biliary tumour, corticosteroid therapy, fever >38C, malignancy-related complications | Several bacteria, tested for resistance towards several antibiotics | Low | Yes | 6.4 | 10 | 7 | The authors used stepwise regression but also included clinically relevant variables in the final model regardless if they were significant or not in the univariate model. The authors did not find an association between multidrug-resistance and mortality, and do not include it in the final, multivariable model |
| 2017 | Clinical Impact of Colonization with Multidrug-Resistant Organisms on Outcome after Autologous Stem Cell Transplantation: A Retrospective Single-Center Study | Scheich, Reinheimer, Brandt et al [51] | 184 | 45 | Germany | To assess patient outcomes after auto-HSCT in relation to colonization with MDRGN and/or VRE and/or MRSA | Patients admitted to a haematological and oncological department for auto-haematopoietic stem cell transplantation between January 2012 and October 2015, screened for multi drug resistant organisms | multi drug resistant organism colonisation (MDRO), age >55 yr, prior therapies >2, ECOG | MDRO | Medium | No | 11.3 | Indeterminable | 4.0 | The authors find an association between higher mortality and colonisation by multidrug-resistant organisms |
| 2018 | Bloodstream infections with gram-negative organisms and the impact of multidrug resistance in patients with hematological | Scheich, Weber, Reinheimer et al [62] | 109 | 25 | Germany | To analyze the impact of BSI with different gram-negative multidrug-resistant bacteria | Patients with haematological malignancies and bloodstream infection with Gram-negative rods | Sex, age > 65 years, multidrug resistant gram negative bloodstream infections (BSI), nonfermenter BSI, ANC < 500/ μ l duration until BSI (days), antibiotic prophylaxis, ICU admission, Charlson index > 4 points | Gram-negative bacteria, multidrug-resistance | Low | Yes | 3.1 | 18 | 8 | The authors used stepwise regression but they also included sex factor in the final model. The authors found that both being infected by a |

| | | | | | | | | | | | | | | | |
|------|---|---|-----|-----|-------------|--|---|---|--|--------|-----|-----|----------------|----|---|
| | malignancies | | | | | (MDRGN) compared to BSI with antibiotic susceptible gram-negative bacteria | between January 2008 and December 2016 | | | | | | | | multidrug-resistant Gram-negative bacterium or a non-fermenter is associated with higher mortality |
| 2018 | Prognosis of Acute Respiratory Distress Syndrome in Patients With Hematological Malignancies | Seong, Lee, Hong et al [52] | 185 | 106 | South Korea | To investigate the clinical characteristics and outcomes of ARDS in patients with hematological malignancies admitted to the ICU | All adult patients admitted to the Intensive care unit with haematological malignancy and acute respiratory distress syndrome between January 1, 2008, and December 31, 2015 | Initial low tidal volume ventilation, severe acute respiratory distress syndrome, carbapenem resistant gram negative bacteria (CR - GNB), age, underlying malignancies, status of disease, neutrophil count, platelet count, SOFA score, prone positioning treatment, vasopressors treatment, renal replacement therapy, gram negative bacteria, blood transfusion, pulmonary aspergillosis | Several bacteria and fungi, tested for resistance towards several antimicrobials | Medium | Yes | 8.8 | 33 | 12 | The authors used stepwise regression but also included clinically relevant variables in the final model regardless if they were significant or not in the univariate. The authors found that the mortality of patients with haematological malignancies that are moved to the ICU with ARDS was associated with carbapenem-resistant Gram-negative bacteria |
| 2019 | Risk factors for mortality due to <i>Acinetobacter baumannii</i> bacteremia in patients with hematological malignancies – a retrospective study | Shargian-Alon, Gafter-Gvili, Ben-Zvi et al [82] | 46 | 33 | Israel | To explore risk factors for short-term mortality in patients with hematological malignancies and carbapenem resistant <i>Acinetobacter baumannii</i> (CRAB) bacteremia in our hospital | Hospitalised adult patients with either active haematological malignancy or past treatment for haematological malignancy in the preceding five years and <i>Acinetobacter baumannii</i> bacteremia between January 2010 and August 2018 | Appropriate empirical antibiotics within 48 h, SOFA score, ventilated at infection onset, urinary catheter at infection onset, duration of hospitalisation prior to bacteremia, absolute neutrophil count, creatinine level | <i>Acinetobacter baumannii</i> | Low | Yes | 4.7 | 25 | 7 | The authors found that there was a much lower mortality associated with being put on appropriate empirical antibiotic therapy within 48 hours |
| 2020 | Colonization with | Stratmann, | 295 | 31 | Germany | To | Patients | Multi drug resistant organism | MDRO | Low | No | 2.8 | Indeterminable | 11 | The authors |

| | | | | | | | | | | | | | | | |
|------|--|----------------------------|-----|-----|-------|--|--|--|---|--------|----------------|------|----------------|----|---|
| | multi-drug-resistant organisms negatively impacts survival in patients with non-small cell lung cancer | Lacko, Ballo et al [34] | | | | determine the impact of MDRO colonization in patients who have been diagnosed with Non-small cell lung cancer (NSCLC) who are at known high risk for invasive infections | diagnosed with stage 1-4 non-small cell lung cancer between 2012 and 2016 and screened for multi drug resistant organisms | colonisation (MDRO), male gender, age at diagnosis, extensive diagnosis, histology: squamous cell carcinoma, histology: others, ECOG 1, ECOG 2, ECOG 3, ECOG 4, diabetes mellitus | | | | | | | concluded that the patients who were colonised by MDROs had a poorer survival than patients without such an infection |
| 2020 | Inappropriate initial antimicrobial therapy for hematological malignancies patients with Gram negative bloodstream infections | Tang, Wu, Cheng et al [59] | 361 | 45 | China | To determine whether IIAT affects the prognosis in this patient population and recommend the appropriate antibiotic regimen to minimize IIAT | Patients admitted to three university-affiliated tertiary care hospitals from January 2010 to April 2015 | Age > 60 years, acute respiratory failure, disease relapsed or uncontrolled, platelet < 10 × 10 ³ mm ⁻³ , Pitt score ≥ 4, 72-h IIAT | Gram-negative bacteria, tested for resistance towards several antibiotics | Medium | Indeterminable | 7.5 | Indeterminable | 6 | The authors did not disclose how they selected the variables to be included in the multivariable model of mortality. The authors did not find an association between intrinsically resistant pathogenic species and mortality, but found that inappropriate initial antimicrobial therapy was associated with higher mortality. |
| 2021 | Gram-Negative Bacteria Bloodstream Infections in Patients with Hematological Malignancies – The Impact of Pathogen Type and Patterns of Antibiotic Resistance: A Retrospective | Tang, Xu, Xiao et al [60] | 835 | 313 | China | The authors retrospectively analyzed multi-center clinical data of patients with HMs complicated with GNBBSI over a 9 year timeframe, | Patients aged >16 years old with haematological malignancies and Gram negative bacteria-bloodstream infection, in 3 hospitals of Hunan | Age >60, sex, relapsed or uncontrolled malignancy, MASCC score<21, urine tube, use of vasopressors, acute respiratory failure, renal insufficiency, prior antimicrobial exposure, carbapenem resistant gram negative | Gram-negative bacteria, carbapenem resistance | Medium | Yes | 17.4 | 18 | 18 | The authors used stepwise regression but also included clinically relevant variables in the final model regardless if they were significant or not in the univariate. Authors highlighted that |

| | | | | | | | | | | | | | | | |
|------|--|---|-----|-----|--------|--|--|---|--|--------|-----|------|----|----|--|
| | Cohort Study | | | | | with the purpose of exploring the influence of different pathogen type and antibiotic resistance patterns on prognosis of patients | province, from January 2010 to May 2018. | bacteria , non fermentative bacteria, inadequate antibiotic treatment, hemoglobin <70g/Dl, platelet <10 ×103mm-3 , albumin <30g/L, AST >120 U/L, total bilirubin >34.2µmol/L, prothrombin time >14s | | | | | | | BSI caused by non-fermenting GNB, disease state, presence of acute respiratory failure, use of vasopressors, and inadequate antibiotic treatment were risk factors for a poor prognosis at 7 days. |
| 2016 | Bloodstream infections caused by <i>Klebsiella pneumoniae</i> in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey | Trecarichi, Pagano, Martino et al [101] | 278 | 101 | Italy | To identify risk factors for mortality in patients suffering from hematologic malignancies (HMs) with bloodstream infections (BSIs) caused by <i>Klebsiella pneumoniae</i> (KP) | All episodes of bloodstream infections caused by <i>K. pneumoniae</i> that occurred in hospitalised haematologic malignancy patients | Age>55 years old, ANC<100/mmc, ANC<500/mmc, acute myeloid leukaemia, non Hodgkin's lymphoma, Hodgkin's lymphoma, haematological disease newly diagnosed / relapsed after one remission, hematologic stem cell transplant HSCT, autologous HSCT, septic shock, altered state of consciousness, acute renal failure, acute respiratory failure, acute hepatic failure, inadequate initial antimicrobial therapy, carbapenem resistant by <i>Klebsiella pneumoniae</i> | <i>Klebsiella pneumoniae</i> , carbapenem-resistance | Medium | Yes | 6.3 | 31 | 16 | Contains one model for carbapenem-susceptible and one model for carbapenem-resistant <i>K. pneumoniae</i> infections. Finds higher mortality among patients with a resistant infection than a susceptible infection. |
| 2021 | Clinical features and outcome of <i>Aeromonas sobria</i> bacteremia in pediatric and adult patients with hematologic malignancies: A single-center retrospective study in Peru | Valcarcel, De-la-Cruz-Ku, Malpica et al [109] | 37 | 10 | Peru | To describe the clinical features and outcome of patients with malignant hematologic diseases diagnosed with <i>A. sobria</i> bacteremia and to identify the factors associated with survival in this population | Adult and paediatric patients with hematologic diseases and <i>A. sobria</i> bacteremia hospitalised in the National institute of Neoplastic diseases from January 2000 to December 2017 | Age group, comorbidities, qSOFA score, type of bacteremia | <i>A. sobria</i> | Low | No | 2.5 | 4 | 4 | The authors showed that organ failure and community acquired bacteremia increased the risk of mortality |
| 2018 | <i>Stenotrophomona</i> | Velázquez- | 76 | 38 | Mexico | To describe | Patients aged | Model 1 in BSI: central venous | <i>S. maltophilia</i> | Medium | Yes | 12.7 | 5 | 3 | This study |

| | | | | | | | | | | | | | | | |
|------|---|--|----|----|-----|--|---|--|---------------------|--------|-----|-----|---|---|--|
| | <i>S. maltophilia</i> bacteremia and pneumonia at a tertiary-care oncology center: a review of 16 years | Acosta, Zarco-Márquez, Jiménez-Andrade et al [146] | | | | the clinical characteristics and antimicrobial patterns of <i>Stenotrophomonas maltophilia</i> bloodstream infections (BSI) and pneumonia episodes in patients with cancer. | >18 years old with cancer hospitalised in Instituto Nacional de Cancerología with <i>S. maltophilia</i> bloodstream infection or pneumonia, from January 2000 to 31 December 2016 | catheter removal; Model 2 in pneumonia: age <65 years, received antibiotherapy with Sulfamethoxazole / trimethoprim, received appropriate treatment for <i>S. maltophilia</i> | | m | | | | | contains 2 mortality models: one for BSI 30 days mortality and one for pneumonia 30 days mortality. Numbers were extracted from the pneumonia mortality model. The authors showed that for patients with pneumonia by <i>S. maltophilia</i> , age>65 and not having received an appropriate treatment were risk factors for higher mortality within 30 days. |
| 2015 | The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality | Wang, Farmakiotis, Yang et al [107] | 67 | 28 | USA | To describe <i>Candida</i> spp. and in vitro susceptibility patterns in a contemporary series of patients with acute leukaemia and candidaemia, in view of the recently updated susceptibility breakpoints. To investigate | Patients ≥18 years of age with Acute myeloid leukaemia, Acute lymphoid leukaemia or myelodysplastic syndrome, with Candidemia from 1 January 2008 to 31 October 2012 | 14 days mortality models 1 and 2 : age >65 years old, intensive care unit stay, APACHE II score >20, mechanical ventilation, vasopressors, caspofungin non-susceptibility, multidrug resistance ; 30 days mortality models 1 and 2 : sex, age >65 years old, ICU stay, APACHE II score >20, mechanical ventilation, vasopressors, caspofungin non-susceptibility, multidrug resistance | <i>Candida</i> spp. | Medium | Yes | 4.0 | 7 | 7 | There are four models displayed in the study. Numbers were extracted from the 14 days mortality model 1: The authors showed, after multivariable analysis, association between 14 or 30 days mortality and <i>Candida</i> spp. BSI that were non-susceptible to caspofungin. However, no statistically significant association was found between mortality and removal of CVC. |

| | | | | | | | | | | | | | | | |
|------|--|--|-----|----|--------|--|---|---|---|--------|-----|-----|----|----|---|
| | | | | | | the association between in vitro resistance of <i>Candida spp.</i> to the most commonly used antifungals and all-cause mortality rates | | | | | | | | | |
| 2020 | Infectious Complications in Patients With Multiple Myeloma After High-Dose Chemotherapy Followed by Autologous Stem Cell Transplant: Nationwide Study of the Infectious Complications Study Group of the Polish Adult Leukemia Group | Waszczuk-Gajda, Drozd-Sokołowska, Basak et al [53] | 336 | 16 | Poland | To evaluate the epidemiology, etiology, and outcome of infections in patients with MM undergoing ASCT in 13 Polish transplant centers | Patients with multiple myeloma having received autologous hematopoietic stem cell transplant during the 3 years period from 2012 to 2014, within one of 13 Polish transplant centres. | Bacterial multi drug resistant infection, coexistence of fungal infection, clinically documented infection | Several fungi and bacterial species, multidrug resistance | Medium | Yes | 5.3 | 9 | 3 | The authors highlighted 3 fatal outcome risk factors: MDR infection, fungal coinfection, Clinically documented infection, to adapt infection control in transplants recipients, with small sample size (16 infection related deaths). |
| 2017 | Bacteraemia due to AmpC β -lactamase-producing <i>Escherichia coli</i> in hospitalized cancer patients: risk factors, antibiotic therapy, and outcomes | Zhang, Zhang, Li et al [154] | 248 | 62 | China | To assess risk factors, antibiotic therapy, and outcomes of AmpC-EC bacteraemia in hospitalized cancer patients | Patients aged >18 years old with solid or haematological tumour, with <i>E. coli</i> bacteremia between September 2012 and December 2015 | Abdominal infection, Urinary tract infection, unknown origin of infection, intensive care unit stay, invasive procedures, previous blood transfusion, cancer with metastasis, septic shock, organ failure, length of stay, timing of appropriate antibiotherapy | <i>E. coli</i> , AMPc Beta-Lactamase positive or negative | Low | Yes | 5.6 | 29 | 11 | The death model includes all bacteremias that were AMPc positive and negative but the study design excludes ESBL <i>E. coli</i> bacteremia. |

Supplementary material 5

Table S5 - All included articles in the systematic review with both an infection/colonisation outcome and a mortality outcome

| Year | Title | Authors | Number of patients | Number of events in the final (and largest) model | Country/setting | Study aim statement | Patient population | Factors included in the final model | Microbial aetiology and resistance | Risk of bias grading (NIH tool) | Bivariable screening/stepwise regression | Events per variable in the final (and largest) model | Number of variables included in the tested/screened/initial model | Number of variables included in the final (and largest) model | Comments |
|------|---|---|--------------------|---|-----------------|---|--|---|---|---------------------------------|--|--|---|---|---|
| 2021 | The Impact of Modifying Empirical Antibiotic Therapy Based on Intestinal Colonization Status on Clinical Outcomes of Febrile Neutropenic Patients | Alrstom, Alsuliman, Daher et al [67] | 201 | 68 | Syria | To assess the intestinal colonization rate of ESBL-E and CRE | Adults older than 18 years of age with haematological malignancies who received chemotherapy and developed febrile neutropenia | Infection model: age, gender, prior quinolone use, prior hospitalization during previous month ; Mortality model: age, sex, extended spectrum beta lactamase carriage, carbapenem resistant <i>Enterobacteriaceae</i> carriage | Extended-spectrum β -lactamase-producing <i>Escherichia coli</i> and Carbapenem-Resistant <i>Enterobacteriaceae</i> | Medium | Yes | 17.0 | 17 | 4 | The stepwise regression also includes the age and sex variables. The authors did not find that carriage of the two resistant microbes increases the risk of dying. Numbers are taken from the infection model. |
| 2018 | Bloodstream infection caused by <i>S.aureus</i> in patients with cancer: a 10-year longitudinal single-center study | Bello-Chavolla, Bahena-Lopez, Garciadieg-o-Fosass et al [152] | 450 | 92 | Mexico | To evaluate incidence, risk factors, clinical course, and 30-day mortality related to <i>S. aureus</i> bloodstream infection (SABIs) in cancer patients | All positive, non-duplicate, blood cultures for <i>S.aureus</i> | Infection model: hematologic neoplasm, solid neoplasia, healthcare associated bloodstream infections (BSI), hospital acquired BSI, foci as healthcare associated pneumonia, central venous catheter (CVC), neutropenia, gram negative bacteria coinfection, gram positive bacteria coinfection, inpatient management, | Methicillin-resistant <i>Staphylococcus aureus</i> | Medium | Yes | 5.8 | 28 | 16 | Authors created a risk stratification based on the regression coefficients from the mortality model. The final model table can be found in supplementary material. The final model is also adjusted for CCI and glycemia >140 mg/dL. Numbers extracted from the infection model of MRSA |

| | | | | | | | | | | | | | | | |
|------|--|------------------------------------|-----|---|-----|---|---|---|---|--------|-----|-----|----|---|--|
| | | | | | | | | specific anti SA treatment, CVC removal, days from infection to CVC removal, intensive care admission, septic shock, relapse after <i>S. aureus</i> bacteremia. Mortality model: abdominal source, hematologic malignancy, Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA), glucose > 140 mg/dL, catheter removal, anti-staph treatment < 48 h, infectious endocarditis | | | | | | | infection in hematologic malignancies. |
| 2019 | Carbapenem versus Cefepime or Piperacillin-Tazobactam for Empiric Treatment of Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing <i>Escherichia coli</i> in Patients with Hematologic Malignancy | Benanti, Brown, Shigle et al [103] | 103 | 8 | USA | To compare mortality in patients with hematologic malignancy and ESBL-producing <i>E. coli</i> bacteremia treated empirically with carbapenems or the potential carbapenem-sparing alternative cefepime or piperacillin tazobactam. To compare other clinically relevant outcomes | Patients with hematologic malignancy and a first episode of mono-microbial extended spectrum beta lactamase-producing <i>E. coli</i> bacteremia | Infection model: cefepime treatment, piperacillin-tazobactam treatment (all vs Carbapenem treatment), age. Mortality model: cefepime treatment, Pitt bacteremia score, intensive care unit residence | Extended-Spectrum-β-Lactamase-Producing <i>Escherichia coli</i> | Medium | Yes | 4.0 | 11 | 2 | The stepwise regression included the cefepime treatment variable. The infection outcome is persistent bacteraemia. Authors found that only Pitt bacteraemia score is associated with an increased mortality. Numbers were extracted from 14 days mortality model |

| | | | | | | | | | | | | | | | |
|------|---|---|--------|-------|--------|--|--|---|---|------|-----|---------|----------------|---|---|
| | | | | | | achieved with these agents, including the persistence of bacteremia and fever | | | | | | | | | |
| 2019 | Associated factors and clinical outcomes of bloodstream infection due to extended-spectrum β -lactamase-producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> during febrile neutropenia | Ben-Chetrit, Eldaim, Bar-Meir et al [126] | 80 | 80 | Israel | To evaluate factors associated with ESBL-positive bacteremia among neutropenic patients, as well as its impact on clinical outcome | All patients with hematologic or oncologic (solid tumours) diseases who were diagnosed with extended spectrum beta lactamase (ESBL) - positive and ESBL-negative <i>Escherichia coli</i> or <i>Klebsiella pneumoniae</i> bacteremia during febrile neutropenia between January 2010 and October 2017 | Infection model: pathogene type, fungal infection within 30 days, presence of central venous catheter long term during index culture, admission days prior index culture, index culture >48h, previous antimicrobial therapy (6 months). Mortality model: extended spectrum beta lactamase-positive bacteremia, appropriate empirical antimicrobial therapy, charlson comorbidity index (CCI) >4, Pitt bacteremia score \geq 4, underlying disease. | Extended-spectrum β -lactamase-producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> | Low | Yes | 16.0 | 25 | 5 | Authors found that a central venous catheter and previous antibiotic use is associated with ESBL-positive Gram-negative bacteraemia, but that the ESBL-positivity is not associated with an increase in mortality. Both models are the same size hence we chose the infection model to extract the data : extended-spectrum β -lactamase(ESBL)-positive Gram-negative bacteremia. |
| 2018 | Risk, Outcomes, and Predictors of <i>Clostridium difficile</i> Infection in Lymphoma: A Nationwide Study | Bhandari, Pandey, Dahal et al [79] | 236312 | 19358 | USA | To determine the risk of CDI in hospitaliza | All adult patients aged 18 years or older with the primary diagnosis of lymphoma between 2007 and 2011 | Age, sex, race, Hodgkin lymphoma, hematologic stem cell transplant, chemotherapy, radiotherapy, gastro | <i>Clostridioides difficile</i> | High | No | 19358.0 | Indeterminable | 1 | Authors found that HSCT, chemotherapy and surgery in the gut is associated with |

| | | | | | | | | | | | | | | | |
|------|--|------------------------------------|---------|--------------|--------|--|--|---|---|--------|----------------|--------------|----------------|--------------|---|
| | | | | | | tions with lymphoma along with its trend, outcomes, and predictors | | intestinal surgery, infection, GVHD, IBD, CCI, year of admission. Mortality: <i>C. difficile</i> infection. | | | | | | | CDI, which increases the risk of death. Numbers were extracted from the mortality model. Most of the dataset is simulated using weights to create national estimates. |
| 2018 | Risk factors for bloodstream infections due to extended-spectrum β -lactamase producing <i>Enterobacteriaceae</i> in cancer patients | Ceken, Iskender, Gedik et al [127] | 122 | 31 | Turkey | To identify the risk factors and outcomes related to BSIs caused by extended-spectrum beta-lactamase (ESBL)-producing <i>Enterobacteriaceae</i> in cancer patients | Haematology/oncology patients with culture positive bloodstream infections with <i>E. coli</i> or <i>Klebsiella</i> spp from January 2013 to December 2014 | Infection model: Quinolone prophylaxis, piperacillin-tazobactam previous 90 days, carbapenem previous 90 days, GNB infection previous 3 months and total parenteral nutrition. Mortality model : neutropenia, duration of neutropenia before infection, inappropriate treatment, delay for appropriate treatment, complications (hypoxia, septic shock etc.). | Extended-spectrum β -lactamase producing <i>Escherichia coli</i> and <i>Klebsiella</i> spp. | Medium | Yes | 10.3 | 4 | 3 | It is not clear whether the authors used $p < 0.05$ to include the variables in the multivariable models. Numbers were extracted from the 30 days mortality model. For the infection model, authors found out that quinolone prophylaxis, total parenteral nutrition, piperacillin or carbapenem for the previous 90 days, or previous infection with GNB previous 90 days were risk factors to develop ESBL-P BSIs. Authors found that two factors were associated with an increased mortality in BSI cancer patients - prolonged neutropenia and complications. |
| 2017 | Poorer outcomes | Delgado, | 3024442 | Indeterminab | USA | To | Patients ≥ 18 years | Indeterminable | <i>Clostridioides</i> | High | Indeterminable | Indeterminab | Indeterminable | Indeterminab | Authors found |

| | | | | | | | | | | | | | | | |
|------|---|--------------------------------------|-----|----|--------|---|--|---|---|-----|-----|-----|----|----|--|
| | among cancer patients diagnosed with <i>Clostridium difficile</i> infections in United States community hospitals | Reveles, Cabello et al [138] | 6 | le | | describe CDI incidence and health outcomes nationally among cancer patients in the United States | old with a principal or secondary ICD-9-CM code (discharge diagnosis of cancer) obtained from the U.S. National Hospital Discharge Surveys from 2001 to 2010 | | <i>difficile</i> | | | le | | le | that CDI significantly increased the risk for mortality and prolonged hospital stays among cancer patients. But overall the authors do not give any details about the model which was computed here. |
| 2018 | Role of Lock Therapy for Long-Term Catheter-Related Infections by Multidrug-Resistant Bacteria | Freire, Pierotti, Zerati et al [112] | 212 | 75 | Brazil | To analyze outcomes in cancer patients with LTCVC associated infection, identify risks for unfavorable outcomes, and determine the impact of MDR bacteria and antibiotic lock therapy (ALT) in managing such infections | All long-term central venous catheter (LTCVC)-associated infections diagnosed at the a cancer institute between January 2009 and December 2016 | Haematological malignancies, type of CT last 3 months, palliative care, ICU admission, hemodynamic instability, SOFA score, CVC duration, <i>A.baumani</i> , polymicrobial infection, Nadir WBC count, adherence to protocol, antibiotic lock therapy | Several bacteria and fungi, tested for resistance towards several antibiotics | Low | Yes | 6.3 | 28 | 12 | Model of relapse and mortality model. Numbers were extracted from the treatment failure or relapse model. The authors found that ALT is a protective factor for relapse risk and that there is an increased hazard of death when the patient is infected by multidrug-resistant bacteria, but that antibiotic lock therapy is associated with a decrease in death. |
| 2018 | Gut Colonization with Carbapenem-resistant <i>Enterobacteriaceae</i> Adversely Impacts | Jaiswal, Gupta, Kumar et al [68] | 225 | 48 | India | To evaluate the prevalence of colonisation with | Patients with newly diagnosed haematological malignancy admitted from October 2013 to January 2016 | Age, gender, acute leukaemia, acute myeloid leukaemia, Charlson comorbidity index, performance status | <i>Enterobacteriaceae</i> , carbapenem-resistance | Low | No | 8.0 | 6 | 6 | The authors concluded that there is an association between having acute leukaemia and being at risk |

| | | | | | | | | | | | | | | | |
|------|---|----------------------------|---------|-------|-----|--|---|--|---------------------------------|------|----|---------|---|---|---|
| | the Outcome in Patients with Hematological Malignancies: Results of A Prospective Surveillance Study | | | | | CRE in patients with haematological malignancies and its impact on the outcome of the patients undergoing treatment for these disorders | | | | | | | | | of both contracting and dying to a CRE infection. Numbers were extracted from the model for risk to be colonised to CRE before hospital admission. |
| 2015 | Outcomes of <i>Clostridium difficile</i> Infection in Hospitalized Leukemia Patients: A Nationwide Analysis | Luo, Greenberg, Stone [80] | 1243107 | 95355 | USA | To determine the trend of incidence of CDI in hospitalized leukemia patients, to evaluate the impact of CDI on mortality and expense, and to identify the risk factors for developing CDI in | Adults, aged ≥18 years, with a primary diagnosis code for leukaemia | Infection model: age, gender, race (Caucasian, Black, Hispanic, Asian/Pacific Islander, Native American), length of stay (days: 2, 3–5, 6–10, 11–15, ≥16), hospital teaching status, leukaemia type, complications (several), Charlson index (0, 1, 2, 3, 4, >5). Mortality model: age <65, gender, race, Charlson index score, teaching status of hospital, the presence of complications or comorbidities (eg, hypertension, | <i>Clostridioides difficile</i> | High | No | 13622.1 | 7 | 7 | The authors found a number of demographic or clinical associations with CDI, and that CDI was also associated with mortality. It is not reported how much of the dataset is individual data or projections based on weights. Numbers were extracted from the mortality model because no details are given concerning the other infection model. |

| | | | | | | | | | | | | | | | |
|------|---|---------------------------------------|-----|----|----------|---|--|--|--|-----|-----|-----|----|----|--|
| | | | | | | this population | | diabetes, pneumonia, etc.), and the performance of bone marrow vs stem cell transplant during hospitalisation. | | | | | | | |
| 2017 | Carbapenem-resistant <i>Klebsiella pneumoniae</i> in high-risk haematological patients: factors favouring spread, risk factors and outcome of carbapenem-resistant <i>Klebsiella pneumoniae</i> bacteremias | Micozzi, Gentile, Minotti et al [102] | 19 | 10 | Italy | To identify conditions favouring CRKP spread in a haematological unit, assess risk factors for bacteremia in haematological patients colonized with CRKP, and analyse risk factors for poor outcome among haematological patients with CRKP bacteremia. | All patients with haematological malignancies infected or colonised with carbapenem resistant <i>K. pneumoniae</i> (CRKP), hospitalised between 24 February 2012 and 31 May 2013 | Infection model: underlying disease, age, gender, intensive chemotherapy, ≥ 7 days colonised by carbapenem resistant <i>K. pneumoniae</i> . Mortality model 1: <i>Klebsiella</i> producing carbapenemase- <i>K. pneumoniae</i> bloodstream infection developing during inactive antibiotic treatment. Mortality model 2 and 3: initial adequate therapy, breakthrough bacteremia occurrence within 48 h of ongoing antibiotics, intensive Chemotherapy. | <i>Klebsiella pneumoniae</i> , carbapenem-resistance | Low | Yes | 3.3 | 19 | 3 | The infection outcome is bacteraemia. The authors found an association between AML and CRKP bacteraemia, and further that there was an association between survival and initial adequate therapy. Data was extracted from the final mortality model. |
| 2015 | Bacteraemia caused by <i>Escherichia coli</i> in cancer patients at a specialist center in Pakistan | Parveen, Sultan, Raza et al [155] | 227 | 80 | Pakistan | To analyse the antimicrobial susceptibility patterns of <i>Escherichia coli</i> | Cancer patients with <i>E. coli</i> bacteraemia during the 12 months from December 2012 to November 2013. | Infection model: sex, age less than 18 years, haematological malignancy, hospitalization within 30 days prior to infection, intensive care unit admission, Charlson score, | <i>Escherichia coli</i> , multidrug-resistant | Low | No | 6.7 | 12 | 12 | The infection outcome is MDR in <i>E. coli</i> bacteraemia. The authors concluded that MDR <i>E. coli</i> is not associated with an increase in mortality. |

| | | | | | | | | | | | | | | | |
|------|--|--|----|----|--------|---|--|---|---------------------|-----|-----|------|----|---|---|
| | | | | | | bacteraemia among cancer patients, and to assess the risk factors and outcomes of multidrug-resistant <i>Escherichia coli</i> bacteraemia | | central venous catheter use, previous chemotherapy within 30 days, previous surgery within 30 days, previous radiation within 30 days, absolute neutrophil count (ANC) less than 100 cells/mm ³ , use of quinolones within 90 days of index sampling, use of third generation cephalosporins within 90 days of index sampling, use of Piperacilin/Tazobactam within 90 days of index sampling, use of carbapenems within 90 days of index sampling. Mortality model: sex, age less than 18 years, haematological malignancy, hospitalisation within 30 days prior to infection, admission to intensive care unit, previous chemotherapy within 30 days, previous surgery within 30 days, previous radiation within 30 days, ANC less than 100 cells/mm ³ , Charlson score, multi drug resistant <i>E.coli</i> , inappropriate empiric antibiotic therapy. | | | | | | | Numbers were extracted from the mortality model. |
| 2020 | <i>Candida</i> spp bloodstream infections in a Latin American Pediatric Oncology | Paixao de Sousa da Silva, de Moraes-Pinto, Teofilo | 90 | 90 | Brazil | To characterize <i>Candida</i> spp bloodstream | Paediatric patients admitted to a paediatric oncology institute who presented with <i>Candida</i> spp. BSI | Model of treatment failure or infection model: age, hospitalisation, corticosteroid, prior antifungal use, skin | <i>Candida</i> spp. | Low | Yes | 10.0 | 31 | 9 | There are 2 models in this study, one for antifungal treatment failure (then an |

| | | | | | | | | | | | | | | | |
|------|--|--------------------------------------|-----|-----|-----|---|---|---|--|--------|----|------|----|----|---|
| | Reference Center: Epidemiology and associated factors | Pignati et al [160] | | | | m infections (BSI) in a reference centre for paediatric oncology and to describe the most prevalent risk factors associated with candida infections | from January 2004 to December 2016. | lesion, dissemination, <i>Candida</i> spp Species, <i>C. tropicalis</i> , treatment. 30 days Mortality model: Age, Hospitalisation, intensive care unit, corticosteroid, prior antifungal use, skin lesion, dissemination, <i>Candida</i> spp Species, <i>C. parapsilosis</i> | | | | | | | infection model), the other one for 30 days mortality. Numbers were extracted from the infection model. The authors found that older age and thrombocytopenia were good independent predictors of therapeutic failure and that <i>Candida parapsilosis</i> infection was associated with a lower mortality, while there was no association between <i>Candida tropicalis</i> and mortality. |
| 2017 | Epidemiology, risk factors, and outcomes of infections in patients undergoing liver transplantation for hilar cholangiocarcinoma | Ramanan, Cummins, Wilhelm et al [35] | 124 | 255 | USA | To describe the incidence, types, and risk factors of post-transplant infections in LT patients with CCA. | Adult patients who underwent liver transplantation for biopsy-proven hilar cholangiocarcinoma at a clinic between January 2004 and March 2013 | Infection model: vancomycin resistant enterococcus (VRE) colonisation pre-transplant, living donor transplant, cold ischemia time, cytomegalovirus donor seropositivity, hepatic artery thrombosis post-transplant, biliary stricture post-transplant, intra-abdominal fluid collection post-transplant, number of re-operations in 1st month post-transplant. Mortality model: abdominal infection, recurrent Hilar cholangiocarcinoma | Several bacteria and fungi, tested for resistance towards several antimicrobials | Medium | No | 15.9 | 16 | 16 | There are two more models with an infection outcome in the article, of abdominal infection and bloodstream infection, but the model of any post-transplant infection is included here. The authors modelled subsets of 10 variables for infections and 2 variables for death and selected the best model based on score. They found that |

| | | | | | | | | | | | | | | | |
|------|---|------------------------------------|------|----|-------------|--|--|---|---------------------------------|--------|-----|-----|----|----|--|
| | | | | | | | | , Post-transplant <i>C. difficile</i> infection, Bloodstream infection | | | | | | | infections are associated with increased mortality, and that VRE colonisation pre-transplant is associated with infection post-transplant. Numbers were extracted from the infection model. |
| 2016 | <i>Clostridium difficile</i> Infections amongst Patients with Haematological Malignancies: A Data Linkage Study | Selvey, Slimings, Joske et al [81] | 2085 | 65 | Australia | To identify risk factors for <i>Clostridium difficile</i> infection (CDI) and assess CDI outcomes among Australian patients with a haematological malignancy | Patients admitted at least once to any hospital in the region for treatment or management of a haematological malignancy in the period 1 July 2011 to 30 June 2012 | Infection model: acute lymphocytic leukaemia not in remission, neutropenia at any time, any bacterial pneumonia, other bacterial infection, any bacterial pneumonia and neutropenia at any time. Mortality model: acute myeloid leukaemia not in remission, <i>C. difficile</i> infection, age 65 and over, cerebrovascular disease, dementia, neutropenia at any time. | <i>Clostridioides difficile</i> | Low | Yes | 4.1 | 30 | 16 | There are two infection models, one with all patients and one with patients from October 2011. There are also two mortality models, one with death within 60 days and one with death within 90 days. The authors found that a <i>C. difficile</i> infection is associated with an increased mortality. Univariate analysis included both table 1 and 2. It is unclear where the dementia variable was taken from, but it is included in the mortality model. Numbers were extracted from the CDI model in all patients |
| 2020 | Risk factors for and clinical | Shin, Shin, Kang et al | 489 | 63 | South Korea | To explore | Adult patients (aged | Infection model: age, chemotherapy, | Gram-negative bacilli, | Medium | + | 4.5 | 22 | 14 | The authors found that |

| | | | | | | | | | | | | | |
|--|---|------|--|--|---|---|--|----------------------|--|--|--|--|--|
| | outcomes of carbapenem non-susceptible gram negative bacilli bacteremia in patients with acute myelogenous leukemia | [61] | | | the risk factors for carba-NS GNB bacteremia and its clinical outcomes in patients that underwent induction or consolidation chemotherapy for AML | ≥18 years) with acute myeloid leukaemia that contracted gram negative bacteremia during induction or consolidation chemotherapy, from January 2000 to December 2015 | isolation of VRE in the prior 1 year, isolation of ESBL in the prior 1 year, isolation of carbapenem resistant <i>A. baumannii</i> (CRAB) in the prior 1 year, presence of preceding bacteremia during the hospitalisation, central line associated infection, <i>E.coli</i> , <i>Pseudomonas</i> spp., <i>S. maltophilia</i> , <i>Acinetobacter</i> spp, antibiotics at the onset of gram negative bacteria (GNB) bacteremia, inappropriate empiric antibiotics, days from chemotherapy to GNB bacteremia, hospital days to GNB bacteremia. Mortality model: age, mean (± SD), induction or re-induction chemotherapy, isolation of vancomycin resistant enterobacteriaceae (VRE) in the prior 1 year, isolation of extended spectrum beta lactamase (ESBL) in the prior 1 year, isolation of CRAB in the prior 1 year, history of GNB bacteremia in the prior 1 year, presence of preceding bacteremia during the hospitalisation, pneumonia, Pitt score, septic shock, carba-non sensitive, inappropriate empiric antibiotics, days | carbapenem-resistant | | | | | carbapenem treatment at the onset of Gram-negative bacteraemia and infection with carbapenem-resistant <i>Acinetobacter baumannii</i> was associated with a carbapenem-resistant Gram-negative bacteraemia, and also that infection with VRE the previous year and carbapenem-resistance was associated with an increased mortality in patients with Gram-negative bacteraemia. Numbers were extracted from the mortality model. |
|--|---|------|--|--|---|---|--|----------------------|--|--|--|--|--|

| | | | | | | | | | | | | | | | |
|------|--|----------------------------------|--------|----------------|-------|---|--|--|---------------------------------|--------|-----|----------------|----|----|---|
| | | | | | | | | from chemotherapy to GNB bacteremia, hospital days to GNB bacteremia. | | | | | | | |
| 2019 | Trends in Incidence and Outcomes of <i>Clostridium difficile</i> Colitis in Hospitalized Patients of Febrile Neutropenia A Nationwide Analysis | Siddiqui, Khan, Khan et al [139] | 394987 | Indeterminable | USA | To assess the risk factors for development and mortality of CDI in patients with FN | All patients with primary and secondary diagnosis of febrile neutropenia, with and without <i>C. difficile</i> infection from years 2008 to 2014, according to the Nationwide Inpatient Sample (NIS) | Age, race, gender, Charlston Comorbidity Index, malignancy type, admission days, hospital region, hospital location, sepsis | <i>Clostridioides difficile</i> | High | No | Indeterminable | 23 | 23 | Authors showed that patients older than 65 years old, Hispanic race, and presence of sepsis were associated with increased risk of mortality in cancer patients with FN. In addition, Hispanic race, haematological malignancies, and sepsis were significant risk factors for development of CDI in these patients. Both models are the same size. |
| 2019 | Increase in <i>Candida Parapsilosis</i> Candidemia in Cancer Patients | Sun, Chen, Xiao et al [163] | 323 | 47 | China | To identify the risk factors of candidemia and assess possible clinically significant differences between <i>Candida parapsilosis</i> and other <i>Candida</i> species in a Chinese tertiary cancer center over six years | All patients with positive blood culture for <i>Candida</i> species at a cancer hospital from 1 March 2012 to 28 February 2018 | Infection by <i>C. parapsilosis</i> model: age, hematologic malignancy, in intensive care unit (ICU) at diagnosis, parenteral nutrition, neutropenia, previous surgery last 3 months, abdominal surgery, chemotherapy, previous antifungal use, duration of antifungal; Infection by <i>C. albicans</i> model: age, hematologic malignancy, ICU at diagnosis, neutropenia, abdominal surgery, central venous | <i>Candida</i> spp. | Medium | Yes | 5.2 | 23 | 9 | The authors concluded that there are several risk factors associated with a <i>Candida non-albicans</i> infection, but did not model the role of these infections in the mortality of patients. To compute the number of events per variable we chose the infection model by <i>C. parapsilosis</i> . |

| | | | | | | | | | | | | | | | |
|------|--|--------------------------------------|----|----|--------|--|--|--|--|-----|-----|-----|----|---|--|
| | | | | | | | | catheter (CVC) related candidemia, chemotherapy, previous antifungal use, duration of antifungal; Mortality model: age, ICU at diagnosis, mechanical ventilation, CVC related candidemia, removal of CVC. | | | | | | | |
| 2017 | <i>Pseudomonas aeruginosa</i> bacteraemia in patients with hematologic malignancies: risk factors, treatment and outcome | Tofas, Samarkos, Piperaki et al [83] | 64 | 23 | Greece | To identify factors associated with <i>Pseudomonas aeruginosa</i> (PA) bloodstream infection (BSI) in patients with hematologic malignancies and evaluate the outcome of the affected patients | Cases: Consecutive patients with hematologic malignancy who developed <i>P. aeruginosa</i> (PA) bloodstream infection (BSI) between January 2012 and December 2014. Controls: Patients with hematologic malignancies without PA infection. | Infection with <i>P. aeruginosa</i> model: severity of underlying disease (Ultimately fatal, Rapidly fatal), hospitalisation in preceding 3 months, surgery in preceding 3 months, neutropenia, use of steroids, Prior use of any antimicrobial, prior use of anti-pseudomonal lactams including carbapenems, prior use of Aminoglycoside, prior use of Fluoroquinolones. Infection with carbapenem-resistant PA model: hospitalization in preceding 3 months, anti-pseudomonal lactams, carbapenems, aminoglycoside, fluoroquinolones. Mortality model : severity of sepsis (Sepsis, Severe sepsis or septic shock), empirical treatment (No active drug, At least one active drug), definitive treatment (One active drug, | <i>Pseudomonas aeruginosa</i> , carbapenem resistant | Low | Yes | 7.7 | 19 | 3 | There are three models here, one for PA BSI, one for carbapenem-resistant PA BSI and one for mortality in patients with PA BSI. All numbers are extracted from the 28 days mortality model. The authors found that prior use of antibiotics were associated with PA BSI, and that prior hospitalisation was associated with carbapenem-resistance. |

| | | | | | | | | | | | | | | | |
|------|---|--|-----|----|-------|--|---|---|--|--------|----------------|-----|----------------|---|--|
| | | | | | | | | More than one active drugs). | | | | | | | |
| 2021 | Oral fluoroquinolones for definitive treatment of gram-negative bacteremia in cancer patients | Tossey, El Boghdady, Reed et al [122] | 211 | 39 | USA | To compare the outcomes of cancer patients transitioned from IV to oral (PO) therapy compared to continuation of IV treatment | Patients at a cancer centre with positive blood cultures for gram-negative organisms during the study period from November 1, 2011, to September 30, 2017 | Intravenous group, hematologic malignancy, neutropenia, <i>P. aeruginosa</i> infection, history of hematologic stem cell transplantation, Pitt bacteremia score, intensive care unit admission | Gram-negative bacteria | Medium | Indeterminable | 5.6 | Indeterminable | 7 | The authors modelled both infection recurrence and mortality as a composite outcome "treatment failure". No method for variable selection is disclosed. They found that having a <i>P. aeruginosa</i> infection is associated with this composite outcome. |
| 2019 | Bloodstream infections caused by <i>Escherichia coli</i> in onco-haematological patients: Risk factors and mortality in an Italian prospective survey | Trecarichi, Giuliano, Cattaneo et al [104] | 342 | 24 | Italy | To identify risk factors for 3GC resistance by EC isolates and prognostic factors, including the impact of 3GC resistance, in HM patients with BSIs caused by EC | All episodes of bloodstream infection caused by <i>E. coli</i> (EC BSI) occurring in hospitalised haematologic malignancies adult patients from January 2016 to December 2017 in 15 haematology wards | Infection model: recent endoscopic procedures, parenteral nutrition, polymorphonuclear leukocytes < 500/mm ³ for at least 10 days, previous antibiotic therapy, multiple myeloma, allogeneic matched unrelated transplant, multi drug resistant bacteria culture-positive surveillance rectal swabs, antibiotic prophylaxis with fluoroquinolones. Mortality model: sex, complete remission, autologous transplant, septic shock, altered consciousness, acute renal failure, acute respiratory failure, acute hepatic failure, 3rd generation | <i>Escherichia coli</i> , 3rd generation cephalosporin-resistant | Medium | Yes | 2.7 | 34 | 9 | The infection outcome here is resistance towards 3rd generation cephalosporins in <i>E. coli</i> bacteraemia. The authors found that such infections are associated with an increased mortality in these patients. All the numbers were extracted from the mortality model |

| | | | | | | | | | | | | | | | |
|------|--|----------------------------|-----|----|-------|---|--|---|--|-----|-----|-----|----|---|---|
| | | | | | | | | cephalosporins resistance by <i>E. coli</i> isolate. | | | | | | | |
| 2019 | Clinical outcome of <i>Escherichia coli</i> bloodstream infection in cancer patients with/without biofilm formation: a single-center retrospective study | Zhang, Gao, Li et al [156] | 324 | 71 | China | To investigate the impact of BF-positive, EC-caused BSI on the clinical outcome of hospitalized cancer patients | Adult patients (aged ≥18 years) with cancer and first episode of <i>E. coli</i> bloodstream infection hospitalised at Tianjin Cancer Institute from January 2013 to September 2017 | Infection models 1 (extended spectrum beta lactamase yes no) and 2 (biofilm formation yes no) : sex, age, hypertension, chronic heart disease, diabetes mellitus, solid tumor, hematological cancer, abdominal infection, urinary tract infection, biliary infection, pulmonary infection, catheter-related infection, unknown origin infection, others, C3G (or cephalosporin (model1) exposure previous month, betalactam with or without inhibitor of betalactamase exposure previous month, carbapanems exposure previous month, combined exposure previous month, aminoglycoside exposure previous month, invasive procedure, surgery previous month, chemotherapy, ESBL, LOS (model 1). Mortality model: sex, age, hypertension, chronic heart disease, diabetes mellitus, solid tumor, hematological cancer, LOS, ICU, invasive procedure, mechanical ventilation, | ESBL-producing <i>Escherichia coli</i> or biofilm-producer <i>Escherichia coli</i> | Low | Yes | 8.9 | 18 | 8 | The authors concluded biofilm is a risk factor for mortality , and also to be ESBL or not (and vice versa). No clear association between infection with biofilm-producer and antibiotics used. Numbers were extracted from the mortality model. |

| | | | | | | | | | | | | | | | |
|------|--|---------------------------|-----|-----|-------|---|---|--|--|--------|---|------|----|---|---|
| | | | | | | | | metastasis, chemotherapy, surgery, previous blood transfusion, ESBL, BF, organ failure and sepsis shock | | | | | | | |
| 2020 | Risk Factors and Outcomes of Antibiotic-resistant Pseudomonas aeruginosa Bloodstream Infection in Adult Patients With Acute Leukemia | Zhao, Lin, Liu et al [84] | 293 | 293 | China | To evaluate clinical factors associated with the outcomes of PA BSI and identify factors associated with the development of PA BSI caused by carbapenem-resistant (CR) or multidrug resistant (MDR) strains | Adult patients hospitalised with Acute Leukaemia and P. aeruginosa bloodstream infection from January 2014 to December 2019 | Infection model 1 : Previous use of fluoroquinolones, previous use of piperacillin-tazobactam, previous use of carbapenems, HSCT. Infection model 2 : Previous use of fluoroquinolones, previous use of piperacillin-tazobactam. Death model : Age>55, Perianal infection, Pulmonary infection, MDR-PA | <i>P. aeruginosa</i> , carbapenem resistant or MDR | Medium | + | 48,8 | 14 | 6 | Outcomes for infection are 1) Carbapenem-resistant <i>P. aeruginosa</i> infection or 2) MDR <i>P. aeruginosa</i> infection. Variables with p<0.1 in the univariate analysis were included in the multivariable model. The authors found that MDR is associated with bad prognosis in BSI <i>P. aeruginosa</i> patients, and they have tried to show as well that exposure to certain classes of antibiotics could lead to developing MDR <i>P. aeruginosa</i> BSI in these patients. They aimed to enhance the role of an appropriate antibioprohylax is in acute leukaemia patients. Numbers were taken from infection model MDR PA BSI. |

Supplementary material 6

Table S6 - All risk factors investigated in the final, multivariable model of the included studies, and their respective categories.

| Infection/colonisation | |
|-------------------------------|--|
| Category | Included risk factors |
| Antibiotic use | <p>Antibiotic use, Mean length of CDI treatment, CDI treatment failure, Ciprofloxacin, Levofloxacin, Meropenem, Antipseudomonal penicillin, Cumulative glycopeptide exposure, Susceptibility to applied perioperative antibiotics, β-lactam/β-lactamase inhibitor, Cephalosporin, Metronidazole, Previous antibiotic therapy, Prior antibiotic use, Days of empiric antibiotics, Cycling vs carbapenem period, Days of carbapenem, Days of cefepime or piperacillin/tazobactam, Antibiotics prior 3 mo, Antibiotics (no.), Antibiotics (d), Antibiotic therapy within 30 days, Prior piperacillin-tazobactam therapy (within 1 mo), Prior fluoroquinolone prophylaxis (within 1 mo), Prior antipseudomonal carbapenem therapy (within 1 mo), Antibiotic days of therapy, Vancomycin IV, Cephalosporin, Previous azole exposure history, Daptomycin, Cefepime received within 90 days, Cumulative Daptomycin days within 90 days, Cumulative Fluoroquinolone days within 90 days, Usage of quinolones inside 95 days of catalogue sample, Usage of third group cephalosporins inside 95 days of index sample, Usage of Piperacillin/Tazobactam within 95 days of index sampling, Usage of carbapenems inside 95 days of index sample, No. of previous antibiotic use ≥ 3, Previous TMP/SMX use, Antibiotic prophylaxis (vs. G-CSF support), Prior use of extended-spectrum cephalosporin, Prior use of glycopeptides, Antibiotic use within 30 days before transplantation (No antibiotic, Any antibiotic except TMP-SMX, TMP-SMX), The total length of antibiotic administration for more than 5 days before diagnosis of anastomosis site leakage. Adjustment variables indeterminable., Days of antibiotics received, Antibiotic use previous 90 days (Antibiotic therapy >14 days), Specific antibiotics previous 90 days (PTZ, Vancomycin), Beta-lactams during the previous month, Oral vancomycin prophylaxis, prophylactic antibiotherapy received, treatment antibiotic duration, Antibiotic exposure, b-lactam/b-lactamase inhibitor within previous 30 days, Carbapenem within previous 30 days, Receiving TMP-SMX at BSI onset, Receiving cephalosporin at BSI onset, Receiving fluoroquinolone at BSI onset, Antibiotic exposure (ceftriaxone, fluoroquinolones, piperacillin/tazobactam, other (daptomycin), other (vancomycin IV), number of antibiotic exposures), Prophylactic antibiotic, IV antibiotics in previous 90 day, Concurrent antibiotics use for PCN infection, antifungals, Antibiotic exposure prior to CDI, non betalactam antibiotic previous exposure, Carbapenem previous exposure, empirical treatment of EB-BSI with carbapenems, empirical treatment with antibiotics combination, prior quinolone use, specific anti SA treatment, cefepime treatment, piperacillin-tazobactam treatment (all vs Carbapenem treatment), previous antimicrobial therapy (6 months)., Quinolone prophylaxis, piperacilline-tazobactam previous 90 days, carbapenem previous 90 days, use of quinolones within 90 days of index sampling, use of third generation cephalosporins within 90 days of index sampling, use of Piperacilin/Tazobactam within 90 days of index sampling, use of carbapenems within 90 days of index sampling., prior antifungal use, vancomycin resistant enterococcus (VRE) colonization pre-transplant, isolation of carbapenem resisant <i>A. baumannii</i> (CRAB) in the prior 1 year, antibiotics at the onset of gram negative bacteria (GNB) bacteremia, inappropriate empiric antibiotics, previous antifungal use, duration of antifungal, previous antifungal use, duration of antifungal, Prior use of any antimicrobial, prior use of anti-pseudomonal lactams including carbapenems, prior use of Aminoglycoside, prior use of Fluoroquinolones. Infection with carbapenem-resistant PA model: hospitalization in preceding 3 months, anti-pseudomonal lactams, carbapenems, aminoglycoside, fluoroquinolones, previous antibiotic therapy, antibiotic prophylaxis with fluoroquinolones, C3G (or cephalosporin (model1) exposure previous month, betalactam with or without inhibitor of betalactamase exposure previous month, carbapenems exposure previous month, combined exposure previous month, aminoglycoside exposure previous month, previous use of fluoroquinolones, previous use of piperacilline- tazobactam, previous use of carbapenems, Previous use of fluoroquinolones, previous use of cephalosporines, previous use of piperacilline- tazobactam, previous use of carbapenems</p> |
| Basic characteristics | <p>Age, BMI, Male sex, Age, Age, Age, Male (vs. female), Gender, Age, Age, Age, Age, Gender female, ESBL-PE. Adjusted for the following confounders: age, sex, Age (≥ 60 years vs <60), Gender (male), Asian race, Man sex, Age fewer than 19 years, Age (per ten years), Hospitalization during previous year, Gender, Race, Age, Year, Age categories, Race/Ethnicity, Female, Obesity, Median household income in quartile., Age at</p> |

| | |
|----------------------------------|--|
| | diagnosis, Age (>65), Smoking history (+ vs -), Sex, Age (<60 vs >60), BMI, age, gender, age., Age, sex, race, year of admission., Age, gender, age, gender, race , age, gender, sex, age less than 18 years, age, age, Age, race, gender, age, age, sex, age, sex |
| Cancer-related | Hematological malignancy, Tumour stage, Tumour localisation, Hematologic malignancy, AML, Karnofsky performance Status, and type of malignancy., HCl-CI (≥ 3 vs 0- 2), KPS (>80 vs ≤ 80), Stage of malignancy, Hematologic malignancy, Hematology/oncology model: Stage of disease (Hematologic malignancy–newly diagnosed, Hematologic malignancy–continuation/consolidation), Neoplasia in remission, Type of Malignancy, Gastrointestinal cancer, Breast cancer, Lung cancer, Prior CRE at any site within the previous 90 days, salvage lymphoma, salvage lymphoma), Leukemia, Lymphoma, Site (Colon vs Rectum), Morphology (Ulcerative vs Exophytic), Differentiation (Poor vs Well), T stage (Non-T4 vs T4), N stage (LNM neg. Vs LN pos.), hematological neoplasm, solid neoplasia, Hodgkin lymphoma, acute leukemia, acute myeloid leukemia, leukemia type, haematological malignancy, acute lymphocytic leukaemia not in remission, malignancy type, hematologic malignancy, hematologic malignancy, severity of underlying disease (Ultimately fatal, Rapidly fatal), hematologic malignancy, multiple myeloma, solid tumor, hematological cancer |
| Chemotherapy/immunosuppressants | Immunosuppressant use, Conditioning regimen, Chemotherapy dose modifications, Intervall chemotherapy to diarrhea, Administration of chemotherapy, Conditioning (RIC vs MAC), Number induction chemotherapy regimens, Clofarabine within 30 days, Previous chemotherapy inside 1 month, No prophylaxis (vs. G-CSF support), \geq VGPR before ASCT (vs. \leq PR), Oncology treatment previous 90 days (Rituximab, Clofarabine)., Immunosuppressive therapy, No chemotherapy, Early de-escalation vs hematopoietic recovery de-escalation, chemotherapy exposure, decitabine, CHOP, Chemotherapy delay OR and mean difference., chemotherapy, intensive chemotherapy, previous chemotherapy within 30 days, chemotherapy, chemotherapy, chemotherapy, chemotherapy |
| Comorbidities/clinical condition | Comorbidities, Diabetes mellitus, Pleural effusion, Hematologic diseases, Diabetes, Hematological disease, Congestive heart failure, Haematological distortion, Carlson score, Diabetes mellitus, Peripheral vascular disease, Chronic renal disease, Atrial fibrillation, Congestive heart failure, Hypertension, Chronic liver failure, Elixhauser score, Renal disease, Chronic renal diseases, Gastroenteritis diseases, CCI, Charlson comorbidity index, Charlson index, underlying disease, Charlson score, cold ischemia time, Charleston Co-Morbidity Index, severity of underlying disease (Ultimately fatal, hypertension, chronic heart disease, diabetes mellitus) |
| Gastrointestinal | Gastrointestinal GVHD, Number of stools/day, Preoperative biliary stenting (yes vs. no), Gastrointestinal bleeding, Diarrhea at presentation, Inflammatory bowel disease, IBD, biliary stricture post- transplant, biliary infection |
| Hospital-related | Previous hospitalization, Same ward, Length of ICU stay >3 days, Hospitalization time, LOS, Hospitalization prior 2 mo, Hospital LOS prior to positive culture, Hospitalization inside 1 month before contagion, ICU admission, Hospital stay of longer than 14 days, Demographic model: Unit ICU, LOS >14 days prior to culture, Healthcare exposures previous 90 days (ICU admission), Transfer from outside hospital, Prolonged hospitalization (≥ 7 days), Hospital bed size, Hospital teaching status, Expected primary payer, Total prior Hospital Stay, Total Prior Admission in ICU, ICU stay within previous 30 days, Longitudinal model: Hospitalized (days), LOS prior to culture, Model 1 Risk for CDI: Lengh of stay before CDI, Model 2 outcomes linked to CDI : LOS, Lengt of hospitalization, Excessive bed rest, prior hospitalization during previous month, inpatient management, intensive care admission, admission days prior index culture, length of stay, hospital teaching status, hospitalization within 30 days prior to infection, intensive care unit admission, hospitalization, presence of preceding bacteremia during the hospitalization, admission days, hospital region, hospital location, in intensive care unit (ICU) at diagnosis, ICU at diagnosis, hospitalization in preceding 3 months, intensive care unit admission, LOS (model 1), previous hospital admission within 60 days, duration of hospital stay |
| Infection-related | Severe/fulminant CDI disease, S. maltophilia oral abundance, Previous bacteremia with another pathogen, Bacterial infection post- UCBT, Hospital-acquired pneumonia, Development of pneumonia within the first 10 days, Prior history of Clostridioides difficile, Healthcare-associated infection, Linezolid-resistant S. epidermidis, VRE colonization (within 30 days of HCT), Culture specimen–BAL fluid, Prior enterococcal infection, Polymicrobial infection, Previous S. maltophilia isolation, Breakthrough infection during carbapenem therapy, CMV reactivation, Herpesviridae reactivation other than |

| | |
|---|---|
| | CMV, culture from sputum specimens, Source of positive culture (Respiratory), Resistance model: History of PTZ-R, Outpatient CDI diagnosis., Type of Organism, Infection, Demographical and traditional model: Severe CDI, PCN exchange within 4 days of infection, CDI exposure, presence of BSBL-Resistant EnteroBacteria, ESBL-EB, and non E. coli EB in blood cultures, CRKP rectal colonization, Fever days, healthcare associated bloodstream infections (BSI), hospital acquired BSI, foci as healthcare associated pneumonia, gram negative bacteria coinfection, gram positive bacteria coinfection, septic shock, relapse after S. aureus bacteriemia., pathogene type, fungal infection within 30 days, index culture >48h, infection, GNB infection previous 3 months and total parenteral nutrition., >= 7 days colonized by carbapenem resistant K. pneumoniae, Candida spp Species, C. tropicalis, any bacterial pneumonia, other bacterial infection, solation of VRE in the prior 1 year, isolation of ESBL in the prior 1 year, central line associated infection, E.coli, Klebsiella spp., Pseudomonas spp, S. maltophilia, Acinetobacter spp, days from chemotherapy to GNB bacteremia, hospital days to GNB bacteremia, P. aeruginosa infection, Pitt bacteremia score, multi drug resistant bacteria culture-positive surveillance rectal swabs, abdominal infection, pulmonary infection, catheter-related infection, unknown origin infection, ESBL |
| Laboratory findings (non-microbiological) | Histology, Admit serum albumin, albumin, Preoperative hemoglobin, Albumin (<35 vs >35), FBG (>7 vs <7), Triglyceride, Total cholesterol, HDL, Hemoglobin, OB, Hypoproteinemia, Procalcitonin, C Reactive Protein, Serum Amyloid, polymorphonuclear leukocytes < 500/mm3 for at least 10 days |
| Neutropenia | Severe neutropenia (<100/mm3), Febrile neutropaenia, Duration of neutropenia, Length of neutropenia ≥3 days, Severe neutropenia, Severe neutropenia, Typhilitis, ANC less than 110 cells/mm3, Profound neutropenia, Neutropenia, neutropenic days, Neutropenia, Haematological risk factors (neutropenia (days), Death during neutropenia, Severe neutropenia, neutropenia, absolute neutrophil count (ANC)less than 100 cells/mm3, neutropenia at any time, any bacterial pneumonia and neutropenia at any time., neutropenia, neutropenia, neutropenia, neutropenia |
| Other | Preceding fallout inside 1 month, Stem cell amount ≥2.5 * (vs. <2.5), Mucositis, [Indeterminable], mucositis, Pancreatic texture (soft vs hard), denture, objective dry mouth scores, NACS (?), Level 2 of patient's I tensity of Treatment Rating Scale, IMV., Indeterminable, performance status, complications (several), skin lesion, dissemination, treatment. 30 days, sepsis, recent endoscopic procedures, others" |
| Other treatments/medications | NSAID use, PPI use, Radiation, Proton pump inhibitors, Preoperative antacid use, Significant use of corticosteroids, proton pump inhibitor, Corticosteroid use, PP inhibitor use, Receiving glucocorticoids at BSI onset, Hemodialysis in previous 30 day, radiotherapy, previous radiation within 30 days, corticosteroid, use of steroids |
| Respiratory | COPD, Respiratory failure, Prior Mechanical Ventilation |
| Surgery-related | Surgical treatment, Portal vein embolization, Operation, Type of operation (pancreatoduodenectomy vs. others), Operation time, Estimated blood loss, Gastro-intestinal/abdominal surgery, Previous surgery inside 1 month, Invasive devices at the time of culture, Previous surgery, Invasive operation, gastro intestinal surgery, previous surgery within 30 days, previous surgery last 3 months, abdominal surgery, abdominal surgery, surgery in preceding 3 months, invasive procedure, surgery previous month |
| Transplantation-related | Organ transplantation, Prior HSCT, ASCT at relapse (vs. first-line treatment), History of HSCT, Stem cell transplantation, Autologous transplant, Allogeneic transplant, level 3 with HCST, level 3 without HCST and the HCST status, hematologic stem cell transplant, GVHD, living donor transplant, cytomegalovirus donor seropositivity, hepatic artery thrombosis post- transplant, intra-abdominal fluid collection post-transplant, number of re-operations in 1st month post- transplant., history of hemotologic stem cell transplantation, allogeneic matched unrelated transplant, hematologic stem cell transplantation |
| Urinary | Urinary catheter, Diversion type, Urinary catheter at culture, Prior Urinary Catheterization, urinary tract infection |
| Intravascular access | Blood transfusion, Presence of CVC, Dominant intravenous tube use, Presence of a CVC, Peripheral or Central CVP Line, central venous catheter (CVC), CVC removal, days from infection to CVC removal, presence of central venous catheter long term during index culture, GNB infection previous 3 months and total parenteral nutrition., central venous catheter use, parenteral nutrition, central venous catheter (CVC) related candidemia, Intravenous group, parenteral nutrition |
| Mortality | |
| Category | Included risk factors |
| Antibiotic use | received vancomycin within 4 weeks prior to bacteraemia, meropenem exposition (yes/no), appropriate empirical antibiotic treatment, inadequate empirical antibiotic therapy, inadequate initial antibiotic treatment, imipenem empirical antibiotic regimen, bacterial growth during antibiotic treatment, |

| | |
|----------------------------------|---|
| | administration of appropriate antibiotic treatment for minimum 72 hours, Use of antibiotics (≥ 3 agents), appropriate treatment/Non-appropriate treatment, Antimicrobial prophylaxis, initial antimicrobial failure, echinocandin pre-exposure, appropriate treatment within 48 h after blood culture collection, 3rd and 4th generation cephalosporines, fluoroquinolones., received appropriate therapy for XDR-ABC bacteraemia, inappropriate antibiotic therapy for multi drug resistant strains, inappropriate antibiotic therapy for multi drug resistant P. aeruginosa, Appropriate treatment vs Inappropriate treatment, previous antibiotics <3, early empirical TMP/SMX antibiotic use within 72 h, exposure to empirical antibiotics, azole monotherapy, Empirical antibiotic combination therapy, Inappropriate empirical antibiotic therapy, antibiotic treatment for the last 3 months before admission, appropriate antibiotic, empirical antifungal, antibiotic prophylaxis, carbapenem empirical therapy, vancomycin empirical therapy, Model 3: guided antibiotics, duration of guided antibiotics, Model 4: empirical antibiotics, guided antibiotics, guided antibiotics, Model 6: duration of empirical antibiotics, Model 7: guided antibiotics, effective empirical antibiotics, inappropriate empirical antibiotic treatment, ultrasonography-driven necrotising enterocolitis NEC therapy with antibiotic regimens including tigecycline., adequate combined treatment within 48 hours, empirically, antibiotic prophylaxis, Appropriate empirical antibiotics within 48 h, 72-h IIAT, prior antimicrobial exposure, inadequate antibiotic treatment, inadequate initial antimicrobial therapy, received antibiotherapy with Sulfamethoxazole / trimethoprim, received appropriate treatment for S. maltophilia, timing of appropriate antibiotherapy, anti-staph treatment < 48 h, cefepime treatment, appropriate empirical antimicrobial therapy, inappropriate treatment, delay for appropriate treatment, antibiotic lock therapy, initial adequate therapy, inappropriate empiric antibiotic therapy., prior antifungal use, inappropriate empiric antibiotics, empirical treatment (No active drug, inappropriate empirical therapy, appropriate definitive therapy |
| Basic characteristics | Paediatric (Compared to adults), sex, age, Age years, Age >60, Age > 65 years, Age>45, Age, male gender, Age <60, Age, Ethnicity, Older age (>65 years old), age, sex, Age, sex, Age <60 years vs. Age >60 years, Clinical model: Demographic data (age), Smoking history (Never smoker/Former smoker/Current smoker), Age, Age, sex, Haematological malignancies: age, sex, Solid tumours: age, sex, Early case fatality: age, sex, Overall case fatality: age, sex, Age, gender, sex, age, Age (>60 vs. <60), year of diagnosis, age, Age group, sex, Sex, age, Sex, age, age >55 yr, Sex, age > 65 years, age, male gender, age at diagnosis, Age > 60 years, Age >60, sex, Age>55 years old, Age group, Model 2: age <65 years, 14 days mortality models 1 and 2 : age >65 years old, 30 days mortality models 1 and 2 : sex, age >65 years old, age, sex, Age, gender, age <65, gender, race, sex, age less than 18 years, Age, age 65 and over, age, Age, race, gender, age, sex, sex, age, age>55, sex |
| Cancer-related | type of malignancies, lung cancer, prostate cancer, advance neoplasm, adverse genetic group acute myeloid leukemia, Complete remission, relapsed/refractory disease, metastatic cancer, solid tumor/Hematologic malignancy, recent diagnosis (vs relapse), Performance status >2, site (respiratory vs other), fatal prognosis according to McCabe index, community site of acquisition, BCLC stage C or D vs. A or B, ALBI grade 3 vs. grade 1 or 2, Solid tumor vs Hematological, Recent diagnosis or remission vs Progression/re-lapse, Existence of distant metastasis, Primary sites of infection (Respiratory tract/Urinary tract/BSI), Underlying leukemia, leukemia, lymphoma, refractory or recurrent disease, primary disease acute myeloid leukemia, remission, Myelodysplastic syndrom, advanced neoplasm, advanced neoplasm, hematological malignancies, hematological malignancies, Nephroblastoma, neuroblastoma, sarcomas, Performance status score, tumor lysis, acute myeloid leukemia, acute myeloid leukemia, 14-day mortality model: solid tumor, cytology Poor vs. Favorable, cytology Poor vs. Intermediate, cytology Poor vs. Unknown, AML/ALL intermediate, AML/ALL/MDS advanced, MDS advanced, Karnofsky performance scale <90, Hodgkin's lymphoma, Myelodysplastic syndrome, Solid neoplasia, haematological malignancy (Compared to solid tumours), solid tumor, malignancy-related complications, pancreatic tumour, biliary tumour, malignancy-related complications, underlying malignancies, disease relapsed or uncontrolled, relapsed or uncontrolled malignancy, acute myeloid leukemia, non Hodgkin's lymphoma, Hodgkin's lymphoma, cancer with metastasis, hematologic malignancy, Hematological malignancies, acute leukemia, acute myeloid leukemia, performance status, haematological malignancy, recurrent Hilar cholangiocarcinoma, acute myeloid leukaemia not in remission, malignancy type, hematologic malignancy, complete remission, solid tumor, hematological cancer, metastasis, complete remission of acute leukemia |
| Chemotherapy/immunosuppressants | type of the last chemotherapy treatment, day 15 bone marrow blast clearance, no recent chemotherapy (vs recent), sorafenib treatment, Chemotherapy, intensive chemotherapy. Model 2: Initial active treatment, intensive chemotherapy., High-dose cytarabine-containing chemotherapy, standard dose cytarabine chemotherapy, receiving chemotherapy, intensive Chemotherapy., previous chemotherapy within 30 days, induction or re-induction chemotherapy, chemotherapy |
| Comorbidities/clinical condition | APACHE-II score at onset of bacteraemia, Dependent functional capacity at baseline, pulmonary disease, liver disease, hæmotologiv stem cell transplant comorbidities index, renal failure, functional capacity at bacteraemia onset, comorbidities, type II diabetes mellitus, cerebrovascular disease, |

| | |
|-------------------|--|
| | <p>congestive heart failure, APACHE II, SAPS II score >40, SOFA score <10/>10, chronic kidney disease, multiorgan failure, end organ disease, APACHE II score, acute kidney infection or acute renal failure, diabetes Mellitus, SOFA score, SOFA score at diagnosis, SOFA score at healthcare associated infection (HAI) diagnosis, acute kidney injury within 30 days after HAI diagnosis, diabetes mellitus, chronic liver disease, and comorbidities., underlying cirrhosis, Child–Pugh class C vs. A or B, ECOG performance status, Comorbidities (Liver disease), Charlson comorbidity index CCI (1–2), CCI≥3, Intrapleural/abdominal infusion (within 30 days), Signs of severity, qSOFA score ≥2, APACHE II score ≥19, hypotension (<90/50), CRI non hemorrhagic, Charlson comorbidity index I>3, renal Replacement Therapy, initial SOFA score, acute kidney injury, APACHE II score, Charlson Comorbidity index>3, Charlson scoring system, Charlson scoring system, comorbidities, chronic obstructive pulmonary disease, diabetes, hypertension, ECOG score binary, Charlson comorbidities index (CCI), number of organ dysfunction, chronic liver disease, HIV-infection. Adjusted for: chronic liver disease, diabetes mellitus, chronic renal failure, Charlson index, ECOG, Charlson index > 4 points, SOFA score, renal replacement therapy, SOFA score, ECOG 1, ECOG 2, ECOG 3, ECOG 4, diabetes mellitus, renal insufficiency, hematological disease newly diagnosed / relapsed after one remission, altered state of consciousness, acute renal failure, acute hepatic failure, comorbidities, qSOFA score, APACHE II score >20, APACHE II score >20, organ failure, charlson comorbidity index (CCI) >4, underlying disease., complications (hypoxia, SOFA score, Charlson comorbidity index, Charlson index score, the presence of complications or comorbidities (eg, hypertension, diabetes, Charlson score, cerebrovascular disease, dementia, Charleston Co-Morbidity Index, altered consciousness, acute renal failure, acute hepatic failure, hypertension, chronic heart disease, diabetes mellitus, organ failure and sepsis shock</p> |
| Gastrointestinal | gastrointestinal symptoms |
| Hospital-related | <p>location in hospital at onset of bacteraemia, inpatient, length of hospital stay in days before onset of bacteraemia, admission-days before bacteraemia, Hospital length of stay, Numbers of co-infected locations, hospital stay >30 days, Ontensive care unit stay, intensive care unit admission for healthcare associated infection (HAI), admission status, Length of hospitalization (≥21.0), intensive care unit admission, hospital stay, intensive care unit stay, previous hospitalisation, intensive care unit, intensive care unit admission, previous hospital admission, intensive care unit entrance, Length of hospital stay, days of hospitalization, intensive care unit requirement., duration of stay in hospital, ICU admission, duration of hospitalization prior to bacteremia, intensive care unit stay, ICU stay, intensive care unit stay, length of stay, intensive care unit residence, ICU admission, teaching status of hospital, and the performance of bone marrow vs stem cell transplant during hospitalization., hospitalisation within 30 days prior to infection, admission to intensive care unit, Hospitalization, intensive care unit, presence of preceding bacteremia during the hospitalization, admission days, hospital region, hospital location, ICU at diagnosis, intensive care unit admission, LOS, ICU, duration of hospital stay.</p> |
| Infection-related | <p>shock at onset of bacteraemia), Clostridium difficile status (no infection/asymptomatic/symptomatic), type of bacteria, polymicrobial bacteraemia, CRGNB, septic shock, bacteremia origin (healthcare/nosocomial), clinical manifestations (Low grade fever (<38 °C/Shock at presentation), colonization with carbapenem resistant enterococci, gram-negative bacterial infection, infection with coagulase negative Staphylococci, infection with Acinetobacter baumannii, infection with Klebsiella spp., infection with extended spectrum beta lactamase-producing bacteria, infection with Gram-negative multi drug resistant bacteria, catheterization focus of infection, isolation of Gram + bacteria in culture, isolation of Gram - bacteria in culture, extended spectrum beta lactamase Enterobacteriaceae, carbapenem resistance, septic shock, multi-resistant Gram-negative BSI, pneumonia, Hemograms of bloodstream infections (white blood cell, Pathogens for bloodstream infections (among them 11 bacteria, fungi, polymicrobial and other), gram negative organisms, gram positive organisms, polyorganisms, and fungi, positive culture of multi drug resistant organism, Source of infection (Pneumonia), polymicrobial bloodstream infection, shock, colonized/Infected, septic shock, concurrent bacterial sepsis, albicans vs non albicans, Biofilm (strong vs weak), colistine resistance, fungal infection, phenotype, multi drug resistant (MDR) vs non-MDR bloodstream infection (BSI), P. aeruginosa vs other BSI, strong vs weak biofilm-producer, septic shock, infection related mortality, septic shock rate, multi drug resistant-polymicrobial bloodstream infections mortality, septic shock, fever, catheter-related candidaemia, mixed bloodstream infection, caspofungin resistance, polymicrobial bacteriemia, vaccine serotype VPV23, septic shock at diagnosis of XDR-ABC bacteraemia (extended drug resistant), days from 1st positive culture to initial treatment, concomitant infection, bloodstream infection, received effective therapy for Klebsiella producing carbapenemase-Kp infection, catheter as a source of bacteriemia, pulmonary source of infection, intra abdominal source of infection, cONs, E.coli, P.aeruginosa, shock at onset, C. difficile infection, multi drug resistant organism-colonization, Gram-positive vs Gram-negative, Monomicrobial vs Polymicrobial, Non-multidrug resistant (MDR) vs MDR and/or extended spectrum beta lactamase, Gram negative bacteria, E.coli, K. pneumoniae, Enterobacter spp, Fungi, C. albicans. Candida spp, enterococcus, Septic shock, documented clinical source, breakthrough fungemia, prior vancomycin resistant enterococcus</p> |

| | |
|---|--|
| | <p>bacteremia (VREB), persistent VREB >48 hours, CoNS (coagulase negative staphylococci). Mortality 7 days model : coNS, polymicrobial infection, previous isolation of <i>S. maltophilia</i>, Focus of infection catheter related infection (CRI), focus of infection hemorrhagic, previous colonization, coinfection, >15 days VRE, MASCC score <21, MASCC score <21, coagulase-negative staphylococci, multi drug resistant gram negative bacteria, septic shock., septic shock at onset, pneumonia, Exacerbation of interstitial pneumonia, interstitial pneumonia, microbiology with or without non-fermenting Gram(-) bacilli, extended spectrum beta lactamase enterobacteria (ESBL-E), multiple bacterial infections, bacteria/fungal coinfections, colonisation by <i>Klebsiella</i> producing carbapenemase, colonisation by <i>Acinetobacter</i>, colonisation by <i>Pseudomonas</i>, pre-chemo infection, shock, shock, catheter related infection, extended spectrum beta lactamase, catheter related infection, PITT bacteremia score, VRE bacteremia, other bloodstream infections, Vancomycin resistant enterococcus bloodstream infection, Pulmonary source, Abdominal source, Shock, Candidemia, HIV, catheter-related source, coagulase-negative staphylococci bacteremia, <i>S. pneumoniae</i> bacteremia, primary source of infection, catheter related source of infection, septic shock, <i>C. tropicalis</i>, <i>Candida albicans</i> (Compared to non-<i>C.albicans</i> or mixed), bacteraemia, shock, receiving Amphotericin B (Compared to those not receiving), after positive culture, MASCC risk score < 21, persistent bacteremia, septic Shock, fever >38C, multi drug resistant organism colonization (MDRO), multidrug resistant gram negative bloodstream infections (BSI), nonfermenter BSI, carbapenem resistant gram negative bacteria (CR - GNB), gram negative bacteria, pulmonary aspergillosis, ventilated at infection onset, Multi drug resistant organism colonisation (MDRO), Pitt score ≥ 4, MASCC score <21, carbapenem resistant gram negative bacteria, non fermentative bacteria, septic shock, carbapenem resistant by <i>Klebsiella pneumoniae</i>, type of bacteremia, caspofungin non-susceptibility, multidrug resistance, caspofungin non-susceptibility, multidrug resistance, Bacterial multi drug resistant infection, coexistence of fungal infection, clinically documented infection, Abdominal infection, unknown origin of infection, septic shock, extended spectrum beta lactamase carriage, carbapenem resistant enterobacteriaceae carriage, abdominal source, Meticillin-resistant <i>Staphylococcus aureus</i> (MRSA), infectious endocarditis, Pitt bacteremia score, extended spectrum beta lactamase-positive bacteremia, Pitt bacteremia score ≥ 4, <i>C. difficile</i> infection., septic shock etc.), <i>A.baumannii</i>, polymicrobial infection, pneumonia, breakthrough bacteremia occurrence within 48 h of ongoing antibiotics, multi drug resistant <i>E.coli</i>, <i>Candida</i> spp Species, <i>C. parapsilosis</i>, abdominal infection, Bloodstream infection, <i>C. difficile</i> infection, isolation of vancomycin resistant enterobacteriaceae (VRE) in the prior 1 year, isolation of extended spectrum beta lactamase (ESBL) in the prior 1 year, isolation of CRAB in the prior 1 year, history of GNB bacteremia in the prior 1 year, pneumonia, Pitt score, septic shock, carba-non sensitive, days from chemotherapy to GNB bacteremia, hospital days to GNB bacteremia., sepsis, severity of sepsis (Sepsis, Severe sepsis or septic shock), <i>P. aeruginosa</i> infection, Pitt bacteremia score, septic shock, 3rd generation cephalosporins resistance by <i>E. coli</i> isolate., ESBL, perianal infection, pulmonary infection, CR-PA, MDR-PA</p> |
| Laboratory findings (non-microbiological) | <p>disseminated Intravascular Coagulation (DIC) score, systolic blood pressure, diastolic blood pressure, Hemoglobin, platelet, Serum albumin, Serum albumin, Alpha-fetoprotein > 400 ng/ml, Laboratory examination results (Hemoglobin g/L <110.0, Platelet count $\times 10^9/L$ <100.0, Lymphocytes count $\times 10^9/L$ <1.0, PCT ng/mL ≥ 1.0, Albumin g/L <30.0), hypoalbuminemia, T cell depletion, platelet count, median albumin level, median Albumin level, histology with or without squamous cells, Albumin to Globulin Ratio, C reactive protein, prothrombin activity, D-Dimer, creatinine, albumin, alkaline phosphatase, total bilirubine, blood lactate level (mmol/L), creatinine, Human leucocyte antigen 7/8, C reactive protein (CRP), Model 2: creatinine, CRP, Model 5: CRP, platelet count, creatinine level, histology: squamous cell carcinoma, histology: others, platelet < $10 \times 10^3 \text{ mm}^{-3}$, hemoglobin <70g/dl, platelet < $10 \times 10^3 \text{ mm}^{-3}$, albumin <30g/L, AST >120U/L, total bilirubin >34.2$\mu\text{mol/L}$, prothrombin time >14s, glucose > 140 mg/dL, Nadir WBC count</p> |
| Neutropenia | <p>prolonged neutropenia prior to infection, Absolute neutrophil count, duration of neutropenia (days), Duration of neutropenia before blood culture, Neutropenia at the onset of bloodstream infection, severe neutropenia at the onset of bloodstream infection (<100/mm³), duration of neutropenia >21 days, neutrophil recovery, monocytopenia, neutropenia past month, current neutropenia, severe neutropenia past month, current severe neutropenia, febrile neutropenia, prolonged neutropenia, Neutrophils >500 vs Neutrophils 500, persistent neutropenia, neutropenia, $5 \times 10^9/L$ neutrophil count while vancomycine resistant enterococcus (VRE) +, absolute monocyte count <100, monocytic acute myeloid leukemia, monocytes, 30-day mortality model: Neutropenia, Model 1: neutropenia, absolute neutrophile count 500 or more, ANC < 500/μl duration until BSI (days), neutrophil count, absolute neutrophil count, ANC <100/mmc, ANC <500/mmc, neutropenia, duration of neutropenia before infection, ANC less than 100 cells/mm³, neutropenia at any time., neutropenia, duration of neutropenia before BSI</p> |
| Other | <p>others(OPD/ ER), disease risk (favourable/intermediate/high), nasogastric tube, Disease status, combination therapy, mucositis, mucositis, < 0, DM, , nasogastric tube, etiology (secondary vs. de novo), white blood cell at diagnosis, Time period, prior therapies >2, Initial low tidal volume</p> |

| | |
|------------------------------|--|
| | ventilation, status of disease, prone positioning treatment, extensive diagnosis, Indeterminable, type of CT last 3 months, palliative care, hemodynamic instability, adherence to protocol, etc.), skin lesion, dissemination, mean (\pm SD), At least one active drug), definitive treatment (One active drug, More than one active drugs)., BF |
| Other treatments/medications | current corticosteroid therapy, steroid administration, corticosteroids, steroid exposure, corticosteroid therapy, corticosteroid therapy, corticosteroid therapy, corticosteroid therapy., administration of steroid, radiotherapy dose in Gy, aciclovir, anthracycline, duration of vasopressors, hemodialysis, hemodialysis, corticosteroid use, receiving steroids, corticosteroid therapy, corticosteroid therapy, vasopressors treatment, use of vasopressors, vasopressors, vasopressors, previous radiation within 30 days, corticosteroid |
| Respiratory | Co-infections (respiratory), mechanical ventilation, positive culture in blood/respiratory tract/urinary tract/skin and soft tissue, respiratory symptoms, mechanical ventilation, mechanical ventilation, chronic lung disease, intubation, mechanical ventilation, bronchial stump fistula, mechanical ventilation, mechanical ventilation, respiratory source, severe acute respiratory distress syndrome, acute respiratory failure, acute respiratory failure, acute respiratory failure, mechanical ventilation, mechanical ventilation, mechanical ventilation, avute respiratory failure, mechanical ventilation |
| Surgery-related | emergent surgery, removal of invasive devices within the first 48 h, removal of invasive device or control deep infection, resection as hepatocellular carcinoma treatment, Surgery, presence of Drains postoperation; Infection-related model: Sample type (Urine/Blood culture), invasive procedures, invasive procedures, previous surgery within 30 days, invasive procedure, surgery |
| Transplantation-related | donor type (related/unrelated), human Leukocyte Antigen compatibility (match/mismatch), stem cell transplantation as consolidation therapy, prior hæmatologic stem cell transplant, Mortality 30 days model : Auto hematologic stem cell transplant treatment, Cord blood allograft, cytomegalovirus donor or receptor positive, hematologic cell transplant during 2010-2012, hematologic stem cell transplant HSCT, autologous HSCT, Post-transplant C. difficile infection, history of hemotologic stem cell transplantation, autologous transplant |
| Urinary | urinary catheter, source of bacteraemia (Urinary tract), urinary tract infection, Presence of indwelling urinary catheters, Model 1: Klebsiella producing carbapenemase-K. pneumoniae (KPC-KP) bloodstream infection (BSI) developing during inactive antibiotic treatment, KPC-KP BSI developing during inactive antibiotic treatment, foley catheter, urinary catheter at infection onset, urine tube, Urinary tract infection |
| Intravascular access | central catheterization, central venous catheter-related bloodstream infection (BSI), central venous catheter removal, central venous catheter removal within 48 h after blood culture collection, central venous catheter, central venous catheter removal within 48 hours, receiving total parenteral nutrition, blood transfusion, Model 1: central venous catheter removal, previous blood transfusion, catheter removal, CVC duration, CVC related candidemia, removal of CVC., Intravenous group, previous blood transfusion |

Supplementary material 7

PRISMA 2020 Main Checklist

| Topic | No. | Item | Location where item is reported |
|-----------------------------|-----|---|---------------------------------|
| TITLE | | | |
| Title | 1 | Identify the report as a systematic review. | pp. 1 |
| ABSTRACT | | | |
| Abstract | 2 | See the PRISMA 2020 for Abstracts checklist | |
| INTRODUCTION | | | |
| Rationale | 3 | Describe the rationale for the review in the context of existing knowledge. | pp. 2 |
| Objectives | 4 | Provide an explicit statement of the objective(s) or question(s) the review addresses. | pp. 3 |
| METHODS | | | |
| Eligibility criteria | 5 | Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses. | pp. 4 |
| Information sources | 6 | Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted. | pp. 3 |
| Search strategy | 7 | Present the full search strategies for all databases, registers and websites, including any filters and limits used. | S1, S2 |

| | | | |
|--------------------------------------|-----|--|---------|
| Selection process | 8 | Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process. | pp. 4 |
| Data collection process | 9 | Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process. | pp. 4-5 |
| Data items | 10a | List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect. | pp. 4-5 |
| | 10b | List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information. | pp. 4-5 |
| Study risk of bias assessment | 11 | Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process. | pp. 4 |
| Effect measures | 12 | Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results. | NA |
| Synthesis methods | 13a | Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item 5)). | NA |
| | 13b | Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions. | NA |
| | 13c | Describe any methods used to tabulate or visually display results of individual studies and syntheses. | pp. 4-5 |

| | | | |
|--------------------------------------|-----|---|------------|
| | 13d | Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used. | pp. 4-5 |
| | 13e | Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression). | NA |
| | 13f | Describe any sensitivity analyses conducted to assess robustness of the synthesized results. | NA |
| Reporting bias assessment | 14 | Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases). | NA |
| Certainty assessment | 15 | Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome. | NA |
| RESULTS | | | |
| Study selection | 16a | Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram. | pp. 5-6 |
| | 16b | Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded. | pp. 12-13 |
| Study characteristics | 17 | Cite each included study and present its characteristics. | S4, S5, S6 |
| Risk of bias in studies | 18 | Present assessments of risk of bias for each included study. | S4, S5, S6 |
| Results of individual studies | 19 | For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots. | pp. 7-8 |
| Results of syntheses | 20a | For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies. | NA |

| | | | |
|----------------------------------|---------|--|----------|
| | 20 b | Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect. | pp. 7-8 |
| | 20c | Present results of all investigations of possible causes of heterogeneity among study results. | pp. 8-12 |
| | 20 d | Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results. | NA |
| Reporting biases | 21 | Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed. | NA |
| Certainty of evidence | 22 | Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed. | NA |
| DISCUSSION | | | |
| Discussion | 23a | Provide a general interpretation of the results in the context of other evidence. | pp. 12 |
| | 23 b | Discuss any limitations of the evidence included in the review. | pp. 14 |
| | 23c | Discuss any limitations of the review processes used. | pp. 14 |
| | 23 d | Discuss implications of the results for practice, policy, and future research. | pp. 15 |
| OTHER INFORMATION | | | |
| Registration and protocol | 24a | Provide registration information for the review, including register name and registration number, or state that the review was not registered. | pp. 3 |
| | 24 b | Indicate where the review protocol can be accessed, or state that a protocol was not prepared. | pp. 3 |

| | | | |
|---|-----|--|--------|
| | 24c | Describe and explain any amendments to information provided at registration or in the protocol. | NA |
| Support | 25 | Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review. | pp. 15 |
| Competing interests | 26 | Declare any competing interests of review authors. | pp. 15 |
| Availability of data, code and other materials | 27 | Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review. | pp. 15 |

PRISMA Abstract Checklist

| Topic | No. | Item | Reported? |
|-----------------------------|-----|--|-----------|
| TITLE | | | |
| Title | 1 | Identify the report as a systematic review. | Yes |
| BACKGROUND | | | |
| Objectives | 2 | Provide an explicit statement of the main objective(s) or question(s) the review addresses. | Yes |
| METHODS | | | |
| Eligibility criteria | 3 | Specify the inclusion and exclusion criteria for the review. | Yes |
| Information sources | 4 | Specify the information sources (e.g. databases, registers) used to identify studies and the date when each was last searched. | Yes |

| | | | |
|--------------------------------|----|---|-----|
| Risk of bias | 5 | Specify the methods used to assess risk of bias in the included studies. | Yes |
| Synthesis of results | 6 | Specify the methods used to present and synthesize results. | Yes |
| RESULTS | | | |
| Included studies | 7 | Give the total number of included studies and participants and summarise relevant characteristics of studies. | Yes |
| Synthesis of results | 8 | Present results for main outcomes, preferably indicating the number of included studies and participants for each. If meta-analysis was done, report the summary estimate and confidence/credible interval. If comparing groups, indicate the direction of the effect (i.e. which group is favoured). | Yes |
| DISCUSSION | | | |
| Limitations of evidence | 9 | Provide a brief summary of the limitations of the evidence included in the review (e.g. study risk of bias, inconsistency and imprecision). | No |
| Interpretation | 10 | Provide a general interpretation of the results and important implications. | Yes |
| OTHER | | | |
| Funding | 11 | Specify the primary source of funding for the review. | Yes |
| Registration | 12 | Provide the register name and registration number. | Yes |